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ABSTRACT 
 
The Research Outcome Study in Ireland Evaluating Drug Treatment Effectiveness (ROSIE) is 
the first prospective study of treatment outcomes for opiate users to be conducted in Ireland. 
The study did not seek to evaluate treatment services but rather treatment outcomes. The 
study recruited opiate users on entry into three index treatments; methadone, structured 
detoxification and abstinence-based treatment programmes. In addition, a sub-sample of 
opiate users was recruited from needle exchanges. These modalities were chosen in 
consultation with the National Advisory Committee on Drugs (NACD) as they were 
considered to represent the most widely implemented interventions for opiate users in Ireland. 
Services and/or individuals providing treatment in both community (local community based 
services, out-patient clinics, and General Practitioner surgeries) and residential (in-patient 
detoxifications, residential rehabilitation and prison-based services) settings throughout the 
country were included in the research. 
 
Baseline data collection officially commenced in September 2003 and concluded in June 
2004. Participants were interviewed at treatment intake, or as soon as possible thereafter, and 
again at 6 months and 12 months and 36 months after the baseline interview, thereby 
providing a natural history of an opiate using cohort.  Data were collected by means of a 
structured interview. Trained fieldworkers carried out all ROSIE interviews. The interview 
instrument contained items and scales developed specifically for the project as well as 
measures adapted from other published research instruments (for example, NTORS and 
DORIS). This comprehensive set of outcome measures detailed the social and psychological 
characteristics, the drug use, the health and the crime characteristics of the cohort. A range of 
treatment processes and treatment pathways were also measured. 
 
The current report presents baseline data on the 404 ROSIE study participants interviewed at 
treatment intake. Over half the study population were recruited from methadone programmes 
(53.2%, n=215) provided across three settings; health board clinics, community-based clinics 
and General Practitioners. One-fifth of the population (20%, n=81) were recruited from 
structured detoxification programmes (in-patient and out-patient facilities). A similar 
proportion of individuals (20.3%, n=82) were interviewed in abstinence-based treatment 
programmes and the remaining 6.4% (n=26) of participants were recruited from needle 
exchanges. The average age of the sample was 28 years (median=27 years) and one-quarter of 
study participants were female (n=102). More than three-quarters (77%, n=306) of the study 
population reported heroin use in the three months prior to interview, the rate and frequency 
of use varied across treatment modality. At baseline interview the majority of participants 
were poly-drug users (76%, n=308). Tobacco, cannabis, alcohol, cocaine and benzodiazepines 
were commonly used in addition to opiates. The majority of study participants, 87% (n=352) 
had engaged in some form of formal treatment for their drug use, prior to commencing their 
index treatment for this study. Most respondents reported a history of injecting drug use 
(76.6%, n=308); the proportion of participants who reported recently injecting (last three 
months) was lower (44%, n=177). This was affected by the fact that one-fifth of the study 
sample was entering an abstinence based programme. The sample experienced a range of 
physical and mental health problems at baseline interview. One-third of the cohort attempted 
suicide at least once, and 46% (n=177) had an accidental overdose at least once. Criminal 
activity was also common among study participants over half of the cohort (65%) had spent 
some time in prison. 
 
The data in this document is presented firstly for the study population as a whole and 
secondly separately, within the appendices, for participants in each of the three treatment 
modalities and needle exchange. The analysis of the ROSIE baseline data highlights that Irish 
treatment services are facing broadly the same challenges identified in other countries.  
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EXECUTIVE SUMMARY 
 
Background to Study 
 
In Ireland, an estimated 14,452 individuals are thought to be problem opiate users in 2001. 
Recognition of the harms associated with opiate dependency, and the chronic nature of this 
condition has led to an increased availability of, and access to treatment and/or rehabilitative 
services, under the National Drug Strategy 2001-2008. At an international level, a number of 
outcome studies (e.g. DATOS, NTORS and DORIS) have supported the overall effectiveness 
of established treatment options available for opiate users. To date, no national longitudinal 
data have been available to determine the overall effectiveness of such treatment options in 
the Irish context. This lack of information coupled with the increased recognition of the need 
for treatment and care services to be informed by evidence based research contributed to the 
National Advisory Committee on Drugs (NACD) commissioning a national drug treatment 
outcome study. The tender was awarded to Dr. Catherine Comiskey at the National University 
of Ireland, Maynooth in 2002. 
 
Study Aims 
 
The Research Outcome Study in Ireland Evaluating Drug Treatment Effectiveness (ROSIE) is 
the first national, prospective, longitudinal drug treatment outcome study in Ireland. The 
primary aim of the study is to evaluate the effectiveness of treatment and other intervention 
strategies for opiate use within Ireland. 
 
Method 
 
The study design was based on the established tradition of longitudinal drug treatment 
outcomes research. For ethical reasons, the study did not advocate the use of a control or non-
treatment group. Consequently, the study employed a before and after research methodology, 
whereby individuals are used as their own reflexive control. To this end, study participants 
were interviewed at service intake or as soon as possible thereafter and then at six months, 
twelve months and thirty six months post service intake.  
 
Drug services were selected from both in-patient and outpatient settings and from three 
modalities; methadone maintenance, structured detoxification programmes, abstinence-based 
treatment programmes. In addition, a sub-sample of individuals were recruited from needle 
exchange. These modalities were selected as they were considered to be the principal 
interventions available to opiate drug users in Ireland. 
 
Using a highly structured questionnaire, 404 service users were recruited from approximately 
60 services provided by 43 separate agencies and/or organizations between September 2003 
and July 2004. Client eligibility criteria were to be (a) over 18 years-of-age, (b) be an opiate 
user, (c) be commencing a ‘new treatment episode’, (d) be prepared to consent to the 
tracking/follow-up procedures and (e) be prepared to provide a range of locator information. 
The main outcome measures included in the study were drug using behaviour (including drug 
type, frequency and quantity of use), health (physical and psychological), social functioning 
(employment, accommodation, family relations), harm (injecting related risk and overdose), 
mortality and crime. 
xi 
 
   
Results: Baseline Population 
 
Demographics: One-quarter of the study population was female (n=102). The average age of 
participants was 28 years, the median age was 27. On average, respondents reported leaving 
school at 15 years-of-age with 28% having left school before the age of 15. Analysis revealed 
that current levels of employment were low; 16% of the population was employed (either full-
time or part-time) at baseline interview, while 21% had been employed over the three months 
prior to baseline interview. The main source of income for the majority of participants (77%) 
was social welfare payments. Less than one-third of the cohort were living in the family home 
at the time of the baseline interview, and 25% were in their own or rented accommodation. 
8% of the study population were homeless at baseline interview, where homeless is defined as 
having no fixed abode or being resident in a hostel, shelter or B&B. However, 18% reported a 
period of homelessness over the preceding three months. The majority of respondents (56%, 
n=216) reported having children under the age of 18 years. However, over half (57% n=122) of 
the participants with children did not have their children in their care. 
 
Treatment History: The majority of study participants had previously sought treatment for 
their drug and/or alcohol use. Only 13% (n=51) of the study population were seeking 
treatment for the first time ever. Of those who had previously been in treatment, over half had 
been on a methadone programme (67%), in a structured detoxification programme (59%) 
and/or seen an addiction counsellor (70%).  
 
Drug Using History: Generally speaking, study participants had a long history of substance 
use, with respondents’ first using alcohol at an average age of 13.7 years (median 14 years), 
cannabis at 14.4 years (median 14 years), ecstasy at 17.6 years (median 16 years) and heroin at 
18.3 years (median 17 years). Moreover, study participants reported their consumption of a 
range of substances as problematic at various stages in their drug using careers. The vast 
majority of the population considered their heroin use a problem (92%, n=355), with 
respondents reporting the onset of problem use at a mean age of 20 years, approximately two 
years after the average age of first use of the drug. 
 
Current Drug Use: Over three-quarters (76.9%, n=306) of the study population had used 
heroin in the three months prior to interview. These participants reported using the drug on an 
average of 52 of the previous 90 days, consuming an average of 0.7 grams of heroin a day. 
Sixty-four percent of the cohort reported recent (last three months) cannabis use. These 
individuals used the drug on average 61 of the last 90 days and smoked an average of 12 
joints a day. Less than half of the cohort reported recent use of non-prescribed or misuse of 
prescribed benzodiazepines, non-prescribed methadone and cocaine use. Patterns of cocaine 
use were somewhat different to other drugs, with respondents using less frequently (on average 
17 of the previous 90 days) and consuming greater quantities on a daily basis (on average 2.3 
grams). Regarding licit drugs, the vast majority of respondents (93%) were daily cigarette 
smokers. Over-half the population (54%) reported drinking alcohol in the preceding three 
months. These individuals reported drinking on average 25 of the last 90 days (median 1 day) 
and drank on average 17 units of alcohol a day.  
 
Injecting Related Risk Behaviour: Over three-quarters of the study population (77%, n=308) 
reported having ever injected a drug. The average age respondents first injected was 20 years 
(median 19 years). Most of the injectors reported lifetime injecting risk behaviour, that is, 
having used someone other user’s needles/syringes (63%), passed their used needles/syringes 
onto others (53%), shared filters/spoons/flush water (64%) and reused their own injecting 
equipment (88%). Despite this fact the majority reported having attended needle-exchanges 
(65%, n=229). 
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Forty-four percent of the study population (n=177), or over half of those that ever injected 
(56%) reported injecting in the three months prior to baseline interview. These individuals 
reported injecting on average 47 of the previous 90 days, with 27% of recent injectors (n=46) 
doing so daily. Levels of recent injecting risk behaviour (last month) were substantially lower 
then lifetime risk behaviour. For example, 12% of the injecting population (n=20) reported 
recently using needles/syringes used by others, and only 10% reported passing their used 
injecting equipment on to others. 
 
Overdose: Analysis revealed that 45% (n=181) of the study population reported having 
overdosed at least once in their lifetime, where overdose was defined as an episode where 
respondents took drugs and as a result went unconscious. Levels of recent overdose were 
substantially lower, with 7% of the cohort reportedly having overdosed in the three months 
prior to baseline interview. 
 
Physical and Mental Health: Participants reported suffering from a range of physical and 
metal health complaints, to varying degrees. For example, 72% (n=269) of the population 
reported suffering from a poor appetite over the three months prior to interview. These 
respondents reported this symptom on average 66 days of the previous 90. Regarding mental 
health complaints, over half of the population reported feeling tense (65%), while 57% 
reported feeling lonely over the three months prior to baseline interview.  
 
Analysis revealed that 4% (n=12) of population that had been tested reported being HIV 
positive at baseline interview. That said, one-fifth of the population (20%, n=73) reporting 
having never been tested and an additional 9% of those tested (n=25) were awaiting their test 
results. However, of those tested for Hepatitis C (50%, n=140) reported being positive at 
baseline interview, with similar proportions of respondents being unaware of their HCV status 
(7%, n=20 awaiting results, & 18%, n=69 having never been tested). 
 
Criminal Activity: The vast majority of study participants (90%, n=339) reported having 
committed some form of crime in their lifetime (excluding drug possession and driving related 
offences). Just under three quarters of the population (70%, n=243) reported having 
dealt/supplied drugs at some point in their lifetime. The proportions of respondents reporting 
recent involvement in crime were substantially lower than lifetime involvement across all 
categories of offences. For example, 30% (n=109) reporting having dealt drugs in the three 
months prior to baseline interview.  
 
Over three-quarters of the population (76%, n=285) reported having ever been arrested for an 
offence, with 18% (n=69) reporting being arrested in the three months preceding baseline 
interview. Although levels of recent arrest were relatively low, 48% (n=219) of the cohort 
reported having legal problems at the time of treatment intake. For example, 22% (n=84) were 
on bail awaiting a trial or sentencing, 12% (n=46) had outstanding warrants and 10% (n=37) 
were serving a probation or community service order. In addition, 65% (n=253) of respondents 
reporting having spent some time in prison with 50% (n=193) of the population reporting 
having served a custodial sentence. 
 
Conclusion 
 
The ROSIE study is the first large-scale national prospective drug treatment outcome study to 
be conducted in Ireland. The data provides a wealth of information on opiate users presenting 
for treatment. The analysis of the ROSIE baseline data highlights that Irish treatment services 
are facing broadly the same challenges identified in many countries. However, the main aim 
of the ROSIE study is to evaluate treatment effectiveness within Ireland and the results 
presented here are but the first step towards providing that evaluation. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Background Information 
 
Opiate users can experience a range of complex health-related and social problems that 
require treatment over time. However, opiate addiction is often referred to as a chronic 
relapsing condition. While many people do successfully recover from opiate dependency or 
addiction most make several attempts to do so, lapsing and relapsing into opiate use in 
intervening periods. While there are an ever-growing number of treatments and psycho-social 
interventions available to opiate users in Ireland, many have not been effectively evaluated. 
Increasingly, it has been recognised that there is a need to ensure that all treatments for opiate 
users are closely informed by research evidence and guided by performance monitoring.  
 
In response to this need for evidence-based practice, an increasing body of research is 
available on the effectiveness of treatment for substance use problems, including several 
major outcome studies. The importance of these national studies cannot be overstated as they 
help to inform national drug policy, planning and resource allocation at a time when national 
resources are under increasing pressure. To address the lack of national research on treatment 
outcomes in Ireland, the National Advisory Committee on Drugs (NACD) commissioned a 
national drug treatment outcome study for opiate users in Ireland. The tender was awarded to 
Dr. Catherine Comiskey at the National University of Ireland, Maynooth in 2002. 
 
1.2 Outcome Studies 
 
Outcome studies have been widely accepted as providing the best evidence on the effects of 
therapeutic and rehabilitative interventions1. Such studies provide information about drug 
users, their associated problems and the nature of their involvement with treatment services. 
They also provide valuable data on the changes in patterns of drug use and other problems 
during and after treatment. To date, four major outcome studies have been carried out; 
 
 
                                                
DARP (Drug Abuse Reporting Programme2). This study, carried out in the USA, 
commenced in 1969 and investigated four types of treatment;  
- Methadone maintenance 
- Therapeutic communities 
- Out-patient drug-free services 
- Out-patient detoxifications 
In addition to investigating the four aforementioned treatment types, DARP used a 
comparison group of individuals who enrolled in, but never started, treatment.  
Between 1969 and 1973, DARP collected data at treatment entry for an initial sample 
of 43,943 clients at 52 treatment agencies and recorded their status ever two months 
until treatment termination. Follow-up data were also collected at one, two, and three 
years after treatment intake. In addition, two waves of ‘post-treatment follow-up’ 
interviews were carried out with over 6,000 individuals completing the first wave of 
interview, after an average of 6 years. The second wave of ‘post-treatment follow-up’ 
interviews were undertaken approximately 12 years after treatment intake, with a 
sample of 600 individuals.  
 
 
1 Kychetnik, L., Frommer, M, Hawe, P & A. Shiell (2002) Criteria for evaluating evidence on public 
health interventions. Journal of Epidemiology & Community Health. 56:119-127 
2 www.datos.org/background.html#DARP 
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DARP found length of treatment contact to be a key factor in determining outcome, 
with a minimum of three months in treatment required to produce positive changes in 
drug using behaviour. In addition, post treatment outcomes improved as the length of 
time in treatment increased. There were no consistent differences between methadone 
maintenance, therapeutic communities and drug free treatment, but all three had 
better outcomes than detoxification and intake group (those who enrolled but never 
started treatment).  
 
 
 
                                                
TOPS (Treatment Outcome Prospective Study3): This study, which commenced in 
1979, was also carried out in the USA and was modelled closely on DARP. It aimed 
to assess short and long term treatment outcomes of four treatment types; 
- Methadone maintenance 
- Detoxification 
- Residential 
- Out-patient drug free treatment 
Data were collected from 12,000 people entering treatment in 42 treatment agencies, 
across 10 cities in the US. The sample was recruited in three waves, 1979, 1980 and 
1981. Clients were interviewed at treatment intake and then one month, three months, 
six months, nine months and one year after treatment admission. Over 4,000 people 
were selected for post treatment interviews, at three months, one year, two years, 
three years and five years. 
 
During the first three months of treatment, TOPS found a dramatic decline in drug 
use and criminal activity in each of the three modalities methadone maintenance, 
residential and out-patients drug free treatment (the detoxification group were 
eventually excluded from the study).  A year after treatment had ended, TOPS found 
reductions in drug use, crime and mental health symptoms for individuals who had 
stayed in treatment for at least three months.  TOPS found that time in treatment 
rather than type of treatment was one of the most important predictors of positive 
outcomes. Relatively long periods in treatment were found to be necessary to effect 
change. However, it should be noted that the ROSIE study design is different to 
TOPS. Clients within ROSIE were interviewed at treatment intake and at six months, 
twelve months and thirty six months post treatment intake. Within TOPS, clients 
interviewed after one year had terminated their treatment. 
 
DATOS (Drug Abuse Treatment Outcome Study4). This study commenced in 1991 
and aimed to investigate the link between patient outcomes, treatment process and 
programme structure in four treatment types; 
- Methadone maintenance 
- Short-term residential  
- Long-term residential (therapeutic communities) 
- Out-patient drug-free treatment 
Data were collected at treatment intake from over 10,000 clients attending 96 
treatment programmes in eleven cities in the US between 1991 and 1993. Data were 
collected at 1 month after treatment admission and again at three and six months. 
Follow-up interviews were carried out on a stratified sample of approximately 3,000 
clients twelve months after treatment termination. An extended follow-up gathered 
data on clients four years post-treatment. 
 
 
3 http://www.datos.org/background.html#TOPS 
4 http/www.datos.org 
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Clients treated in all four modality studies in DATOS showed large and significant 
improvements during one year follow-up. Overall, major outcome indicators for drug 
use, illegal activities, and psychological distress were each reduced by an average of 
50%. However, there were notable distinctions between clients admitted to different 
types of treatment, as well as in the length of time they remained in treatment. There 
were further variations between programmes, even among those of the same general 
type. At five-year follow-up, slightly higher rates of cocaine use were reported; 25% 
compared with 21% reported at one-year follow-up. Note the difference in the 
DATOS study design compared with the ROSIE study. 
 
 
                                                
NTORS (National Treatment Outcome Research Study5). This UK study commenced 
in 1995 when 1,075 individuals from 54 treatment programmes throughout England 
were recruited. Treatment outcomes were sought from the following modalities; 
- Specialist in-patient treatments 
- Residential programmes 
- Methadone maintenance 
- Methadone reduction programmes 
Follow-up data were collected at one year from 72% of the baseline population 
(n=769). Additional waves of interviews were also carried out on a sub-sample of 
participants at 2-3 years and 4-5 years after treatment intake.  
 
At one year follow-up, NTORS reported a substantial reduction in heroin and cocaine 
use. Abstinence rates for opiates (heroin and non-prescribed methadone) more than 
doubled. Among individuals who reported using drugs at follow-up, there were 
reductions in both the quantity and frequency of use. Although there were reductions 
in alcohol use at follow-up, many participants remained heavy drinkers. In addition, 
NTORS reported a significant reduction in criminal activity at 1-year follow-up and a 
number of improvements in both physical and psychological health were reported. As 
in other outcome studies, NTORS results show that there were substantial inter-
agency variation in outcomes. At present, a new study entitled Drug Treatment 
Outcome Research Study (DTORS) is underway in England to update the results of 
the original NTORS.  
 
In addition to the outcome study outlined above, the Drug Outcome Research in Scotland 
(DORIS6) study is ongoing, as is the Australian Treatment Outcome Study (ATOS7). The 
main outcome measures across all the aforementioned studies are drug using behaviour 
(including drug type, frequency and quantity of use), health (physical and psychological), 
social functioning (employment, accommodation and crime) and harm (injecting-related risk 
and overdose). Generally, these studies have found substantial reductions in illegal drug use 
and improved outcomes for injecting risk behaviour. However, alcohol outcomes were often 
poor with many individuals continuing to, or starting to, drink heavily. In addition, reductions 
in levels of crime were also found providing substantial and immediate cost savings for 
society. Time in treatment and treatment completion were also found to be associated with 
better treatment outcomes. 
 
 
5 http://www.dtors.org.uk/NTORS.aspx 
6 http://www.gla.ac.uk/drugmisuse/DORIS.html 
7 http://www.turningpoint.org.au/research/si_research_atos_h.htm 
     3 
   
1.3 Project Aims Overview 
 
The ROSIE study sought to recruit opiate users on entry into one of three index treatments; 
methadone, detoxification and abstinence-based programmes. In addition, a sub-sample of 
individuals was recruited from needle-exchange. Participants were interviewed at treatment 
intake, or as soon as possible thereafter, and at two subsequent six monthly intervals. The 
project was subsequently extended to follow up clients thirty six months post treatment 
intake. The original aims of the study were: 
 
To undertake the first national, prospective, longitudinal opiate treatment outcome 
study; 
 
 
 
 
 
 
To describe the characteristics of people seeking treatment for their opiate use; 
 
To evaluate the effectiveness of different kinds of drug treatments and interventions 
currently available to opiate users in Ireland. The study examines treatment outcomes 
at six, twelve and thirty six months after commencing index treatment; 
 
To provide an economic cost-estimate for the problems associated with drug use 
among the cohort and; 
  
To identify and measure key treatment processes and assess their impact on treatment 
outcomes. 
 
In dealing with the second aim, the current report describes the baseline characteristics of 
individuals seeking treatment for their drug use in Ireland. More details on the project aims, 
key hypotheses, outcome measures and study limitations are provided in Chapter 2. 
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CHAPTER 2:  METHODOLOGY 
 
2.1 Introduction 
 
According to the World Health Organisation (WHO), the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) and the United Nations Drug Control Program 
(UNDCP), the ROSIE study may be described in summary as a naturalistic, observational, 
treatment outcome evaluation study.  In naturalistic or observational studies clients are 
assessed on a set of measures at several points in time usually before, during and after they 
complete a treatment programme of interest. WHO (20008) states that these studies are useful 
for the study of treatment systems where clients engage in multiple treatments of varying 
intensities and duration.  
 
Outcome evaluations look at whether clients of a treatment service or system have changed 
over time and how much of this change can be attributed to the care received. In the past, 
most outcome studies of people treated for substance use problems tended to use post-
treatment abstinence from these substances as a primary indicator of treatment success. 
However, recent studies have focused more on patterns and levels of post-treatment substance 
use while also considering post-treatment functioning in other life areas. Three other problem 
domains usually assessed are health risk behaviours, health problems and various aspects of 
personal/social functioning, including employment, family and other personal relationship 
problems and criminal behaviour.  
 
The Drug Abuse Treatment Outcome Study (DATOS) (http://www.datos.org/) in  
the USA, the National Treatment Outcome Study (NTORS) 
(http://www.dtors.org.uk/NTORS.aspx) in the UK, The Drug Outcome Research in Scotland 
(DORIS) (http://www.gla.ac.uk/drugmisuse/DORIS.html) and the Australian Treatment 
Outcome Study (ATOS) (http://www.turningpoint.org.au/research/si_research_atos_h.htm) 
are all examples of naturalistic, treatment outcome evaluation studies.  
  
2.2 Design  
 
2.2.1 Design Objectives 
 
The primary aim of this study was to evaluate opiate treatment effectiveness. The aim was not 
to have a sample large enough to compare across a range of treatment modalities or across a 
range of treatment settings. Rather the study was designed to describe the nature of treated 
opiate use in Ireland across modalities that reflect the delivery of care in Ireland. More 
specifically, the objectives were: 
 
1. To develop a research model, instrument and study based on the National Treatment 
Outcome Study (NTORS) (http://www.dtors.org.uk/NTORS.aspx) and the Maudsley 
Addiction Profile Questionnaire9.  
2. To define, derive and measure a set of demographic and drug using life history 
measures at national level for opiate users. 
3. To define, derive and measure a set of treatment outcome measures for opiate users. 
4. To present findings in order to highlight current opiate treatment outcomes.  
5. To compare findings at international level. 
 
                                                 
8 Farrell M., Marsden J., Ogborne A., Rush B. International guidelines for the evaluation of treatment 
services and systems for psychoactive substance use disorders 2000: WHO, UNDCP & EMCDDA. 
9 Marsden J, Gossop M, Stewart D, Best D, et al. The Maudsley Addiction Profile (MAP): A brief 
instrument for assessing treatment outcome. Addiction 1998: 93:12:1857-1868. 
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2.2.2 Design Overview 
 
In order to realise the study aims (as set out on page 3), the design of the ROSIE study is 
longitudinal and prospective in nature. It is a cohort study comparing within treatment 
effectiveness in different treatment modalities in a range of treatment settings. Pre-
treatment/post-treatment comparisons were made without a control group. From a statistical 
perspective, it would have been desirable to compare treatment group versus control group. 
However, due to ethical considerations, the control group was omitted, as their inclusion 
would have meant that the opiate users within this group would not have or only belatedly 
received treatment.  In order to measure improvements within a treated group, changes from 
baseline figures were analysed. Accordingly with the ROSIE study, opiate users were 
recruited and interviewed within one month of a new treatment episode. Participants were 
then interviewed on two subsequent occasions at 6 months and at twelve months following 
recruitment. Following the twelve month interviews, the study was extended and participants 
were interviewed again at thirty six months post-intake. An overview of the study execution 
process is given in Figure 2.1. 
 
Figure 2.1 Overview of the study execution process. 
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2.2.3 Limitations 
 
The main limitation of the ROSIE study and similar observational study designs is the 
inability to definitively conclude any observed changes were brought about as a result of the 
treatment of interest. This is because they do not adopt a randomised control study design. 
Such a design randomly allocates participants to either a control or treatment group. Any 
changes observed within the treatment group can then be attributed to the treatment they 
received with observational studies on opiate use. It is deemed unethical to deny a participant 
treatment and therefore the control group must be omitted.  
 
A further limitation of this type of study design is that opiate users were recruited within the 
first month of a new treatment episode and as such it could be argued that the baseline data 
does not truly reflect the opiate users pre-treatment behaviour. In order to control for this bias, 
it is usual in observational studies to define and measure the recruited opiate users behaviour 
in the three months prior to the intake interview. New research suggests that the greatest 
changes occur within the first month of treatment (private communication, Dr Michael 
Farrell,  Kings College, London) 
 
In addition, as opiate users were grouped and assessed initially according to their respective 
baseline modality, there may exist limitations in the interpretation of the 1 year data. The 
longitudinal nature of the study does not account for various treatment pathways which the 
opiate user may have undertaken during this period and consequently the basic descriptive 
and inferential outcome tables may not be reflective of this. For example, an opiate user 
would normally progress from detox modality to abstinence modality. However, as the 
treatment pathway of each opiate user was collected the possible effect of a change of 
modality on outcome may be statistically modeled and reported on in a more detailed 
technical report. 
 
In spite of the limitations of observational studies, these studies can and are used to show if 
the desired client outcome is achieved and to identify which clients change most or least. 
Observational studies can also show quite successfully how outcomes vary with the amount 
or type of treatment received. These types of studies are recommended by the EMCDDA, the 
WHO (http://www.who.int/en/) and the UNDCP (http://www.unodc.org/unodc/undcp.html) 
but they have been excluded from Cochrane reviews on the basis of the lack of a control 
group (http://www.cochrane.org/index.htm). 
 
 
2.3 Treatment Effectiveness  
 
2.3.1 Operational Research Questions 
 
The key operational question of the study was to assess if opiate users are better off after a 
treatment episode than before that episode. More specifically we asked: 
 
1. Have opiate users’ drug use reduced after a treatment episode? 
2. Have opiate users’ physical and mental health improved after a treatment episode? 
3. Have opiate users’ crime levels reduced after a treatment episode? 
4. Have opiate users’ opiate related harm reduced after a treatment episode? 
5. Have opiate users’ living, social and family circumstances improved after a treatment 
episode? 
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2.3.2 Measurable Outcome Criteria 
 
In order to answer these questions and realise the study aims, a range of measurable outcome 
criteria were defined. These criteria are detailed in the original ROSIE Statistical Analysis 
Plan (SAP), submitted to the NACD. As the study evolved, minor changes were made in the 
implementation of the plan but the core plan remained unchanged. The main outcome 
measures were variables on substance use, health risk behaviour, physical and mental health, 
criminal activity and personal and social functioning (see Section 2.6.3. for details). 
 
 
2.4 Treatment 
 
2.4.1 Definition of Index Treatments 
 
ROSIE participants were recruited within residential and out-patient community settings. 
Three residential or in-patient settings were included and these were hospitals, rehabilitation 
programmes and prisons. Three out-patient settings were selected and these were local 
community based clinic services, health board out-patient clinics and General Practitioners 
(GP’s). Four modalities of treatment intervention were selected on the basis that these 
modalities reflected the treatment intervention available at a national level. These were 
methadone (maintenance and reduction), structured detoxification, abstinence programmes, 
counselling and needle exchange. 
 
The provision of methadone, a long-acting opiate agonist, under medical supervision, is the 
main pharmacological substitution intervention for opiate users in Ireland. Initially, a low 
commencing dose (usually between 10-40 mls) is prescribed, aimed at achieving a level of 
comfort while reducing the likelihood of overdose. By the end of six weeks of treatment, the 
individual is usually stabilised on an appropriate therapeutic dose. Methadone maintenance is 
a long-term treatment option of no fixed duration, usually forming part of a wider process of 
assisting an individual to reduce various forms of drug-related-harm and to address social, 
legal and financial problems until the person is ready and willing to withdraw from the drug 
substitution therapy. There are different models of maintenance prescribing, ranging from 
highly structured regimes to low-threshold programmes. 
 
The methadone modality within ROSIE includes methadone maintenance and methadone 
reduction.  At the start of the study when treatment centres were contacted, it was observed 
that many of the clinics, while aspiring to offer methadone reduction, there were in fact 
offering mostly methadone maintenance.  The Rosie Advisory Group (RAG) believed that by 
including the two as one modality we would capture this dichotomy from the client and 
provider perspective. 
 
Structured detoxification is a process whereby individuals are systematically and safely 
withdrawn from opiates, under medical supervision. The most common method of opiate 
detoxification in Ireland is to use methadone and slowly taper the individual down from the 
usual dose to zero over a period of time. Structured detoxification programmes are provided 
in both in-patient and out-patient facilities and can vary in duration from approximately 4-12 
weeks.  
 
ROSIE recruited where detoxification was part of a treatment programme over a specific 
period of time up to a maximum of twelve weeks.   This differentiates from the 10-15 day 
detoxification that occurs in the prison context, for example, without the additional supports, 
which is not aimed at delivering treatment but instead at managing acute withdrawal from 
opiates on arrival in prison.  
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Within ROSIE, the abstinence modality is defined as being any structured programme which 
required individuals to be drug-free (including free from any pharmacological intervention) in 
order to participate in, and remain on, the programme. Such programmes provide intensive 
psychological support and a structured programme of daily activities which participants are 
required to attend. Treatment can occur in an in-patient (often referred to as residential 
rehabilitation) or an out-patient (i.e. structured drug-free day programmes) setting. In-patient 
abstinence-based treatment programmes can differ markedly in their underlying philosophy, 
programme structure, intensity and duration. Programmes may be either short-term (usually 
between four and twelve weeks) or long-term (usually between three and twelve months). 
ROSIE study participants were recruited from the three main types of residential 
rehabilitation programmes identified in the international literature; 12-step/Minnesota model 
programmes, Christian houses and a therapeutic community. 
 
Finally, some clients were recruited within needle exchange services. While needle exchange 
is not a treatment modality, it was desirable to capture the journey of those coming into 
needle exchange and their progress through the services.  
 
With regard to counselling for opiate users, there was a view that counselling was really a 
component of treatment and therefore not valuable to consider as a treatment modality.  
However, given that most of the opiate services are in Dublin and that there are a growing 
numbers of opiate users outside of Dublin, it was felt to be worth considering this aspect of 
counselling.  Addiction counsellors are the backbone of most drug services in the regional 
health boards and as such counselling is the treatment modality for them and would be 
included as a separate modality.  Subsequently during recruitment it was found that very few 
opiate users were offered counselling only, therefore, the RAG took the decision to omit this 
modality.  This decision reflected changes in the delivery of opiate treatment in Ireland with 
the expansion of methadone places as part of the NDS. 
 
2.4.2 Site Selection 
 
All agencies providing treatment to opiate users in Ireland were contacted and informed of the 
ROSIE study. Information was sought from services regarding the nature of the organisation, 
and the range of services provided.  Thereafter, all methadone clinics within the Greater 
Dublin Area, in Ireland which had the capacity to facilitate ‘new treatment intakes’ over the 
recruitment period, were included in the site selection process. Study recruitment was 
eventually carried out in nineteen such clinics. Many clinics outside Dublin were full to 
capacity and unable to facilitate new clients over the study period. Nevertheless, study 
recruitment was undertaken in seven ‘out of Dublin’ clinics. In addition, all GP’s prescribing 
under the Methadone Protocol were informed of the research, and their assistance in study 
recruitment requested. General Practitioners contacted via the Central Treatment List and 
followed up with phone calls and letters resulted in thirty GP’s participating in the study and 
assisting the study with access to clients for study recruitment. All residential drug treatment 
facilities in the country that worked with an opiate using clientele were included in the 
selection process. Interviews were undertaken in nine such facilities. Finally, baseline study 
recruitment was carried out in the three main in-patient facilities in the country and in one 
out-patient facility. 
 
2.4.3 Coverage 
 
ROSIE was not designed as a randomised control trial with specific numbers of clients 
allocated to a treated or control group within certain geographical locations. Rather, the study 
reflects the availability and distribution of treatment service provision nationally. Ideally, it 
would be preferable if all health regions were included in some capacity. However, not all 
treatment modalities are available within all regions. Therefore, we included regions where 
opiate services were available. Consequently, ROSIE reflects the availability and distribution 
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of existing services nationally. Hence, we may say national coverage is not compromised in 
the study. Rather, the study reflects or models national treatment service provision in 2003, 
the time of recruitment. 
 
Recruitment to the ROSIE study began in March 2003 with enrolment of 20 clients to the 
pilot study. The majority of the 404 clients were however recruited between September 2003 
and July 2004.   All clients were defined as a new treatment episode (see Section 2.5.1). At 
national level, a database on all treatment episodes in a calendar year is maintained by the 
National Drug Treatment Reporting System (NDTRS) at ADRU, the Alcohol and Drug 
Research Unit of the Health Research Board, Dublin, Ireland.  Compliance with the NDTRS 
requires that one form be completed for each person who receives treatment for problematic 
drug use at each treatment centre in a calendar year. Service providers at drug treatment 
centres throughout Ireland collect data on each individual treated for drug misuse. At national 
level, the staff of the NDTRS compiles anonymous, aggregated data. 
 
In order to provide some information on the coverage of the treated population by the ROSIE 
study, we compare, where possible, the ROSIE recruitment figures with those of the NDTRS 
for 2003.  The NDTRS reports that there were 4,900 cases that commenced or recommenced 
treatment for problem drug use in 2003 giving ROSIE a national coverage rate of 
approximately 8.2% of all new treatments.  In addition to the 4,900 NDTRS clients, 1,265 
commenced or recommenced methadone maintenance. Within the ROSIE study, 215 clients 
were recruited within the methadone modality giving the study a coverage rate of 
approximately 17% of all new methadone treatments at national level. The NDTRS also 
reports that of the 4,900 clients treated nationally, 682 commenced a detoxification 
programme. Within the ROSIE study, 81 clients were recruited from the detoxification 
modality, giving this modality a national coverage rate of approximately 12%.  However, 
when computing these rates it must be noted that NDTRS figures are based on a calendar year 
and data for 2004 is at present unavailable (private communication, J. Long, NDTRS). Given 
this limitation, the data provides some information on the scale of the ROSIE study. The 
coverage rates within the ROSIE study are well in excess of other national treatment outcome 
studies where coverage rates are seldom published but are estimated to be in single figures 
and below 5% (private communication, N. McKeganey, DORIS, Drug Research Outcome 
Study in Scotland). 
 
 
2.5 Subjects  
 
2.5.1 Case Definition and Inclusion Criteria 
 
In terms of client eligibility, only those opiate users defined as presenting for a 'new treatment 
episode' were recruited to the study, where ‘new treatment episode’ was defined as 
incorporating those who had never presented for treatment before, those who had presented 
for this type treatment previously but were not now in receipt of this type of treatment within 
the last 6 months and those who had presented for other types of treatment previously. 
Following detailed discussions with the NACD treatment subcommittee and the RAG, it was 
decided that ‘new treatment episode’ clients were a pragmatic choice of subject given the 
possible lack of availability of ‘first treatment’ clients. In addition, if opiate users who were 
currently in treatment had been chosen, the comparability of baseline data between clients 
would have been compromised. However, this choice of client definition as opposed to clients 
in treatment did impose the added limitation that such clients could, in some circumstances, 
be difficult to find and recruit due to a possible lack of availability of treatment places. 
 
Inclusion criteria for clients of the study included (a) to be over 18 years of age, (b) starting a 
new treatment episode as defined above, (c) to have used opiates, (d) to be prepared to 
consent to the tracking/follow-up procedures and (e) to be prepared to provide a range of 
     10 
   
locator information. Involvement in the study was voluntary and it was made clear to 
potential participants that refusal to participate would in no way affect the treatment received. 
Participants were told that they could, at anytime, withdraw from the study if they so wished. 
Confidentiality was ensured and individuals were informed that all answers and comments 
provided would remain anonymous. The baseline interview took approximately one hour, 
interviews took place in a variety of settings (treatment services, prisons, café’s, participants’ 
homes) and participants were not paid or financially reimbursed in any way for completing a 
baseline interview. Trained ROSIE fieldworkers carried out all baseline interviews.  
 
2.5.2 Recruitment and Interview 
 
At the study planning stage, it was initially anticipated that 600 opiate users new to treatment 
would be recruited.  In order to ensure adequate sample sizes within the various modalities a 
basic power analysis was conducted and as a result, it was decided that the minimum sample 
size within all settings and modalities would be 50 clients, with the exception of needle 
exchange and the prison setting which would have 25 clients each. Further details of this 
power analysis and decisions relating to sample sizes are available within the original study 
protocol ‘The project objectives document’ from the NACD. The distributions chosen did not 
reflect the exact percentage distribution of treatment setting and modality at national or local 
level, rather the planned distributions were chosen to broadly reflect the known distribution of 
treatment settings and modalities, while providing adequate numbers and sufficient sample 
size to perform comparisons within modalities. In terms of age and gender profiles of 
recruited clients, it was expected that a ratio of 3:1 males to females would be recruited to the 
study, i.e one quarter of the clients recruited would be female. The male to female ratio 
recruited to the study would then reflect the gender ratio observed in treatment. 
 
2.5.3  Sample Achieved 
 
An estimated 60 different services provided by approximately 43 separate agencies and/or 
organisations participated in the ROSIE study baseline recruitment. These agencies provide 
treatment/rehabilitation services to opiate users in both in-patient and out-patient settings. 
Agencies across all former health board areas (Eastern Regional Health Authority, the South-
Eastern, Mid-Western, Western, Midlands and North-Eastern Health Boards) were included 
with the exception of the Southern and North-Western Health Board areas, where participants 
residing in these areas were interviewed. 
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Table 2.1 Baseline Study Recruitment by Modality and Treatment Setting 
 
Modality Setting Numbers 
Hospital 33 
Prison 14 
In-patient 
Community 12 
Structured Detoxification 
Out-patient Health Board* 22 
 
81 
In-patient  70 Abstinence Based programmes 
Out-patient  12 
82 
G.P’s 54 
Community 48 
Out-patient 
Health Board* 108 
Methadone Programmes 
Prison  5 
 
215 
 
Community 17 Needle-Exchange Out-patient 
Health Board* 9 
26 
Total    404 
*A new agency, the Health Service Executive (HSE), as part of the Irish Government’s Health 
Service Reform Programme, assumed responsibility for the health service in the Republic of 
Ireland on January 1, 2005. As part of the Irish government’s Health Service Reform 
Programme, the functions of the former Health Boards have transferred to the HSE. 
 
2.6 Research Instruments 
 
The ROSIE baseline research instrument was adapted from the Maudsley Addiction Profile 
(MAP) and the DORIS instrument. The MAP is a brief, interviewer administered 
questionnaire for treatment outcome research applications that measures problems in the four 
domains of substance use, health risk behaviour, physical and psychological health and 
personal/social functioning (Marsden et al, 1998). The DORIS instrument is an extension of 
the MAP and includes extra quantitative and qualitative components (Private communication, 
Neil McKeganey and Gordon Hay, Centre for Drug Misuse Research, University of Glasgow, 
2002).  
 
2.6.1 Selection and Development 
 
The MAP and DORIS instruments were chosen for use with the ROSIE study. Every question 
within the DORIS baseline instrument was scrutinised and edited by the senior project 
management team to ensure its suitability and rationale for the ROSIE projects aims and 
objectives.  The phrasing and time frame of each question was checked to ensure the question 
captured the required data from the correct time reference. Prior to the execution of the full 
ROSIE survey, the newly developed ROSIE instrument was approved by the RAG and was 
piloted in a range of settings. 
 
2.6.2 Outline of Contents 
 
The baseline survey instrument contained several sections. These included 
 
Locator Information: To facilitate follow-ups at the six and twelve month stages, the 
following information was sought from participants at baseline interview; full-name, 
nicknames/street names, current address, participants’ phone numbers (mobile and 
landline), name, address and phone number of parent (or other family member), name and 
address of treatment referrer, name and address of GP, name and address of social 
worker, name and address of key worker/drug worker who would be able to contact 
 
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participant. 
 
Demographic Characteristics: Demographic variables included age, gender, country of 
birth, nationality, ethnic origins, age left school, highest level of educational 
qualifications, current employment status, usual occupation over previous six months, 
employment status over last three months, ways participants financially supported 
themselves over preceding three months, current accommodation, accommodation over 
previous three months, any housing problems, who they lived with, any problems in the 
area where they resided, marital status, contact/conflict with family/friends, whether they 
had children under 18 years and number of children in their care.    
 
 
The Index Treatment: Participants were asked a number of questions in relation to their 
index treatment including type of index treatment participants were receiving, type of 
treatment they wanted, reasons for coming to index treatment, duration of index 
treatment, length of time attending index treatment at the time of baseline interview, time 
expected to be in index treatment, whether they were on a waiting list prior to 
commencing index treatment and how long they spent on a waiting list.  
 
 
Drug Treatment History: Participants were asked whether they ever had previous 
treatment for their drug and/or alcohol use, what this treatment was and at what age they 
had the treatment. In addition, participants were asked whether they had ever been on a 
methadone programme (age first time on methadone, number of episodes, treatment setting and 
longest period on methadone) had ever had a supervised detoxification (age first time, in-
patient/out-patient setting, how many detoxification episodes, did participants complete 
detoxification programme) had ever been in residential drug treatment (age first time, how 
many times, did participants complete treatment, how long was the programme) had ever had 
one-to-one counselling (age first time, how many counsellors have participants seen, setting, 
longest period of regular attendance) had ever been to Narcotics Anonymous (age first time) 
and had ever been to Alcoholics Anonymous (age first time). Participants were also asked 
whether they had commenced any form of treatment, excluding their index treatment, in 
the six months prior to interview. 
 
 
Drug Use: Participants were asked to provide a detailed drug using history. To this end, 
participants were asked whether they had ever used a list of twelve substances (heroin, 
‘street’ methadone, other opiates, benzodiazepines, cocaine, crack, amphetamines, ecstasy, LSD, 
cannabis, tobacco and alcohol), age of first use, whether they ever considered their use a 
problem, and age they first thought use was a problem. In addition, for all twelve 
substances, participants were asked to report on their frequency of use over the preceding 
three months, the typical amount used in a day and the usual route of administration. 
Participants were asked to identify what drug they would consider their ‘main’ drug over 
the previous three months, and what drug has caused them the most problems in that time 
period. Participants were also asked about their drug use in the previous three days and 
about their prescribed medication over the previous four weeks (including frequency and 
dose). This section also contained questions regarding lifetime history of non-fatal 
overdose and frequency of overdose in the previous three months. 
 
  
Injecting-Related Health: Participants were asked about their drug injecting history (ever 
injected, age first injected, frequency of injecting over the previous three months, and frequency of 
injecting on an average injecting day). Participants were also asked to identify all drugs they 
had injected over the preceding three months. This section also examined, in detail, the 
injecting risk behaviour of the participants, by asking if participants had ever engaged in a 
range of risk behaviours (used needle/syringe that had been used by somebody else, passed on 
their used injecting equipment to others, re-used own injecting equipment, used filter/spoon/flush 
water used by somebody else) and about the frequency of such behaviour over the preceding 
three months. Finally, participants were asked about needle-exchange attendance (age first 
 
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attended and frequency of attendance over last six months). 
 
Physical & Mental Health: Participants were asked to rate their general health. In 
addition, individuals were presented with a 10-item physical health and a 10-item mental 
health assessment, and asked to report the frequency with which they suffered each 
symptom over the preceding three months. Additional questions in the health section 
were concerned with suicidal ideation, suicide attempts and sleeping and eating patterns. 
Participants were also asked an open-ended question about any specific health problems 
they may have had over the preceding month. 
 
 
Contact with Family, Social Care and Other Services: Participants were asked about the 
frequency of contact and conflict with family members, attendance at a range of social 
care services (stayed over night in hospital, hospital accident and emergency departments, GP, 
social services, employment/training services, housing services and church/religious groups) over 
two time periods, in the twelve months prior to the baseline interview and in the 
preceding three months. Participants were also asked whether they ever had HIV, HCV 
and HBV tests, when their last test was taken and what the outcomes of the tests were. 
 
 
Criminal Activity: Participants were asked whether they had ever committed a list of 
offences (including drug dealing, acquisitive crime, assault, fraud/forgery/deception, soliciting 
and criminal damage) and how frequently they committed these crimes in the preceding 
three months. Participants also were asked if they had ever been arrested for any of the 
aforementioned crimes and frequency of arrest over the preceding three months. 
Participants were asked whether they had a prison history, the total length of time they 
had spent in custody, if they had any legal issues at the time of baseline interview, if they 
had any contact with the criminal justice system in the preceding three months, and if 
they had been the victim of a crime in the same time period.   
 
 
2.6.3 Key Outcome Measures 
 
The key outcome measures from the baseline instrument used in the follow up interview and 
outcome analysis were 
 
a) Substance use 
1) Frequency of use of opiate drugs (including heroin and similar). 
2) Intensity of daily consumption of opiate drugs.  
3) Number of days of use in the last three months.  
4) Amount used on a typical day. 
5) Frequency of use of all other drugs (non opiate and including alcohol). 
6) Intensity/quantity of daily consumption of all secondary drugs. 
7) For each other drugs (non opiate and including alcohol): 
I. Number of days of use in the last three months. 
II. Amount used on a typical day. 
 
b) Risk behaviour 
1) Frequency of needle sharing. 
2) Daily frequency of injection.  
3) Number of days injected in the last three months. 
4) Typical number of times injected in one day. 
5) Number of times used or passed a used needle in the past month. 
6) Frequency of unsafe injecting behaviour (excluding needle sharing).  
7) Frequency of unsafe sexual behaviour. 
8) Number of days used someone else’s filter/spoon/flush water in the last month. 
9) Frequency of unprotected sex in the last three months. 
10) Number of accidental overdoses in the past three months. 
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c) Physical and psychological health 
1) Frequency of physical and psychological health symptoms (including, anxiety, 
depression and suicidal behaviour). 
2) Number of times attempted suicide in the past three months. 
3) Number of days experienced physical health symptoms in the past three months. 
4) Number of days experienced psychological health symptoms in the past three 
months. 
5) Number of times attempted suicide in the last six months. 
6) Number of days in treatment (including hospital, accident and emergency, GP and 
community treatment) for a medical condition. 
 
d) Personal/social functioning 
1) Frequency of criminal behaviour (including selling drugs, shoplifting and others). 
2) Number of times crime committed in the last three months. 
3) Number of weeks of non-criminal employment in the past three months. 
4) Contact with dependent, partner, family/relatives and friends. 
5) Type of relationship with your children. 
6) Number of days conflict with partner (if any) in the last three months. 
7) Number of days conflict with relatives in the last three months. 
8) Number of days conflict with friends in the last three months. 
 
 
2.7 Data Processing and Analysis 
 
2.7.1 Ethics, Confidentiality and Security 
 
The ROSIE study received ethical approval from the National University of Ireland 
Maynooth. In addition, data protection procedures for the ROSIE study were developed 
according to the Data Protection Act. NUI Maynooth is a fully registered organization with 
the Data Protection Commissioner of Ireland and approval of compliance to their rules were 
sought and gained. 
 
Information was given and an Informed Consent Form was obtained from each client at the 
beginning of the interview. The interviewer explained the meaning, purpose and requirements 
of the study to the client before starting the interview and provided full contact details for the 
ROSIE Project.  
 
Name and contact details of each client were recorded at first visit on a separate sheet. The 
list of names and contact details of all clients were kept separate from the client files and 
access to such a list and combining client numbers was restricted to the Project Manager and 
project administrator. One hard copy of this list was stored in the main project office in NUI 
Maynooth.  
 
Hard copies of client files were stored in the main project office at NUI Maynooth. Access to 
this office and to the computers allocated to the project was permitted only to authorized 
personnel. The electronic copy of the client file was stored on a secure server connected by 
internal network to the relevant terminals. Access to the network was password protected.  
A backup system was in place involving regular back-up of the data. All details of the original 
data management plan for the ROSIE study are with the NACD. 
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2.7.2 Data Management 
 
A written and electronic file for every client participating in the study was kept. This file 
contains the interviewing questionnaire and any available demographic and medical 
information of a client.  A randomized list of client numbers was generated and a unique 
random number was assigned to each client file. All documents contained a client number and 
a treatment site number and were filed by client number. The Project Manager or 
administrator ensured that the confidential details of each client were removed from the file 
and stored safely in the project office and that the questionnaire and any other documents 
contained no mention of any client names. 
 
Data collectors entered the information required by the protocol in the printed questionnaire 
during the interview with the client. Interviews were held at treatment sites. If such locations 
were not suitable, an agreement was made between the client and the data collector for a more 
suitable meeting location. Details of interviewing time and location were recorded on the 
appropriate forms and held in the main project office. Interviews would last approximately 
one hour. 
 
After completion of the interviews, the forms were then forwarded to the main project office 
where the appropriate research assistants checked accuracy and completeness. Only the 
original copy of the form was available at all times. No copies were ever made of any part of 
the form, once completed.  Data from the forms were entered into the study database using 
single entry with verification. Text items (for example, comments) were entered and checked 
manually against the original form. A codebook was available, which contained all coding 
procedures for data entry. The data management process flowchart is displayed in Figure 2.2. 
  
Figure 2.2 The data management process flowchart 
 
 
Study
Protocol
DMP
SAP
Data Management
Activities*
Programming Validating & Testing
Database 
Release
Draft Tables 
&
 Statistical Analysis
Review
 Meetings
Final Tables 
&
Stats Report
 
The information entered into the database was systematically checked by the data 
management staff (data collectors, research assistants and Project Manager) using the 
following validation system.  
 
• The number of clients in the datasets was to match the number of unique interviews 
completed or partially completed. 
• Acceptable ranges of values were to be set for appropriate variables and regular 
checks performed. 
• The number of variables and sub-variables entered per client was to match the 
number of questions and sub-questions completed by the same client during 
interview. 
 
If errors occurred after validation, a query form was entered and the Project Manager or Data 
Manager signed details of the error(s) and correction(s).  
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2.7.3 Data Quality Audit 
 
Quality control procedures were put in place to check the following: 
 
• The number of clients in the datasets was to match the number of unique interviews 
completed 
• Acceptable ranges of values were to be set for appropriate variables 
• Appropriate coding of medical and non-medical terms, consistent units of measures 
and interpretation of verbatim data were to be entered and regularly checked 
according to the codebook. 
• The number of variables and sub-variables entered per client was to match the 
number of questions and sub-questions completed by the same client during 
interview. 
 
To check the completeness and correctness of the data, tables and listings were run for a set of 
variables. The methods were 
 
Population size: 
• It was crucial to ensure all data had been entered for all clients. Each client was to 
have one record and one client number. Client numbers were unique. A frequency 
distribution of patient numbers was to be derived and presented on a table to confirm 
that there no clients had the same ID number. 
• The number of questionnaires completed or partially completed and returned to the 
office was to match the number of records entered in the database. 
• The number of patients in the derived datasets was to match the number of unique 
interviews completed for that derived section of the questionnaire. 
 
Missing values:  
• Missing values were to be coded with a uniquely identifying number that could not be 
confused with any other value in the database. The interpretation of missing values 
was to follow the procedures outlined in the codebook and a clear representation of 
missing/not valid/not appropriate values were to be presented in all the tables. 
• The frequency of missing values was to be derived and presented on a table for some 
key variables. Abnormalities in the frequency distribution were to be reviewed and 
presented by the Project Manager in the monthly reports. 
 
Ranges and units of measurement: 
• Acceptable ranges were to be set for appropriate variables (for example, age, visit date 
(applicable to follow-up), dosage for medication, amount of illegal drug taken). 
• Units of measurement were to be coded uniformly (for example, weight in 
fraction/multiple of grams, length of time in fraction/multiple of months and so on).  
 
A quality assurance audit was run on a regular basis following these procedures. 
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2.7.4 Data Analysis 
 
The current report focuses on baseline data. Firstly, data is presented for the study population 
as a whole, and, secondly, for each modality within the appendices. Descriptive statistics 
throughout the results section will include proportion, means and standard deviations for 
various baseline characteristics. When the data is highly skewed, medians are presented.  All 
analysis was conducted using SPSS for Windows, Version 11.0 or 12.0. However, the key 
question of the ROSIE study is ‘Is treatment effective?’ Hence, the null hypothesis of the 
study states that treatment has no effect on outcomes. It is the aim of the study to make a 
decision on whether or not to reject this null hypothesis, hence providing an answer to the key 
question. The outcome results described within this report provide the first part of the data 
required to answer this question. In addition, when answering this question cases with missing 
values were excluded.  
 
2.8 Conclusion 
 
The study design was developed from a consultative, evolving process. An initial outline was 
presented within the original tender brief. This brief was developed further within the tender 
submission. Following the awarding of the tender, a Research Advisory Group (RAG) was 
consulted on an ongoing basis regarding details of the study design. This consultative process 
culminated in the writing of the study protocol by the Principal Investigator and the formal 
acceptance of this protocol by the RAG and the NACD. As the study progressed, any 
deviations from this protocol were presented to the RAG for consideration, advice and 
approval. This process ensured that all interested stakeholders had an input into the design 
and execution of the study.  
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Glossary of Statistical Terms 10 
 
Mean – the average of a collection of values calculated by adding up all the values and dividing by the 
total number of observations. 
 
Median – the value that when the observations are arranged in ascending or descending order of 
magnitude they fall into two equal groups, the middle value is the median.  Thus it can be said that 
50% of the population under study fall above or below a mid-point value. 
 
Standard Deviation – a measure of the average dispersion of values around their central value.  It 
shows how closely the individual values in the distribution are dispersed around the central value.  The 
greater the spread of values in a particular distribution, the greater the value of the standard deviation. 
 
Normal distribution - a continuous probability distribution that is bell shaped and symmetric, with 
different distributions distinguished by their mean and standard deviation. 
 
Skewed medians - A distribution is skewed if the right side of the histogram (containing the half of the 
observations with larger values) extends much farther out than the left or if the left side of the 
histogram extends much farther out than the right. 
 
Descriptive statistics - Methods for organizing and summarizing statistics. 
 
Statistical significance- An observed effect so large that it would rarely occur by chance is called 
statistically significant. 
 
T-tests-  
One sample: Suppose that a simple random sample of size n is drawn from a normal population with 
mean µ and standard deviation σ. Then the one-sample statistic 
ns
xt
/
µ−= , where s is the sample 
standard deviation and x is the sample mean, has the t-distribution with n-1 degrees of freedom. 
 
Two sample: Suppose that a simple random sample of size n1 is drawn from a normal population with 
unknown mean µ1 and that an independent simple random sample of size n2 is drawn from another 
normal population with unknown mean µ2. To test the hypothesis µ1=µ2, compute the two sample t-
statistic 
2
2
21
2
1
21
// nsns
xxt
+
−=   and use critical values for the t-distribution, where the degrees of 
freedom are the minimum of n1-1 and n2-1. 
 
Chi square- a measure of how far the observed counts in a two-way table are from the expected 
counts. 
 
ANOVA (analysis of variance) - tests whether several populations have the same mean by comparing 
how far apart the sample means are with how much variation there is within the samples. 
                                                 
10 Daly, L.E., Bourke, G.J., McGilvray, J.  1992 4th Ed .  Interpretation and Uses of Medical Statistics.  Oxford. 
ISBN 0-632-02911-0 
 
Moore, D. S. 2004 3rd Edition. The Basic Practice of Statistics. W.H. Freeman and Company. ISBN 0-7167-9623-
6. 
 
Moore, D. S. and McCabe, G.P. 2003 4th Edition. Introduction to the Practice of Statistics. W.H. Freeman and 
Company. ISBN 0-7167-9657-0. 
 
Peck, R., Olsen, C., Devore, J. 2005 2nd Ed. Introduction to Statistics and Data Analysis. Brooks/Cole. ISBN 0-
534-46710-5. 
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CHAPTER 3: RESULTS FOR THE STUDY POPULATION AT BASELINE 
 
Background to Treatment 
 
3. 1 Index Treatment  
 
Within this chapter and the appendices, the results are first provided on the lifetime 
experiences of the cohort followed by results of outcome measures at baseline. The order of 
the results is in line with the measures discussed in Chapter Two, Section 2.6.3. It is these 
outcome measures that will be followed up and reported on at six, twelve and thirty six 
months and will be used to evaluate treatment within modality. Table 3.1(a) shows that one 
quarter of the cohort were female (n=102). This male to female gender ratio of 3:1 is reflective 
of the overall treatment population. The mean age for study participants was 27.9 years 
(median 27) for male participants and 27.6 years (median 25.5) for female participants. 
 
Baseline study recruitment was carried out across the three main treatment options available 
to opiate users in Ireland; methadone programmes, structured detoxification programmes and 
abstinence-based treatment programmes. In addition, a sample of individuals was recruited 
within needle-exchanges throughout the city. Chapter two provides details and definitions for 
these modalities. Table 3.1(b) illustrates that over half the cohort of opiate users were 
recruited from methadone programmes, one fifth were commencing a structured 
detoxification programme, an additional 20% were in drug free treatment and 6% were 
attending needle-exchanges. 
 
Opiate users were also recruited across a range of treatment settings. As illustrated in Table 
3.1(b), over one quarter of the cohort were recruited from in-patient settings including nine 
residential drug treatment programmes (n=70) and three detoxification programmes (n=45). 
Over half the cohort were recruited from out-patient settings. More specifically, four drug-
free day programmes (n=12), two detoxification programmes (n=22), ten community-based 
clinics (n=65), sixteen health board clinics (n=117) and thirty GP’s, prescribing under the 
methadone protocol (n=54). Finally, 5% of the cohort was recruited in a prison setting (n=19) 
for both the methadone and detoxification modality. 
 
 
  Table 3.1(a) Gender and Age of Study Population 
 
  n % 
 Gender  
 Male 302 74.8 
 Female 102 25.2 
 
 Mean (sd) Median 
Age    
 Age of  male study participants (years) 27.9(6.1) 27.0 
 Age of  female study participants (years) 27.6(6.7) 25.5 
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Table 3.1(b) Treatment Modality and Setting for the Study Population 
 
  n % 
 Treatment Modality   
 Methadone programmes 215 53.2 
 Detoxification programmes 81 20.0 
 Abstinence-based programmes 82 20.3 
 a Needle-exchange 26 6.4 
 Treatment Setting   
 In-patient treatment 115 28.5 
 Out-patient treatment 270 66.8 
 Prison based treatment 19 4.7 
  a Attendance at needle exchange is not considered treatment. 
Table 3.1(c) illustrates that average length of time opiate users were in their index treatment 
at baseline interview was 26.9 days (median 21 days). Not all respondents reported having to 
wait for treatment (39.3%, n=154). However, looking at the sub-sample of those who waited 
(60.7%, n=238), the average lengths of time participants spent waiting for entry into their index 
treatment was 14.7 weeks (median 6 weeks). However, the majority of participants (86%, 
n=338) stated that they were receiving the type of treatment they wanted, with 10% (n=41) 
explicitly stating they had wanted another type of treatment to that they were commencing. 
 
Table 3.1(c) Time in Index Treatment at Baseline and Time Waiting for Treatment 
 
 Mean (sd) Median 
 a Time in baseline treatment (days)           26.9 ( 19.4) 21 
 b Length of time waiting for treatment (weeks) 14.7(21.3) 6 
           a Excluding individuals in needle-exchange and participants on methadone in prison  
as all were not new to index treatment. 
                        b Includes only  those on waiting lists for treatment. 
 
3.2 Treatment History 
 
Treatment history variables for the study population are provided in Table 3.2(a). This shows 
the majority of study participants (87.3%) engaged in some form of formal treatment prior to 
commencing their index treatment. Here, formal treatment excludes self-detoxification (in 
both the community and prison) and needle-exchange attendance, that is, only 12.7% of 
ROSIE study participants were engaging in treatment for the first time.  
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Table 3.2(a) Treatment History at Baseline: Previous Treatment Received 
 
 n % 
 Percentage in previous treatment   
 Previous treatment received 352 87.3 
 No previous treatment received 51 12.7 
 
 n % 
 a Previous types of formal treatment   
 One-to-one counselling 243 69.6 
 Prescribed methadone 236 67.4 
 Structured/supervised detoxification 205 59.2 
 Residential drug treatment 127 36.6 
 b Needle exchange 229 65.2 
   a These categories are not mutually exclusive. Percentages are for those who previously  
      attended treatment 
  b Attendance at needle-exchange is not considered ‘treatment’.  
 
From Table 3.2(b), the analysis indicates that the cohort first sought formal treatment for 
their drug use at an average of 21 years (median 20 years). With the average age of first heroin 
use being 18 years, the population had been using heroin for an average of 3 years before 
seeking treatment for the first time. The average age participants first received methadone 
treatment was 22 years (median 20 years) with respondents reporting an average of two 
previous episodes of methadone treatment. Individuals were on average 23 years (median 22 
years) when they first entered residential treatment, with respondents reporting an average of 
two such treatment episodes. The average age respondents first attended needle-exchange was 
21 years, with 16% presented before the age of 17 years and 46% before 20 years. In addition, 
the duration of the time from first opiate use prior to first entering treatment was computed (n 
= 332), where relevant, and found to have a mean of 3.7 ( 3.9) years. 
 
  Table 3.2(b) Details of Previous Treatment  
 
  Mean (sd) Median 
 Age first sought treatment (years) 21.3 (5.5) 20 
 Age first attending counselling (years) 21.9 (5.6) 21 
 Number of counsellors 2.9 (2.8) 2 
 Longest period of regular attendance (months) 11.0 (14.3) 6 
 Age first on methadone/physeptone (years) 22.1 (5.7) 20 
 Number of episodes 2.2 (2.0) 2 
 Longest period of attendance (months) 29.4 (33.0) 24 
 Age first on supervised detoxification (years)  22.5 (5.2) 22 
 Number of episodes 2.4 (2.4) 2 
 Age first in residential treatment (years) 23.2 (5.1) 22 
 Number of episodes 2.0 (1.7) 1 
 
 
Having analysed the treatment history of the cohort we look now at the lifetime experiences 
of the participants. 
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Lifetime Measures 
 
3.3  Substance use 
 
Table 3.3(a) illustrates that the vast majority of study participants reported lifetime use of 
heroin. The overwhelming majority of participants also reported lifetime use of cannabis 
(97%), tobacco (95%), alcohol (93%), cocaine (92%) and ecstasy (90%).  
 
In addition, Table 3.3(a) illustrates that high proportions of respondents reported lifetime use 
of 11benzodiazepines (87%), 12 Non-prescribed methadone (86%) and amphetamines (80%). Just 
under three quarters of respondents reported having ever used LSD, 64% reported having 
used other opiates (such as DF118 and morphine sulphate tablets) and 58% of participants 
reported lifetime use of crack cocaine. 
 
   Table 3.3(a) Drug Using History: Ever Used 
  
  n % 
 Drugs ever used   
 Heroin 398 98.8 
 Cannabis 375 96.9 
 Tobacco 379 95.2 
 Alcohol 352 92.9 
 Cocaine 348 91.8 
 Ecstasy 314 90.5 
 a Benzodiazepines 324 87.1 
 Non-Prescribed Methadone  335 85.9 
 Amphetamine 278 80.3 
 LSD 237 72.9 
 Other opiates 232 64.1 
 Crack 212 58.4 
a benzodiazepine use refers to both the non-prescribed use of the drug and the misuse of   
prescribed   benzodiazepines. 
 
Table 3.3(b) reveals that, on average, the smokers in the population first started smoking 
tobacco at 13 years. The average age for first use of alcohol and cannabis was 14 years. 
Participants reported that, on average, they first began using heroin and benzodiazepines at 18 
years. The mean age participants reported first using cocaine and methadone was 20 years and 
the mean age of first crack cocaine use was 23 years. 
 
                                                 
11 Throughout the document, ‘benzodiazepine use’ refers to both the non-prescribed use of the drug and 
the misuse of prescribed benzodiazepines.  
12 At baseline, individuals were asked about their non-prescribed methadone use.  
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Table 3.3(b) Drug Using History: Age First Used 
 
  Mean (sd) Median 
 Age first smoked tobacco (years) 13.2 (3.2) 13 
 Age first used alcohol (years) 13.7 (2.3) 14 
 Age first used cannabis (years) 14.4 (3.3) 14 
 Age first used LSD (years) 16.3(2.8) 16 
 Age first use amphetamine (years) 17.5 (3.6) 16 
 Age first used ecstasy (years) 17.6 (4.6) 16 
 Age first used heroin (years) 18.3 (4.7) 17 
 aAge first used benzodiazepines 18.6  (5.0) 18 
 Age first used other opiates (years) 19.6 (4.9) 18 
 Age first used cocaine (years) 19.7 (4.5) 18 
 Age first used non-prescribed 
methadone (years) 
20.5 (5.4)  19 
 Age first used crack (years) 22.6 (4.8) 21 
 a benzodiazepine use refers to both the non-prescribed use of the drug and the misuse of   
prescribed   benzodiazepines. 
 
Participants were asked whether they ever considered their use of each type of drug a 
problem. Of those that smoked tobacco, the majority (62%, n=202) considered their smoking a 
problem. Whereas 38% of those who had taken alcohol reported their use as being a problem 
(n=112). Regarding illicit drugs, the majority (92.4%, n=355) of heroin users reported their use 
as being problematic. Table 3.3(c) illustrates that the average age respondents first considered 
their heroin use a problem was 20 years. Respondents were less likely to consider their use of 
other substances as problematic; less than half of those who have ever used benzodiazepines 
(41.5%, n=120), 38% of those who ever used cocaine (n=123), 37% of those who ever used 
ecstasy (n=103), 32% of those who ever used non-prescribed methadone (n=96), 30% of 
cannabis users (n=102), 29% of crack smokers (n=55) and 30% of users of ‘other’ opiates 
(n=60) believed their drug use to be problematic.  
 
In addition, Table 3.3(c) illustrates the average lifetime use of each type of drug for those 
respondents who reported using each substance. For example, it shows that when participants 
were interviewed at treatment intake they had been using heroin on average 9.4 years. On the 
other hand, participants had been using crack cocaine for on average 5.3 years. It should be 
noted that the data above may overestimate participants average lifetime use of drugs, as it is 
calculated on the basis of age first used, rather than age commenced ‘regular’ use. 
 
Table 3.3(c) Drug Using History: Problem Drug Use 
 
  Mean ( sd) Median 
 Age cannabis use became a problem 17.6 ( 5.4) 16 
 Duration since first use of cannabis (years)    13.2(5.9)   
 Age heroin use became a problem  20.3 ( 4.9) 19 
 Duration since first use of heroin (years)    9.4 (5.5)  
 Age benzodiazepine use first became a problem  20.5 (4.5) 20 
 Duration since first use of benzodiazepine(years)     8.8(6.3)  
 Age methadone use first became a problem 22.0 ( 6.0) 20 
 Duration since first use of methadone (years)     7.1(5.0)  
 Age other opiate use first became a problem 20.5 ( 5.9) 19 
 Duration since first use of other opiates (years) 8.9(6.0)  
 Age Cocaine use became a problem 22.0 ( 4.2) 22 
 Duration since first use of cocaine (years) 8.1(5.6)  
 Age crack use became a problem 22.3 ( 4.3) 21 
 Duration since first use of crack  (years) 5.3(4.5)  
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3.4 Health Risk Behaviour 
 
Table 3.4(a), and (b) summarises a number of injecting-related health variables. Analysis 
revealed that the majority of the study population (77%, n=308) reported that they had injected 
a drug. Table 3.4(a) illustrates the average age participants first injected was 20 years. 
Notably, 17% of injectors had intravenously administered a drug before the age of 17 years 
and 44% had done so before the age of 19 years. With participants accessing needle-exchange 
at an average of 21 years, individuals were injecting for seven months, on average, before 
utilising the services of a needle-exchange programme. Table 3.4(a) also shows that of those 
who reported having injected (n=308) the majority stated that they had, at some point in time, 
used another user’s needles/syringes (63%), passed their used needles/syringes to others (53%) 
and shared filters/spoons/flush water (63%). In addition, a high proportion of respondents 
stated that they had reused their own injecting equipment (88%). 
 
  Table 3.4(a) Injecting-Related Health Variables 
 
  n % 
 Percentage injected   
 Ever injected 308 76.6 
 
 a Ever shared injecting equipment   
 Ever used needle after someone 178 62.7 
 Somebody ever used needle after you 152 53.3 
 Ever reused own injecting equipment 250 87.7 
 Ever shared filter/spoons/flush water 179 63.5 
  Mean (sd)  Median 
 ªAge first injected 20.4 (4.7) 19 
    
                                                         aPercentages for those who have ever injected 
 
Table 3.4(b) shows that over half the study population (55%) reported never having had an 
overdose. While 13% of the cohort reported having had one overdose, 7% had more than five 
overdoses in their lifetime.  Analysis also revealed that injectors were significantly more 
likely then non-injectors to report ever having had an overdose (54% vs. 19%, χ21=34.3; p< 
0.001). 
 
  Table 3.4(b) Overdose Rates 
 
  n % 
 Proportion of participants ever overdosed   
 Never overdosed 214 54.7 
 Overdosed once 52 13.3 
 More than 1 but maximum of 3 times 66 16.9 
 More than 3 but maximum of 5 times 30 7.7 
 Overdosed more than 5 times 29 7.4 
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3.5 Physical and Psychological Health 
 
Table 3.5(a) presents the data for lifetime experiences of suicidal thoughts of the cohort. 
Analysis revealed that one third of the respondents had attempted suicide in their lifetime and 
over half had thought seriously of committing suicide. 
 
 
  Table 3.5(a) Suicidal Thoughts and Attempts 
 
   
  n % 
 Suicide   
 Seriously thought of ever committing suicide  199 51.6 
 Ever attempted suicide 127 32.8 
 
 
Table 3.5(b) illustrates the HIV, HBV and HCV status of study participants. It illustrates that 
4% of the cohort who had tested for HIV were positive with one fifth having never been 
tested. Similarly, 18% of the population at baseline had never been tested for HCV. Of those 
that were tested (n=305) 50% were reportedly HCV positive. Only 17% (n=20) of the 
participants who self-identified as HCV positive were receiving treatment for their hepatitis.  
 
 
                 Table 3.5(b) HIV, HBV and HCV Status 
 
  HIV Status HBV Status HCV Status 
  n % n % n % 
        
 Ever tested 297 80.3 296 80.4 305 81.6 
 Negative* 231 86.2 233 87.9 122 43.3 
 Positive* 12 4.5 9 3.4 140 49.6 
 Awaiting results* 25 9.3 23 8.7 20 7.1 
                                                         *Of those ever tested 
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3.6 Personal and Social Functioning 
 
Table 3.6(a) summarises a number of educational demographic variables for the study 
population. The majority of participants (59%) left school in lower secondary levels either 
before or just after the Junior Certificate. On average, participants reported leaving school at 
15.1 years. However, analysis revealed that 28% of the study population had left school 
before the age of 15.  
 
Table 3.6(a) Demographics: Education 
 
  Mean ( sd) Median 
 Age left school (years) 15.1( 1.8) 15 
 
  n % 
 Highest Educational Level  
 No formal education 12 3.0 
 Primary 68 16.9 
 Lower secondary 236 58.7 
 Upper secondary 65 16.2 
 Third level 21 5.2 
 Highest Educational Qualification  
 No qualifications 133 32.9 
 Junior cert/basics skills/ NVCA level 1 198 49.0 
 Leaving cert 43 10.6 
 Apprenticeship 5 1.2 
 National cert./dip./NCEA 20 5.0 
 Third level 5 1.2 
 
The majority (56.3%, n=216) of respondents reported having children under the age of 18 
years. These respondents were parents of, in total, 370 children (under 18 years). Table 3.6(b) 
shows that over half (57%, n=122) of the participants who had children did not have their 
children in their care. Just over one fifth of the parents had one child in their care and a 
similar proportion had two or more children in their care.  In addition, eleven female 
participants, and ten males participants (5.6%) reported that they or their partner were 
expecting a baby. 
 
Table 3.6(b) Demographics: Children 
 
  n % 
 Have children under 18 years   
 No 168 43.8 
 Yes  216 56.3 
 Parents: Number  of children in care of participant  
 None 122 57.0 
 One  45 21.0 
 Two or more 47 22.0 
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3.7 Criminal Activity 
 
The vast majority of the study population (90.2%, n=339) reported that they had committed 
some form of crime in their lifetime (excluding drug possession, and traffic related offences). Only 
37 (9.8%) respondents reported not having previously committed crime. Table 3.7(a) 
illustrates the self-reported rates of all individual offences. It illustrates, for example, that over 
half the population (54.8%) reported having ever committed theft from a person with self-
reporting rates of theft from a commercial property higher at 73%. Later in this chapter, 
evidence will be presented showing levels of self-reported recent crime (last three months) 
were substantially lower across all crime categories.   
 
Table 3.7(a) also illustrates the proportions of respondents who reported ever committing the 
main categories of offences. It illustrates that 70% of the population reported having dealt 
drugs in their lifetime. 
 
  Table 3.7(a) Types of Crime Ever Committed 
 
  n % 
 Crime committed   
 Selling/supply drugs 243 70.4 
 Theft from a person 182 54.8 
 Theft from house/home 136 41.0 
 Theft from shop/commercial property 247 72.6 
 Theft from a vehicle 173 52.4 
 Theft of a vehicle 170 51.2 
 Handling stolen goods 262 76.4 
 Fraud/forgery/deception 171 51.4 
 Assault 163 49.7 
 Criminal damage 177 54.3 
 Soliciting 28 8.6 
 Breach of the peace 176 53.7 
 
 
Over three quarters of the cohort (75.6%, n=285) reported having ever been arrested for an 
offence. Table 3.7(b) illustrates the proportion of study participants who were ever arrested 
for each category of offence. For example, 31.4% of respondents were arrested for supplying 
drugs. We shall see presently that only 4% were arrested in the preceding three months for 
this offence. 
Table 3.7(b) Arrests by offence 
 
  Ever arrested 
  n % 
 Crime committed   
 Selling/supply drugs 107 31.4 
 Theft from a person 91 29.6 
 Theft from house/home 61 21.1 
 Theft from shop/commercial property 158 48.0 
 Theft from a vehicle 77 25.3 
 Theft of a vehicle 96 31.5 
 Handling stolen goods 92 27.5 
 Fraud/forgery/deception 52 17.0 
 Assault 104 34.4 
 Criminal damage 114 37.4 
 Soliciting 8 3.1 
 Breach of the peace 133 44.3 
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Finally, Table 3.7(c) illustrates the prison experience of the study population. Sixty five 
percent of participants reported having been in prison (n=253) at some point in time. These 
participants spent on average 41.2 months in custody (SD 50.3 months) and in total account for 
approximately 844 years in prison. A total of 63% of the cohort reported having previously 
been remanded in custody and half the study participants reported having received a custodial 
sentence.  
 
Table 3.7(c) Prison Experience 
 
  n % 
 Imprisonment   
 Ever been in prison 253 64.9 
 Ever remanded in custody 243 62.6 
 Ever received custodial sentence 193 49.7 
 
Having analysed the lifetime experiences of the study participants, we provide below an 
analysis of the baseline outcome measures. It is these outcomes that will be followed up at 
six, twelve and thirty six months. The comparison of the baseline outcome measures with the 
future measures will be used to assist with the evaluation of treatment outcomes.  
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Key Outcome Measures at Baseline 
 
3.8 Substance Use 
 
Tables 3.8(a), (b) and (c) illustrate the current drug use (last 3 months) of the study population 
at baseline interview. The results show that over three quarters of the population (77%) had 
used heroin in the three months prior to interview. Most of the study cohort had smoked 
cigarettes (93%) and high proportions reported recent cannabis (64%) and alcohol (54%) use. 
In addition, rates of cocaine, benzodiazepine and non-prescribed methadone use were 
relatively high with just under half of the respondents reporting consumption in the preceding 
three months. Lower rates of current use of other opiates (10%) and amphetamines (4%) were 
reported.  
 
  Table 3.8(a) Drug Use in Last Three Months: Percentage Used 
 
  n % 
 Drug use in last three months   
 Tobacco 359 93.0 
 Heroin 306 76.9 
 Cannabis 243 64.1 
 Alcohol 204 53.8 
 Cocaine 179 44.3 
 Benzodiazepines  174 44.3 
 Non-Prescribed methadone  162 40.6 
 Crack cocaine 59 14.6 
 Ecstasy 46 12.2 
 Other opiates 39 9.9 
 Amphetamine 17 4.5 
 
Table 3.8(b) illustrates the average number of days on which participants used each 
substance for the population as a whole and for those participants who reported having used 
each class of drug in the three months prior to baseline interview. The results show that 
participants who used tobacco were smoking on average 87.5 out the previous 90 days. 
Heroin users took the drug on an average of 52 days of the last 90, while those who took 
cannabis did so on an average of 61 of the last 90 days. Cocaine use was less frequent with 
those who took the drug doing so on an average of 17 days in the previous three months. 
Analysis also revealed that 95% (n=342) of cigarette smokers were daily consumers and half 
(50%, n=121) of the cannabis users smoked daily. Over one-quarter of those that used heroin in 
the last three months (28%, n=87) and 22.4% (n=39) of benzodiazepine users, were daily 
consumers. Patterns of consumption of other substances were somewhat different. For 
example, only 9% (n=19) of those that consumed alcohol and methadone (10%, n=16) in the 
last three months did so on a daily basis. Substantially lower rates of cocaine use were 
apparent with 2.3% (n=4) of participants who reported using cocaine powder and 3.4% (n=2) 
of those who smoked crack cocaine in the last three months, doing so on a daily basis. 
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Table 3.8(b) Drug Use in Last Three Months:  Mean Days Used 
 
   
Population 
Sub-sample Used in 
Last Three Months 
  Mean sd Mean sd 
 Mean days used in last three months   
 Tobacco 81.4 25.1 87.5 11.9 
 Heroin 40.1 35.8 52.3 32.2 
 Cannabis 39.0 40.1 60.8 34.3 
 Benzodiazepines 15.5 29.1 35.0 35.0 
 Non-Prescribed Methadone  11.6 23.2 28.6 29.0 
 Alcohol 13.3 23.7 24.8 27.5 
 Cocaine 7.6 17.3 17.2 22.7 
 Crack cocaine 2.1 9.9 14.5 22.5 
 Ecstasy 0.7 4.5 5.8 11.8 
 Other opiates 1.9 10.3 19.5 27.5 
 Amphetamine 0.3 3.0 7.2 12.6 
 
 
Table 3.8(c) shows the average amount of each substance consumed on a typical using day 
for the population as a whole and for those participants who used each type of drug in the 
three months prior to interview. On average, 20 cigarettes were smoked a day by those who 
used tobacco. Cannabis users smoked on average 12 joints a day. For those participants who 
used heroin in the three months prior to baseline interview, 0.7 gram was the average amount 
consumed daily. Levels of benzodiazepine use were high; with those reporting use in the last 
three months, taking on average 116.7 mgs a day. Cocaine users reported using an average of 
2.3 grams a day. We should also note that 76% (n=308) of the cohort reported the recent use 
of two or more substances and were therefore engaging in polydrug use.  
 
  Table 3.8(c) Drug Use in Last Three Months: Mean Amount used  
 
   
Population 
Sub-sample 
used in last 3 mts 
  Mean sd Mean sd 
 Mean amount used in a day in last 
three months 
  
 Tobacco (cigarettes) 18.3 13.0 19.6 12.5 
 bHeroin (grams) 0.6 0.8 0.7 0.8 
 Cannabis (joints) 7.7 16.5 12.0 19.1 
 Alcohol (units) 9.1 15.2 16.9 17.0 
 Cocaine (grams) 0.9 2.4 2.3 3.3 
 Non-Prescribed Methadone 
(mls) 
23.3 37.7 58.9 38.6 
 Benzodiazepines (mgs) 41.9 105.5 116.7 149.6 
a Crack Cocaine was excluded due to the inconsistency in how the data was reported. 
bThese figures were based on 1 bag of heroin containing on average 0.25grams at the time of 
fieldwork 
     32 
   
3.9 Health Risk Behaviour 
 
  
 Table 3.9(a) Injecting-Related Health Variables in Last Three Months 
 
 
Analysis revealed that over half of those who have injected did so in the three months prior to 
interview (44.0%, n=177), with these individuals reporting on average 47.3 injecting days over 
the previous three months. Table 3.9(a) shows the levels of recent (last three months) self-
reported injecting risk behaviour. Only 11.8% (n=20) of the injecting population reported 
using needles/syringes after someone else in this time period, 10.2% (n=17) passed their used 
injecting equipment onto others and the same proportion had used filters/spoons/flush water 
that had been used by others. However, a higher proportion of participants reported reusing 
their own injecting equipment (38.6%, n=51).  
  n % 
 Percentage who injected in last three months 177 44.0 
   
 Frequency of injecting in last three months   
 Infrequent (1-9 days) 40 
 Frequent (10 –24 days) 19 
 Very frequent (25-79 days) 65 
 Daily (80-90 days) 46 
 Used needle after someone in last month  
 No times 150 
 One time 11 
 More than once 9 
 Someone used needle after you in last month  
 No times 150 
 One time 9 
 More than once 8 
 
 
23.5 
11.2 
38.2 
27.1 
 
88.2 
6.5 
5.3 
 
89.8 
5.4 
4.8 
Reused own needles in last month    
No times 81 61.4 
One time 2 1.5 
 
 
 More than once 49 37.1 
 Used filter/spoons/flush water/ after someone    
 No times 137 89.0 
 One time 6 3.9 
 More than once 11 7.1 
 
  
  Median 
aDays injected in last three months 47.3 ( 33.8) 49.5 
aTimes injected on typical day last three months 4.0 ( 4.8) 3 
Mean ( sd) 
 a relates to those who have injected in the last three months 
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Table 3.9(b) shows that 6.6% of study participants reported having had an overdose in the 
preceding three months (n=26). 
 
  Table 3.9(b) Overdose Rates in Last Three Months 
 
  n % 
 Overdose in last three months   
 Zero 366 93.4 
 One or more times 26 6.6 
 
 
Table 3.9(c) shows the sexual history of the participants. In the last three months, 83% 
(n=203) were having sex with a regular partner and 33% (n=76) were having sex with 
someone other than a regular partner. With regards to condom use, 37 % (n=23) of those 
having sex with someone other than a regular partner in the last three months stated that they 
never used a condom, while another 17% (n=11) stated that they only use a condom 
sometimes. 
 
Table 3.9(c) Frequency of Unsafe Sex in the Last Three Months 
 
   
          n % 
   Sexual history in last three months   
 Participants having sex 261 68.1 
 Participants not having sex  122 31.9 
 ab Sexual partners in last three months   
 Having sex with a regular partner 203 82.5 
 Having sex with someone other than 
regular partner 
76 33.2 
 bCondom use with regular partner   
 Always used condom 47 24.4 
 Sometimes used condom 19 9.8 
 Never used condom 127 65.8 
 bCondom use with someone other than 
a regular partner 
  
 Always used condom 29 46.0 
 Sometimes used condom 11 17.5 
       Never used condom 23 36.5 
  aThese categories are not mutually exclusive. 
  b This is only of those who had sex in the last three months 
 
 
3.10 Physical and Psychological Health 
 
Participants were asked to assess their own physical health at baseline interview. Figure 3.1 
below shows that just less than half of the respondents (46%, n=180) reported that their health 
was good, an additional 5% (n=19) stated that it was excellent. One third of the study 
population reported their health as being fair (n=132) and 16% felt that it was poor (n=64). 
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Figure 3.1 Participants self assessment of health (n=395)
Excellent
n=19, 5%
Fair
 n=132,
33%
Poor
n=64
16%
Good
n=180
46%
 
In addition to rating their own health, participants were asked to complete a short health 
assessment. Table 3.10(a) and (b) presents the data for a range of physical health symptoms. 
Table 3.10(a) shows the average number of days respondents reported suffering from each 
physical health symptom for the population as a whole and for those participants who 
suffered each category of symptom, over the three months prior to interview. It illustrates 
that, on average, the population reported having a poor appetite 47 of the previous 90 days. 
However, Table 3.10(b) shows that not all respondents reported these symptoms whilst also 
illustrating the number of participants from the study population that reported experiencing 
each physical health symptom.  
 
 
Table 3.10(a) Physical Health Symptoms: Mean Days Experienced in Last Three 
Months 
 
      Population Sub-sample 
 Mean (sd) Mean ( sd) 
Physical health symptoms over previous three months     
 Poor appetite 47.3 (38.6) 66.0 (29.0) 
 Tiredness/fatigue 43.0 (38.5) 60.1 (32.2) 
 Nausea (feeling sick) 14.2 (27.2) 35.6 (33.2) 
 Stomach pains 14.5 (26.6) 36.4 (31.4) 
 Difficulty breathing 13.4 (28.6) 47.4 (35.9) 
 Chest pains 8.2 (21.4) 36.3 (31.6) 
 Joint/bone pains 13.4 (27.7) 37.3 (35.2) 
 Muscle pains 9.8 ( 22.1) 30.0 (29.8) 
 Numbness/tingling 8.5 ( 22.6) 37.7 (34.1) 
 Tremors/shakes 10.2 ( 23.5) 35.4 (32.2) 
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Table 3.10(b) Physical Health Symptoms: Percentages Experienced in Last Three 
Months 
 
  n % 
 Poor appetite in last three months   
 Experienced 269 71.7 
 Didn’t experience 106 28.3 
 Tiredness/fatigue in last three months   
 Experienced 268 71.5 
 Didn’t experience 107 28.5 
 Nausea (feeling sick) in last three months   
 Experienced 148 39.8 
 Didn’t experience 224 60.2 
 Stomach pains in last three months   
 Experienced 148 39.8 
 Didn’t experience 224 60.2 
 Difficulty breathing in last three months   
 Experienced 105 28.2 
 Didn’t experience 267 71.8 
 Chest pains in last three months   
 Experienced 85 22.7 
 Didn’t experience 289 77.3 
 Joint/bone pains in  last three months   
 Experienced 135 36.0 
 Didn’t experience 240 64.0 
 Muscle pains in last three months   
 Experienced 122 32.7 
 Didn’t experience 251 67.3 
 Numbness/tingling in  last three months   
 Experienced 84 22.6 
 Didn’t experience 288 77.4 
 Tremors/shakes in last three months   
 Experienced 105 28.7 
 Didn’t experience 261 71.3 
 
 
Table 3.10 (c) and (d) presents the data for mental health symptoms. Table 3.10(c) shows the 
mean number of days respondents reported suffering from the mental health symptoms for the 
population as a whole and for those participants who suffered from each category of symptom 
over the preceding three months. For example, the study population reported having suicidal 
thoughts on an average of 8 days of the previous 90. However, Table 3.10(d) illustrates that 
the majority of participants (75%) did not have suicidal thoughts. Adjusting the data for this, 
Table 3.10(c) illustrates that those with suicidal thoughts, reported having them on an average 
of 32 days of the previous 90 days. Table 3.10(d) shows that not all respondents reported 
these symptoms and illustrates how many of the study population reported experiencing each 
mental health symptom.  
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Table 3.10(c) Mental Health Symptoms: Mean Days Experienced in Last Three Months 
 
  Population Sub-sample 
  Mean (sd) Mean  (sd) 
 Mental health symptoms over last three months     
 Feeling Tense 36.8 (38.0) 56.4 (33.2) 
 Suddenly scared for no reason 15.5 (29.7) 43.6 (35.5) 
 Feeling fearful 19.6 (31.7) 46.2 (33.8) 
 Nervous/shaking inside 19.8 (32.3) 46.6 (34.7) 
 Spells of terror/panic 9.0 (23.0) 36.8 (33.9) 
 Feeling hopeless about future 29.6 (37.0) 53.1 (34.8) 
 Feelings of worthlessness 28.6 (37.1) 54.1 (35.0) 
 Feeling no interest in things 31.1 (36.7) 54.2 (33.0) 
 Feeling lonely 32.7 (37.8) 57.0 (33.2) 
 Thoughts of ending your life 8.1 (22.3) 31.9 (34.6) 
 
 
Table 3.10(d) Mental Health Symptoms: Percentages Experienced in Last Three Months 
 
  n % 
 Feeling tense in last three months   
 Experienced 234 65.2 
 Didn’t experience 125 34.8 
 Suddenly scared for no reason in last three months   
 Experienced 129 35.6 
 Didn’t experience 233 64.4 
 Feeling fearful in last three months   
 Experienced 149 42.3 
 Didn’t experience 203 57.7 
 Nervousness or shaking inside in last three months   
 Experienced 153 42.6 
 Didn’t experience 206 57.4 
 Spells of terror or panic in lastthree3 months   
 Experienced 90 24.5 
 Didn’t experience 277 75.5 
 Feeling hopeless about the future in last three months 
 Experienced 196 55.8 
 Didn’t experience 155 44.2 
 Feelings of worthlessness in last three months   
 Experienced 188 52.8 
 Didn’t experience 168 47.2 
 Feeling no interest in things in last three months   
 Experienced 206 57.4 
 Didn’t experience 153 42.6 
 Feeling lonely in last three months   
 Experienced 202 57.4 
 Didn’t experience 150 42.6 
 Thoughts of ending you life in last three months 
 Experienced 88 25.4 
 Didn’t experience 259 74.6 
 
 
In addition to the mental health questions above, Table 3.10(e) illustrates that 25% (n=95) of 
respondents reported having suicidal thoughts over the six months prior to baseline interview 
and 10.2% (n=39) attempted suicide in the six months before baseline interview. 
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Table 3.10(e) Suicidal Thoughts and Attempts in Last Six Months 
 
   
  n % 
 Suicide   
 Seriously thought of committing suicide in last six months 95 25.3 
 Attempted suicide in the last six months 39 10.2 
 
 
3.11 Personal and Social Functioning 
 
Table 3.11(a) shows that 53.8% of the participants reported they had not worked in the six 
months prior to baseline interview. One quarter of the cohort reported being in employment 
either full-time or part-time (including CE Schemes) over the same time period. However, 
levels of current employment were substantially lower with 16% of respondents employed at 
the time of baseline interview. The main source of income for the majority of study 
participants (77%) was social welfare payments (including disability). One quarter of 
respondents reported drug dealing as a main source of income over the preceding three 
months. In addition, involvement in ‘other’ crime was cited by 36% of respondents. Twenty 
eight percent of participants stated that ‘family’ provided a source of income. 
 
  Table 3.11(a) Recent Employment and Income Status  
 
  n % 
 Occupation over last six months  
 Not working 211 53.8 
 Working (FT/PT) 99 25.3 
 In prison 41 10.5 
 Disability 36 9.2 
 In treatment 5 1.3 
 aRecent employment  
 Employed last 3 months 84 21.3 
 Currently employed 64 16.0 
 aMain sources of income in  last three months  
 Wage/salary 83 20.9 
 Family/friends 113 28.3 
 Social welfare 309 77.4 
 Drug dealing 101 25.3 
 Other crime 142 35.7 
  aThese categories are not mutually exclusive. 
 
Table 3.11(b) shows that just less than one third of the cohort reported living in the family 
home and 25% reported living in their own or rented house/flat at baseline interview. At 
recruitment, 29% of participants were in a drug treatment residence and 5% were in prison. 
Recognising the transient nature of accommodation for many problem drug users, participants 
were asked to identify everywhere they had stayed in the preceding three months. This 
analysis revealed higher levels of imprisonment and homelessness among the study 
population with 12% (n=49) of the cohort reported having spent some time in prison and 18% 
(n=70) reported having a period of homelessness over the three months prior to baseline 
interview. This included participants who reported staying in a hostel/B&B, and those who 
reported having no fixed abode.  
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At baseline, 38% of participants reported that they usually lived with their parents and an 
additional 4% were living with their parents and their children. Nineteen percent of 
participants reported usually living with their partner, over half of these were also living with 
their children resulting in a total of 24% (n=93) of the study population reporting living with 
their children. Twelve percent of respondents reported living alone and 19% reported ‘other’, 
which included participants who were in prison (n=19), participants who were living with 
friends (n=11) and participants in residential treatment (n=20). 
 
  Table 3.11(b) Recent Accommodation Status  
 
  n % 
 Current accommodation   
 Family home 118 29.7 
 Drug treatment residence 115 29.0 
 Own house/flat or rental 101 25.4 
 Hostel/shelter/B&B 24 6.0 
 Prison 19 4.8 
 Home of friends 11 2.8 
 No Fixed Abode 9 2.3 
 ªAccommodation over last three months   
 Family home 182 46.8 
 Drug treatment residence 120 30.2 
 Own house/flat or rental 134 33.8 
 Hostel/shelter/B&B 45 11.4 
 Prison 49 12.4 
 Home of friends 40 10.2 
 No Fixed Abode 25 6.3 
 Usually lives with   
 Partner/spouse 30 7.6 
 Parents 148 37.7 
 Alone 47 12.0 
 b Children 32 8.1 
 b Parents and children 17 4.3 
 b Partner and children 44 11.2 
 Other 75 19.1 
ªThese categories are not mutually exclusive. 
b Includes children over the age of 18 years. 
 
We saw earlier the treatment history of the respondents. In terms of recent treatment, Table 
3.11(c) illustrates the proportions of participants who commenced any formal treatment in the 
6 months prior to starting their index treatment for the ROSIE study. 
 
 
 Table 3.11(c) Treatment Over Last Six Months: Previously Treated Cohort  
 
 n % 
 Treatment in last six months   
 Structured/supervised detoxification  45 13.3 
 One-to-one counselling 44 13.2 
 Group work 30 9.0 
 Residential drug treatment 20 5.9 
 Prescribed methadone 18 5.6 
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The number of times participants attended services for medical treatment is outlined in Table 
3.11(d) and the mean number of times they attended these services is outlined in Table 
3.11(e). The mean number of days spent overnight in hospital in the last three months was 6.3 
(8.7), while the mean number of visits to an Accident and Emergency department was 1.3 
(0.8). 
 
Table 3.11(d) Treatment Received for a Medical Condition in the Last Three Months 
 
 n % 
 Treatment received in last three months   
 Attended hospital and stayed overnight 34 8.7 
 Attended an A&E 67 17.4 
 Visited a GP (not methadone G.P.)  124 33.6 
 Visited an out-patient department 
/received community treatment  
49 12.7 
 
 
Table 3.11(e) Mean Number of Times in Treatment for a Medical Condition in the Last 
Three Months 
 
  Mean ( sd) Median 
 aNumber of times attended service    
 Number of days overnight stay in hospital  6.3 ( 8.7) 2.25 
 Number of visits to A&E 1.3 ( 0.8) 1.0 
 Number of visits to a GP (not methadone G.P.)  3.7 ( 4.1) 2.0 
 Numbers of visits for out-patient 
appointment/community treatment  
4.2 ( 7.4) 1.0 
 a Of those who attended these services in the last three months 
 
 
In Table 3.11(f), the mean number of days contact participants had with a partner, if relevant, 
mother, father, siblings and friends is displayed. This table also illustrates the mean number of 
days conflict participants had with each of these people.  
 
Table 3.11(f) Frequency of Contact and Conflict with Partner, Family/Relatives and 
Friends (Days)   
  
  Mean (sd) Median 
 Number of days contact in last three months  
with  
  
 Partner 75.5 (26.4) 90 
 Mother 54.1 (37.5) 69 
 Father 43.4 (39.6) 36 
 Siblings 44.9 (39.1) 36 
 Friends  41.6 (39.1) 31.25 
    
 Number of days conflict in last three months 
with 
  
 Partner 10.1 (21.6) 0.5 
 Mother 8.2 (19.9) 0.0 
 Father 8.2 ( 20.8) 0 
 Siblings 5.2 ( 18.1) 0 
 Friends  2.0 ( 9.4) 0 
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Table 3.11(g) illustrates the self-reported quality of parent’s relationships with their children. 
We can see that the over half of the participants, who were parents, (56.9%) reported their 
relationship as very good while 11% reported their relationship as very poor.  
  
  Table 3.11(g) Quality of Relationship with Children 
 
  
 n        % 
 Type of relationship with children   
 Very good              119 56.9 
 Good               41 19.6 
 Okay/alright               19 9.1 
 Poor                 7 3.3 
 Very poor               23 11.0 
 
  
3.12 Criminal Activity 
 
Table 3.12(a) illustrates the self-reported rates of all individual offences. Comparing Table 
3.12(a) with Table 3.7(a), it is apparent levels of self-reported recent crime (last three months) 
were substantially lower than lifetime measures across all crime categories.   
 
Table 3.12 (a) also illustrates the proportions of respondents who reported committing the 
main categories of offences in the three months prior to baseline interview. It illustrates that 
30% of the respondents reported having dealt drugs in the 3 months prior to the baseline 
interview. 
 
 
  Table 3.12(a) Crimes Committed in the Last Three Months 
 
  n % 
 Crime committed   
 Selling/supply drugs 109 30.0 
 Theft from a person 39 10.8 
 Theft from house/home 23 6.3 
 Theft from shop/commercial property 63 17.5 
 Theft from a vehicle 22 6.1 
 Theft of a vehicle 22 6.0 
 Handling stolen goods 91 25.3 
 Fraud/forgery/deception 40 11.2 
 Assault 29 8.1 
 Criminal damage 26 7.2 
 Soliciting 14 3.9 
 Breach of the peace 24 6.7 
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Table 3.12(b) presents the mean number of self-reported crimes committed in the last three 
months for the population as a whole and for the sub-sample of participants who reported 
having ever committed each category of offences. For example, it illustrates that the 
population reported dealing drugs on an average of 12 days of the previous 90. However, as 
illustrated above, 30% of the cohort reported dealing in the previous three months doing so on 
average 46 days of the previous 90. Similarly, the 14 individuals who reported soliciting did 
so on average 50 out of the last 90 days.  
 
 
Table 3.12(b) Mean Days Crimes Committed in Last Three Months 
  
  Population  Sub-sample  
committed last  
three months 
  Mean (sd) Mean (sd) 
 Frequency of crime in last three months     
 Selling/supply drugs 12.4 (26.3) 45.7 (32.3) 
 Theft from a person 0.9 (6.2) 9.7 (18.7) 
 Theft from house/home 0.5 (4.4) 10.7 (17.2) 
 Theft from shop/commercial property 5.0 (22.6) 32.6 (49.4) 
 Theft from a vehicle 0.4 (4.0) 8.2 (16.1) 
 Theft of a vehicle 0.1 (0.7) 2.5 (1.7) 
 Handling stolen goods 5.9 (23.2) 26.7 (43.5) 
 Fraud/forgery/deception 1.8 (9.6) 17.7 (25.7) 
 Assault 0.1 (0.7) 1.9 (1.9) 
 Criminal damage 0.3 (1.9) 4.0 (6.8) 
 Soliciting 1.9 (12.0) 50.1 (37.7) 
 Breach of the peace 0.3 (2.9) 7.3 (13.4) 
 
 
We saw earlier that over three quarters of the cohort (75.6%, n=285) reported having ever been 
arrested for an offence and now we see that 18.3% (n= 69) reported having been arrested in 
the three months prior to baseline interview. Table 3.12(c) illustrates the proportion of study 
participants arrested over the three months prior to baseline interview. For example, it 
illustrates that although we saw previously that 31% of respondents were arrested for drug 
supply, only  4% were arrested in the preceding three months for this offence. 
 
 
  Table 3.12(c) Arrests by Offence in Last Three Months 
 
  n % 
 Crime committed   
 Selling/supply drugs 14 4.1 
 Theft from a person 7 2.3 
 Theft from house/home 4 1.3 
 Theft from shop/commercial property 20 6.2 
 Theft from a vehicle 2 0.6 
 Theft of a vehicle 4 1.3 
 Handling stolen goods 9 2.7 
 Fraud/forgery/deception 4 1.3 
 Assault 8 2.6 
 Criminal damage 11 3.6 
 Soliciting 3 1.1 
 Breach of the peace 11 3.6 
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Finally, at baseline interview participants were asked whether they had any legal problems. 
Table 3.12(d) illustrates that just over half the cohort reported having no legal issues (to their 
knowledge). However, 10% were serving a probation or community service order at the time 
of interview. In addition, over one fifth of participants were on bail, either awaiting a trial or 
sentencing.  
 
Table 3.12(d) Current Legal Status 
 
  n % 
 aCurrent legal problem   
 None 199 51.6 
 On probation/community service 37 9.8 
 Serving a sentence in prison 20 5.3 
 On bail – awaiting trial/hearing 60 16.0 
 On bail – awaiting sentencing 24 6.4 
 On temporary release 10 2.7 
 Outstanding warrants 46 12.2 
 Outstanding fines 22 5.9 
a Categories are not mutually exclusive. 
 
In this chapter, we have documented in detail the cross sectional results of the cohort of opiate 
users recruited to the ROSIE study. They provide a comprehensive and detailed snapshot of 
such users entering treatment in a single year. In the following chapter, we discuss these 
results in an international comparative context and we also discuss the implications these 
results have for policy makers. However, it is the results of the outcome variables at one and 
subsequent years that will provide some evidence towards the measurement of effectiveness 
in Ireland of treatment for opiate use. 
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CHAPTER 4: CONCLUSION 
 
4.1 Introduction 
 
The primary aim of the ROSIE study is to evaluate treatment for opiate use in Ireland. This 
report on population characteristics and outcome measures at treatment intake provides the 
first step in that evaluation. Within this short chapter, we highlight and summarise the key 
information on outcome variables at baseline and provide a brief discussion of the results in 
an international context, we reiterate the hypothesis being tested and methodological 
challenges faced and we conclude by providing a statement on future research needs. 
 
4.2 Summary of Key Outcome Measures at Baseline 
 
Key outcome variables are measured across five domains, substance use, health risk 
behaviour, physical and mental health, personal and social functioning and crime.  
 
We found that with regard to the outcome variable current drug use, over three quarters of the 
study population had used heroin in the three months prior to interview. These participants 
reported using the drug on an average of 52 of the previous 90 days and consumed on average 
0.7 grams of heroin a day. Forty-two percent of the study population (n=170), or over half of 
those that ever injected (56%), reported having done so in the three months prior to baseline 
interview. These individuals reported injecting on average 47 of the previous 90 days, with 
15% of the recent injectors (n=46) having done so on a daily basis. In terms of physical and 
mental health, participants reported suffering from a range of physical and metal health 
complaints to varying degrees. For example, 72% (n=269) of the population reported suffering 
from a poor appetite over the three months prior to interview. These respondents reported this 
symptom on average 66 days out of the previous 90.  
 
Analysis revealed that current levels of employment were low, with only 16% of the 
population employed (either full-time or part-time) at baseline interview, while 21% had been 
employed over the three months prior to baseline interview. The main source of income for 
the majority of participants (77%) was social welfare payments. Less than one third of the 
cohort were living in the family home at the time of the baseline interview and 25% were in 
their own or rented accommodation. Eight percent of the study population were homeless at 
baseline interview, where homeless was defined as having no fixed abode or being resident in 
a hostel, shelter or B&B. 
 
Finally, in terms of crime outcomes, we found that in the three months prior to baseline 
interview 30% (n=109) reported having dealt drugs during that time period. In addition, 18% 
(n=69) reported being arrested in the three months preceding baseline interview. Although 
levels of recent arrest were relatively low, almost half the cohort reported having legal 
problems at the time of treatment intake (48%, n=219). 
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4.3 ROSIE in an International Context 
 
While the vast majority of study participants were opiate users and reported problematic 
heroin use, polydrug use was usual among the cohort, with 76% (n=308) reporting the recent 
use of two or more substances. This is comparable to the rates of polydrug use (81%) reported 
in NTORS13. A relatively high proportion of ROSIE study participants reported recent (last 90 
days) cocaine use (44%, n=179). This was substantially higher than the proportions reporting 
recent cocaine use in the DORIS14 study, where only 27% of the cohort reported using the 
drug over the same time period at treatment intake15. While 59% of the NTORS cohort 
reported recent stimulant use, only 18% had used powder cocaine. However, 35% reported 
recent crack cocaine use, compared with only 14% of the ROSIE cohort (n=48). Over half the 
cohort (54%, n=204) reported recent alcohol use, which was markedly less than the 68% in the 
NTORS sample who reported drinking alcohol during the three months prior to treatment. But 
as with NTORS, the exploratory analysis of the data suggests that drinking patterns among 
ROSIE participants tend to be dichotomous, with relatively high proportions of non-drinkers 
(46%) and heavy drinkers (42%).  
 
In the three months prior to interview, we saw that ROSIE study participants reported 
suffering from a range of physical and mental health problems. In addition, one quarter of the 
population reported having thoughts of suicide in the six months prior to treatment intake, 
slightly less then the 29% reported in NTORS5. One-third of the cohort reported having 
attempted suicide in the past, and 10% (n=39) attempted suicide in the 6 months prior to 
baseline interview. Such findings are relevant to the elevated death rates among drug addicts 
and should be taken into account when interpreting death rates among addicts. 
 
The analysis of the ROSIE baseline data highlights that Irish treatment services are facing 
broadly the same challenges identified in many countries, namely high levels of poly-drug use 
(including cocaine, benzodiazepines, alcohol and cannabis), frequent though often petty crime, 
frequent low-level drug-dealing, a high incidence of somatic and mental health problems and 
extensive histories of contact with a range of agencies and treatment services.   
 
 
4.4 Key Question and Hypothesis 
 
The key question of the ROSIE study is ‘Is treatment effective?’ Hence, the null hypothesis of 
the study is that treatment has no effect on outcomes. It is the aim of the study to make a 
decision on whether or not to reject this null hypothesis and hence provide an answer to the 
key question. The outcome variables described within this report provide the first part of the 
data required to answer this question. The hypothesis itself will be tested when results at six, 
twelve and thirty six months are available.  However, while the question and hypothesis are 
easy to pose, we may see in future reports that these are not easy to answer. As we have seen 
within this report, there are considerable differences at treatment intake in the profile of 
clients entering different treatment modalities. This results in different patterns of behaviour 
change over the six, twelve and thirty six month follow-ups, not only in terms of changes 
from baseline but also within and between modalities. If over the follow-up period clients also 
have different patterns of utilisation of their index treatment and differing degrees of contact 
with other agencies, then interpretation of treatment outcomes and the decision on how best to 
answer our key question will be very complex. Given the cyclical, often relapsing pattern that 
characterises the lives of many opiate users and given the extensive and overlapping histories 
of other treatments and agency contacts, it is likely to be difficult to draw clear conclusions 
                                                 
13 http://www.dtors.org.uk/NTORS.aspx 
14 http://www.gla.ac.uk/drugmisuse/DORIS.html 
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regarding the effectiveness of one modality compared to another and the key question may 
change to ‘What factors are associated with ‘successful outcomes’?’  
 
 
4.5 Future Research 
 
As we have said earlier, this baseline report presents a detailed snapshot of opiate users 
entering treatment in Ireland but this is just the first step in the projects’ key aim of opiate 
drug treatment evaluation in Ireland. In order to realise this aim, we have shown within the 
methodology section that there are a range of key outcome variables across the five domains 
of drug use, crime, health, risk and social functioning. Variables within these five domains 
will be measured again and compared with the baseline measures provided in this report. The 
hypothesis will be revisited, clarified and tested and evidence towards a conclusive answer to 
the key question will be sought from observations in how these variables have changed.   
 
Finally, the remit of the design for the ROSIE study is to measure outcomes at six, twelve and 
thirty six months and compare these outcomes with the baseline observations. However, 
future research, as indicated previously, may wish to model outcomes in a more 
comprehensive way by addressing questions on which factors, whether personal, programme 
or process, are associated with successful outcomes. It is anticipated that future publications 
from the ROSIE team will address these questions and that these results along with the 
ROSIE Findings Series 1,2,3 and 4 on outcomes will give service providers and policymakers 
the necessary evidence to make informed decisions for all opiate users and their communities.   
 
Finally, the data presented in this report provides a wealth of information on opiate users 
presenting for treatment in Ireland. The results presented here provide, for the first time, a 
depth and breadth of information to assist services providers, policy makers and researchers 
involved in the planning and implementing of drug service provision throughout the country.  
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APPENDIX 1: RESULTS FOR METHADONE GROUP AT BASELINE 
 
Background to Treatment  
 
a1. 1 Index Treatment  
 
Over half of the ROSIE study population (53%, n=215) were recruited from methadone 
programmes throughout the country. In Ireland, methadone is provided in the three main 
settings of health board clinics (including satellite clinics), community-based clinics and 
General Practitioner surgeries. In addition, individuals in certain prisons in the State are 
eligible to receive methadone maintenance. Study participants were recruited across all these 
four settings16. To this end, 48 individuals were interviewed in ten community-based clinics 
in Dublin City, 108 individuals were recruited from 16 health board clinics throughout the 
country, 54 participants were recruited from 31 GP’s prescribing under the Methadone 
Protocol and 5 participants were interviewed in prison. This index presents data on the 
methadone group as a whole, while the next index examines differences within the methadone 
cohort, across setting. 
 
Table a1.1 (a) Gender and Age of Methadone Group 
 
  n % 
 Gender  
 Male 147 68.4 
 Female 68 31.6 
    
  Mean Median 
 Age  
 Age of  male study participants (years) 28.5(6.5) 28.0 
 Age of  female study participants (years) 28.4(6.8) 27.0 
 
Table a1.1 (b) Time in Index Treatment and Time Waiting for Treatment 
 
 Mean (sd) 
 aTime in baseline treatment (days)           30.1(22.1) 
 bLength of time waiting for treatment (weeks) 20.4 (27.0) 
a Excluding participants on methadone in prison, as all were not new to index treatment. 
                         b Includes only those on waiting lists for treatment. 
 
 
 
 
 
 
 
                                                 
16 Accessing prisons in Ireland, for both baseline study recruitment and subsequent follow-up 
interview, involved a lengthy process of obtaining ethical approval from the Irish Prison Service, 
gaining security clearance for fieldworkers and negotiating access with individual prison governors. 
Consequently, recruitment in this setting did not commence until June 2004. Unfortunately, at this time 
there was a doctors’ strike in the prisons and as a result new inmates were not placed on methadone 
programmes. As access had already been negotiated, the fieldworkers went into Mountjoy Prison and 
interviewed five people on methadone. However, these inmates were not ‘new to treatment’. The 
decision was made not to return to the prison setting until the strike was resolved, which did not occur 
before the end of baseline study recruitment. 
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a1.2 Treatment History 
 
Table a1.2(a) Treatment History for Methadone Group: Previous Treatment Received  
 
 n % 
 Percentage in previous treatment   
 Previous treatment received 177 82.7 
 No previous treatment received 37 17.3 
    
  
Population 
Sub-sample 
previously treated 
 n % n % 
 aPrevious types of formal treatment     
 One-to-one counselling 113 53.1 113 64.2 
 Prescribed methadone 123 57.7 123 69.9 
 Structured/supervised detoxification 91 43.1 91 52.3 
 Residential drug treatment 46 21.8 46 26.4 
 bNeedle exchange 128 61.0 112 63.6 
aThese categories are not mutually exclusive.  
 bAttendance at needle-exchange is not considered treatment. 
 
Table a1.2(b) Details of Previous Treatment 
 
  Previously treated 
  Mean (sd)  
 Age first sought treatment (years) 21.5 (5.5)  
 Age first attended counselling (years) 22.5 (6.2)  
 Number of counsellors 2.0 (1.5)  
 Longest period of regular attendance (months) 10.5 (12.9)  
 Age first on methadone/physeptone (years) 22.4 (6.1)  
 Number of episodes 2.2 (2.3)  
 Longest period of attendance (months) 25.0 (24.2)  
 Age first on supervised detoxification (years)  22.5 (5.6)  
 Number of episodes 2.4 (3.1)  
 Age first in residential treatment (years) 23.5 (5.8)  
 Number of episodes 1.8 (2.0)  
 
a1.3 Substance Use 
  
Table a1.3(a) Drug Using History: Ever Used 
 
  n % 
 Drugs ever used   
 Heroin 213 99.1 
 Tobacco 205 97.2 
 Cannabis 195 96.5 
 Alcohol 183 92.9 
 Cocaine 178 90.8 
 Non-Prescribed methadone  183 87.6 
 Benzodiazepines 166 85.6 
 Ecstasy 158 90.8 
 Amphetamine 134 77.5 
 Other opiates 125 67.9 
 LSD 110 66.7 
 Crack cocaine 110 60.1 
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Table a1.3(b) Drug Using History: Age First Used 
 
  Mean (sd) 
 Age first smoked tobacco (years) 13.4 (3.0) 
 Age first used alcohol (years) 14.2 ( 2.2) 
 Age first used cannabis (years) 14.6 ( 3.4) 
 Age first used LSD (years) 16.3 ( 3.0) 
 Age first used ecstasy (years) 17.9 ( 4.3) 
 Age first use amphetamine (years) 17.8 (3.5) 
 Age first used heroin (years) 18.7 (5.0) 
 aAge first used benzodiazepines 19.2 (5.5) 
 Age first used other opiates (years) 19.8 ( 5.5) 
 Age first used cocaine (years) 20.1 ( 4.5) 
 Age first used non-prescribed methadone 
(years) 
20.7 ( 5.3) 
 Age first used crack (years) 23.2 ( 5.0) 
a benzodiazepine use refers to both the non-prescribed use of the drug and the misuse of   
prescribed   benzodiazepines. 
 
 
Table a1.3(c) Drug Using History: Problem Drug Use 
 
  Mean (sd) 
 Age cannabis use became a problem 17.8 ( 5.9) 
 Duration since first use of cannabis (years) 13.5 ( 6.2) 
 Age heroin use became a problem  20.9 ( 5.4) 
 Duration since first use of heroin  (years) 9.7 ( 5.8) 
 Age benzodiazepine use first became a problem  21.0 ( 4.8) 
 Duration since first use of benzodiazepine (years) 8.7 ( 6.6) 
 Age cocaine use became a problem 21.7 ( 4.1) 
 Duration since first use of cocaine (years) 8.3 ( 6.4) 
 Age other opiate use first became a problem 21.1 (7.3) 
 Duration since first use of other opiate (years) 9.1 (6.7) 
 Age methadone use became a problem 21.7 ( 5.9) 
 Duration since first use of methadone (years) 7.0 ( 5.5) 
 Age crack use became a problem 23.2 ( 4.8) 
 Duration since first use of crack (years) 5.4 ( 4.5) 
 
 
a1.4 Health Risk Behaviour 
 
Table a1.4(a) Injecting-Related Health Variables  
 
  n % 
 Percentage injected  
 Ever injected 164 77.0 
 aEver shared injecting equipment  
 Ever used needle after someone 82 52.6 
 Somebody ever used needle after you 74 47.1 
 Ever reused own injecting equipment 136 86.6 
 Ever shared filter/spoons/flush water 85 54.8 
   
  Mean (sd) 
 aAge first injected 21.0( 5.2) 
aPercentages for those who have ever injected. 
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Table a1.4(b) Overdose Rates  
 
  n % 
 Proportion of participants ever overdosed   
 Never overdosed 117 57.6 
 Overdosed once 28 13.8 
 More than 1 but maximum of 3 times 31 15.3 
 More than 3 but maximum of 5 times 11 5.4 
 Overdosed more than 5 times 16 7.9 
 
 
a1.5 Physical and Psychological Health 
 
Table a1.5(a) Suicidal Thoughts and Attempts  
 
  n % 
 Suicide   
 Seriously thought of committing suicide ever 95 47.3 
 Ever attempted suicide 65 32.0 
 
Table a1.5(b) HIV, HBV, HCV Status  
 
  HIV Status HBV Status HCV Status 
  n % n % n % 
        
 Ever tested 157 82.6 157 83.1 162 83.9 
 Negative* 114 79.2 118 83.7 67 44.1 
 Positive* 8 5.6 4 2.8 66 43.4 
 Awaiting results* 22 15.3 19 13.5 19 12.5 
*Of those ever tested 
 
a1.6 Personal/Social Functioning 
 
Table a1.6(a) Demographics: Education 
 
  Mean ( sd) 
 Age left school (years) 15.11 (1.70) 
 Highest Educational Level n % 
 No formal education 5 2.3 
 Primary 28 13.1 
 Lower secondary 145 68.1 
 Upper secondary 26 12.2 
 Third level 9 4.2 
 Highest Educational Qualification   
 No qualifications 85 39.5 
 Junior cert/basic skills/ NVCA level 1 102 47.4 
 Leaving cert 15 7.0 
 Apprenticeship 1 0.5 
 National cert./dip./NCEA 9 4.2 
 Third level 3 1.4 
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Table a1.6(b) Demographics: Children 
 
 n % 
  
 74 36.3 
 130 63.7 
  
 65 50.8 
One  29 22.7 
 
 Have children under 18 years 
No 
Yes 
Parents - number of children under care 
None 
 
 Two or more 34 26.6 
 
 
a1.7 Criminal Activity  
 
Table a1.7(a) Types of Crime Ever Committed  
 
 n %  
Crime committed    
 Selling/supply drugs 107 62.6 
 Theft from a person 66 41.8 
 Theft from house/home 51 32.5 
 Theft from shop/commercial property 105 63.3 
 Theft from a vehicle 65 41.4 
 Theft of a vehicle 66 42.0 
 Handling stolen goods 112 67.1 
 Fraud/forgery/deception 66 42.0 
 Assault 59 37.8 
 Criminal damage 62 40.5 
 Soliciting 15 9.7 
 Breach of the peace 67 42.4 
 
Table a1.7(b) Arrests by Offence 
 
 Ever Arrested  
 n %  
Crime committed    
 Selling/supply drugs 45 25.6 
 Theft from a person 33 21.0 
 Theft from house/home 26 17.3 
 Theft from shop/commercial property 68 40.5 
 Theft from a vehicle 27 17.2 
 Theft of a vehicle 33 20.8 
 Handling stolen goods 29 17.0 
 Fraud/forgery/deception 20 12.7 
 Assault 37 24.2 
 Criminal damage 45 29.4 
 Soliciting 5 3.5 
 Breach of the peace 46 29.7 
 
Table a1.7(c) Prison Experience 
 
  n % 
 Imprisonment   
 Ever been in prison 123 60.0 
 Ever remanded in custody 118 58.1 
 Ever received custodial sentence 94 46.3 
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Key Outcome Measures 
 
a1.8 Substance Use 
 
Table a1.8(a) Drug Use in Last Three Months: Percentage Used 
 
  n % 
 Drug use in the last three months   
 Tobacco 193 94.1 
 Heroin 175 81.8 
 Cannabis 135 66.5 
 Alcohol 108 54.0 
 Benzodiazepines 95 45.0 
 Non-prescribed methadone  95 44.4 
 Cocaine 87 40.5 
 Crack cocaine 32 14.9 
 Ecstasy 26 12.9 
 Other opiates 24 11.2 
 Amphetamine 9 4.5 
 
Table a1.8(b) Drug Use in Last Three Months: Mean Days Used 
 
   
Population 
Sub-sample used in 
last three months 
  Mean (sd) Mean (sd) 
 Mean days used in last three months   
 Tobacco 83.6 (22.5) 88.8 (8.7) 
 Cannabis 42.3 (42.0) 63.6 (36.0) 
 Heroin 47.3 (36.6) 57.8 (32.1) 
 Non-prescribed methadone  13.6 (24.6) 30.7 (29.0) 
 Benzodiazepines 16.9 (31.8) 37.5 (38.5) 
 Alcohol 12.1 (22.3) 22.4 (26.4) 
 Cocaine 5.0 (12.8) 12.4 (17.8) 
 Crack cocaine 2.4 (11.2) 16.1 (25.1) 
 Other opiates 2.1 (11.3) 18.5 (29.4) 
 Ecstasy 0.3 (1.0) 2.2 (2.0) 
 Amphetamine 0.1 (0.9) 2.6 (3.6) 
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Table a1.8(c) Drug Use in Last Three Months: Mean Amount Used 
 
   
    Population 
Sub-sample used in 
last three months 
  Mean (sd) Mean (sd) 
 Mean amount used in a day in last 
three months 
  
 Tobacco (cigarettes) 19.5 (14.2) 20.6 (13.7) 
 bHeroin (grams) 0.6 (0.8) 0.7 (0.9) 
 Cannabis (joints) 6.0 (12.9) 9.4 (15.2) 
 Alcohol (units) 8.1 (14.1) 15.2 (16.6) 
 Cocaine (grams) 0.7 (2.3) 2.0 (3.5) 
 Non-Prescribed Methadone 
(mls) 
29.8 (43.3) 69.2 (40.3) 
 Benzodiazepines (mgs) 40.1 (95.0) 113.8 (131.8) 
a Crack cocaine was excluded due to the inconsistency in the way data was reported. 
bThese figures were based on 1 bag of heroin containing on average 0.25grams at the time of 
fieldwork 
 
 
a1.9 Health Risk Behaviour 
 
Table a1.9(a) Injecting-Related Variables in the Last Three Months  
 
 
  n % 
 Percentage who injected in last three months 93 43.7 
    
 Frequency of injecting in last three months   
 Infrequent (1-9 days) 17 19.3 
 Frequent (10 –24 days) 9 10.2 
 Very frequent (25-79 days) 31 35.2 
 Daily (80-90 days) 31 35.2 
 Used needle after someone in last month    
 No times 83 92.2 
 One time 3 3.3 
 More than Once 4 4.4 
 Someone used needle after you in last month   
 No times 79 88.8 
 One time 5 5.6 
 More than once 5 5.6 
 Reused own needles in last month   
 No times 38 58.5 
 One time 0 0 
 More than once 27 41.5 
 Used filter/spoons/flush water/ after someone    
 No times 70 88.6 
 One time 3 3.8 
 More than once 6 7.6 
 
  Mean (sd) 
 aDays injected in last three months 53.1 ( 33.9) 
 aTimes injected on typical day 3.4 ( 2.2) 
aRelates to those who have injected in last three months 
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Table a1.9 (b) Overdose Rates in the Last Three Months 
 
  n % 
 Overdose in last three months   
 None 187 91.7 
 One or more times 17 8.3 
 
Table a1.9(c) Frequency of Unsafe Sex in the Last Three Months 
 
          n % 
  Sexual history in last three months   
 Participants having sex 150 74.6 
 Participants not having sex  51 25.4 
 ab  Sexual partners in last three 
months 
  
 Having sex with a regular partner  124 87.9 
 Having sex with someone other than 
regular partner 
 
bCondom Use with regular partner 
32 25.4 
 Always used condom 27 23.1 
 Sometimes used condom 12 10.3 
 Never used condom 78 66.7 
  
bCondom use with someone other than 
a regular partner 
  
 Always used condom 13 54.2 
 Sometimes used condom 5 20.8 
       Never used condom 6 25.0 
aThese categories are not mutually exclusive 
b This is only of those who had sex in the last three months 
 
 
a1.10 Physical and Psychological Health 
 
Figure a1.1 Participants Self-Assessment of Health
Good
n=90, 
43%
Poor
n=33,
16%
Fair
n=77,
37%
Excellent
n=8, 
4%
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Table a1.10(a) Physical Health Symptoms: Mean Days Experienced in Last Three 
Months 
 
  Population Sub-sample 
  Mean (sd) Mean (sd) 
 Physical health symptoms over previous three months     
 Poor appetite 52.9 (39.1) 73.1 (25.2) 
 Tiredness/fatigue 42.7 (39.5) 64.9 (30.3) 
 Nausea (feeling sick) 16.3 (31.2) 45.9 (37.2) 
 Stomach pains 14.0 (27.9) 44.1 (33.7) 
 Difficulty breathing 14.1 (30.7) 58.0 (36.3) 
 Chest pains 7.1 (21.6) 42.3 (36.4) 
 Joint/bone pains 11.2 (27.3) 47.1 (38.2) 
 Muscle pains 7.2 21.1) 34.7 (34.7) 
 Numbness/tingling 7.1 (21.6) 41.3 (36.4) 
 Tremors/shakes 9.1 (23.2) 40.8 (33.6) 
 
Table a1.10(b) Physical Health Symptoms: Percentages Experienced in Last Three 
Months 
 
  n % 
 Poor appetite in last three months   
 Experienced 140 72.5 
 Didn’t experience 53 27.5 
 Tiredness/Fatigue in last three months   
 Experienced 127 65.8 
 Didn’t experience 66 34.2 
 Nausea (feeling sick) in last three months   
 Experienced 68 35.6 
 Didn’t experience 123 64.4 
 Stomach Pains in last three months   
 Experienced 61 31.8 
 Didn’t experience 131 68.2 
 Difficulty breathing in last three months   
 Experienced 47 24.4 
 Didn’t experience 146 75.6 
 Chest pains in last three months   
 Experienced 32 16.8 
 Didn’t experience 159 83.2 
 Joint/Bone pains in last three months   
 Experienced 46 23.7 
 Didn’t experience 148 76.3 
 Muscle pains in last three months   
 Experienced 40 20.8 
 Didn’t experience 152 79.2 
 Numbness/tingling in last three months   
 Experienced 33 17.2 
 Didn’t experience 159 82.8 
 Tremors/shakes in last three months   
 Experienced 42 22.3 
 Didn’t experience 146 77.7 
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Table a1.10(c) Mental Health Symptoms: Mean Days Experienced in the Last Three 
Months  
 
  Population Sub-sample 
  Mean (sd) Mean  (sd) 
 Mental health symptoms over last three months     
 Feeling tense 32.0 (37.5) 57.5 (32.5) 
 Suddenly scared for no reason 13.7 (29.3) 51.7 (35.7) 
 Feeling fearful 16.0 (30.6) 54.1 (33.3) 
 Nervous/shaking inside 15.6 (30.3) 50.7 
(22.1) 
Feeling hopeless about future 
(35.5) 
(34.8) 
 Spells of terror/panic 7.9 40.5 (34.9) 
 26.1 (35.9) 50.8 (35.5) 
 Feelings of worthlessness 23.8 (35.3) 51.8 
 Feeling no interest in things 27.5 (35.8) 51.7 (34.1) 
 Feeling lonely 29.3 (37.4) 59.5 (32.1) 
 Thoughts of ending your life 7.0 (20.8) 32.3 (34.7) 
 
Table a1.10(d) Mental Health Symptoms: Percentages Experienced in Last Three 
Months  
 
  n % 
 Feeling tense in last three months   
 Experienced 104 55.6 
44.4 
 
26.5 
73.5 
  
 55 
Didn’t experience 
   
  
Experienced 19.5 
Didn’t experience 
 
94 51.4 
48.6 
 
45.9 
54.1 
  
101 53.2 
89 
  
Didn’t experience 
21.5 
 Didn’t experience 83 
 Suddenly scared for no reason in last three months  
 Experienced 50 
 Didn’t experience 139 
Feeling fearful in last three months  
Experienced 29.6 
 131 70.4 
Nervousness or shaking inside in last three months 
 Experienced 58 30.7 
 Didn’t experience 131 69.3 
 Spells of terror or panic in last three months 
 37 
 153 80.5 
Feeling hopeless about the future in last three months 
 Experienced 
 Didn’t experience 89 
 Feelings of worthlessness in last three months  
 Experienced 85 
 Didn’t experience 100 
 Feeling no interest in things in last three months 
 Experienced 
 Didn’t experience 46.8 
 Feeling lonely in last three months 
 Experienced 90 49.2 
 93 50.8 
 Thoughts of ending you life in last three months 
 Experienced 39 
 Didn’t experience 142 78.5 
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Table a1.10(e) Suicidal Thoughts and Attempts in Last Six Months 
 
  n % 
 Suicide   
 Seriously thought of committing suicide in last six months 44 22.8 
 Attempted suicide in the last six months 23 11.4 
 
a
 
1.11 Personal and Social Functioning  
Table a1.11(a) Recent Employment and Income Status  
 
  n % 
Occupation over last six months 
 Not working 132 
45 
In treatment 
 
Employed in last three months 44 
38 
 aMain sources of Income last three months 
 
Family/friends 61 
63.8 
 Working (FT/PT) 21.7 
 In prison 15 7.2 
 Disability 15 7.2 
 0 0.0 
aRecent Employment  
 21.3 
 Currently employed 18.1 
 
Wage/salary 41 19.3 
 28.6 
 Social welfare 172 80.8 
 Drug dealing 36 16.9 
 Other crime 63 29.7 
  
a These categories are not mutually exclusive. 
 
Table a1.11(b) Recent Accommodation Status  
 
  n % 
 Current Accommodation   
 Family home 90 43.3 
38 
4.3 
9.1 
2.4 
2.9 
   
Family home 
Hostel/shelter/B&B 23 
17 
Home of friends 21 
Usually lives with   
Alone 
 23 
 11 
 
 Own house/flat or rental 79 
 House/home of friends 9 
 Hostel/shelter/B&B 19 
 Prison 5 
 No Fixed Abode 6 
aAccommodation - over last three months spent time in 
 90 44.3 
 Own house/flat or rental 76 36.5 
 11.1 
 Prison 8.2 
 10.1 
 No Fixed Abode 13 6.3 
 
 Partner/spouse 20 9.6 
 Parents 74 35.4 
 25 12.0 
bChildren 11.0 
bParents and children 5.3 
bPartner and children 28 13.4 
 Other 28 13.4 
aThese categories are not mutually exclusive  
bIncludes children over the age of 18 years 
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Table a1.11(c) Treatment Over Last Six Months: Previously Treated Cohort  
 
 Sub-sample 
 n % 
 Treatment in the last six months   
 Structured/supervised detoxification  13 
Prescribed methadone 7 
7 
7.5 
 One-to-one counselling 15 8.8 
 Residential drug treatment 3 1.8 
 4.3 
 Group work 4.1 
 
 
Table a1.11(d) Treatment Received for a Medical Condition in Last Three Months 
 
 n % 
 Treatment in last three months   
Attended hospital and stayed overnight 21 10.0 
Attended an A&E               38 18.9 
Visited a GP (not methadone G.P.)  62 32.0 
Visited an out-patient department 
/received community treatment  
22 11.1 
 
 
 
 
 
 
 
Table a1.11(e) Mean Number of Times in Treatment for a Medical Condition in Last 
Three Months 
 
 Mean ( sd) 
aNumber of times attended service  
 Number of days overnight stay in hospital  9.0 (10.3) 
 Number of visits to Accident and Emergency 1.4 (1.1) 
 Number of visits to a GP (not methadone GP)         4.2 (4.9) 
 Numbers of visits for out-patient 
appointment/community treatment  
       5.3 (8.7) 
 
  a Of those who attended these services in the last three months 
 
 
Table a1.11(f) Frequency of Contact and Conflict with Partner, Family/Relatives and 
Friends  
 
  Mean (sd) 
 Number of days contact with   
 Partner 83.2 (19.0) 
 Mother 54.7 (38.4) 
 Father 47.4 
Siblings 45.8 
42.1 (40.9) 
 
Mother 7.4 
8.0 (22.3) 
(40.6) 
 (40.9) 
 Friends  
   
 Number of days conflict with  
Partner 8.3 (20.4)) 
 (19.0) 
 Father 
 Siblings 5.9 (19.7) 
 Friends  1.4 (9.4) 
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Table a1.11(g) Quality of Relationship with Children 
 
n  % 
 
58.7 
 20.6 
9 7.1 
 4.8 
11 8.7 
Type of relationship with children   
 Very good  74 
Good 26 
 Okay/alright 
Poor 6 
 Very poor 
 
 
a1.12 Criminal Activity  
 
  % 
Table a1.12(a) Crime Committed in Last Three Months 
 
n 
  
22.5 
 Theft from house/home 
 Theft from shop/commercial property 
 Theft from a vehicle 9 
 Theft of a vehicle 9 
 Handling stolen goods 21.7 
 Fraud/forgery/deception 8.2 
Assault 9 4.9 
Criminal damage 9 4.9 
 10 5.3 
 Breach of the peace 12 
 Crime committed 
 Selling/supply drugs 42 
 Theft from a person 15 8.0 
9 4.8 
36 19.3 
4.8 
4.8 
40 
15 
 
 
Soliciting 
6.5 
 
 
Table a1.12(b) Means Days Crimes Committed in Last Three Months 
  
 
Population Sub-sample 
 Mean (sd) Mean 
 Frequency of crime in last three months    
 Selling/supply drugs (35.4) 
 9.7 
0.3 (2.6) (12.2) 
 Theft from shop/commercial property 5.6 
Theft from a vehicle (0.5) 2.4 
5.0 (26.5) (58.8) 
(5.0) 
Assault 
0.2 (1.4) 5.4 (6.1) 
 Soliciting 2.6 (13.7) 51.0 (35.6) 
8.7 (23.9) 48.8 
Theft from a person 0.6 (6.0) (24.3) 
 Theft from house/home 9.8 
(26.8) 34.0 (59.1) 
 0.09 (1.4) 
 Theft of a vehicle 0.1 (0.7) 2.6 (1.8) 
 Handling stolen goods 28.6 
 Fraud/forgery/deception 0.7 11.5 (17.1) 
 0.04 (0.27) 1.3 (0.8) 
 Criminal damage 
 Breach of the peace 0.2 (1.7) 5.3 (7.0) 
 (sd) 
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Table a1.12(c) Arrest by Offence in Last Three Months 
 
  n % 
 Crime Committed   
 Selling/supply drugs 7 4.0 
 Theft from a person 4 
 1.2 
 2 1.2 
3.2 
2.5 
 Theft from house/home 3 1.9 
 Theft from shop/commercial property 12 7.2 
Theft from a vehicle 2 
Theft of a vehicle 
 Handling stolen goods 2 1.2 
 Fraud/forgery/deception 2 1.2 
 Assault 2 1.3 
 Criminal damage 5 
 Soliciting 2 1.3 
 Breach of the peace 4 2.5 
 
 
Table a1.12(d) Current Legal Status 
  n % 
a   
117 
On probation/community service 13 6.7 
Serving a sentence in prison 4 2.1 
On bail – awaiting trial/hearing 29 15.2 
On bail – awaiting sentencing 8 4.2 
On temporary release 4 2.1 
Outstanding warrants 16 8.3 
Outstanding fines 8 
 Current legal problem 
 None 58.2 
 
 
 
 
 
 
 4.2 
a Categories are not mutually exclusive. 
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APPENDIX 2: RESULTS FOR DETOXIFICATION GROUP AT BASELINE 
 
Background to Treatment 
 
a2. 1 Index Treatment  
 
Twenty percent (n=81) of the ROSIE Study baseline population were recruited from 
detoxification programmes.  To this end, participants were recruited from the two main 
statutory in-patient detoxification facilities in the country.  These two facilities are located 
within a hospital setting, the first a purpose built detoxification unit (providing a six week 
structured programme) and the second in a ward off the psychiatric wing of a large city 
hospital.  These units provide a medically supervised detoxification programme delivered by 
a psychiatrist and a nursing team.  The third in-patient detoxification facility was a non-
statutory in-patient unit located outside Dublin city.  A multi-disciplinary team delivers this 
in-patient programme, and the individual’s detoxification is usually supervised by their own 
prescribing GP.  Recruitment was also carried out in a community-based out-patient facility, 
which provides a structured, supervised detoxification programme.  This programme, run by a 
multi-disciplinary team, lasts twelve weeks and requires morning attendance by participants.  
Finally, recruitment occurred in the detoxification programme provided within Mountjoy 
Prison – the Medical Unit.  In short, ROSIE interviews were carried out in all the main 
detoxification programmes in the country.   
 
Table a2.1 (a) Gender and Age of Detoxification Group 
% 
 
  n 
 Gender  
 Male 62 76.5 
 Female 19 23.5 
    
  Mean Median 
 Age  
 Age of  male study participants (years) 26.9(6.0) 26.0 
 Age of  female study participants (years) 24.3(5.6) 23.0 
 
 
Table a2.1 (b) Time in Index Treatment at Baseline and Time Waiting for Treatment 
 
 Mean (sd) 
aTime in baseline treatment (days)           21.4 ( 14.1) 
b Length of time waiting for treatment (weeks) 9.4 (10.9) 
 
 
a Excluding participants on methadone in prison as all were not new to index treatment. 
                         b Includes only those on waiting lists for treatment. 
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a2.2 Treatment History 
Table a2.2(a) Treatment History at Baseline for Detoxification Group: Previous 
Treatment Received  
 
 n % 
Percentage in previous treatment  
 Previous treatment received 77 95.1 
 No previous treatment received 4 4.9 
    
  
Population 
Sub-sample –
previously treated 
n % n 
aPrevious types of formal treatment   
 One-to-one counselling 61 75.3 61 79.2 
 Prescribed methadone 52 65.0 52 
Structured/supervised detoxification 
35.1 
 67.5 
68.4 
 51 63.8 51 67.1 
 Residential drug treatment 27 33.3 27 
bNeedle exchange 53 65.4 52 
  
 % 
   
aThese categories are not mutually exclusive.  
 bAttendance at needle-exchange is not considered treatment 
 
  Previously treated 
Table a2.2(b) Details of Previous Treatment 
 
  Mean (sd)  
 Age first sought treatment (years) 20.9 (6.0)  
 Age first attending counselling (years) 20.6 (4.4)  
Number of counsellors 
 Longest period of regular attendance (months) 
 Age first on methadone/physeptone (years) 21.4 (5.8) 
Number of episodes 2.1 (1.2) 
Longest period of attendance (months) 34.0 (34.0) 
Age first on supervised detoxification (years)  22.3 (4.5) 
Number of episodes 2.2 (1.8) 
21.9 (3.8) 
 3.0 (2.2)  
11.2 (15.7)  
 
  
  
  
  
 Age first in residential treatment (years)  
 Number of episodes 1.7 (1.1)  
 
 
a2.3 Substance Use 
  
Table a2.3(a) Drug Using History: Ever Used 
 
  n % 
Drugs ever used   
 Heroin 80 98.8 
 Tobacco 73 91.3 
 Cannabis 76 95.0 
 Alcohol 75 92.6 
 Cocaine 70 89.7 
 
 Benzodiazepines 
 
53.8 
54 76.1 
 Crack cocaine 41 
Non-prescribed methadone  68 87.2 
68 88.3 
 Ecstasy 67 85.9 
Amphetamine 60 77.9 
 Other opiates 42 
 LSD 
51.9 
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Table a2.3(b) Drug Using History: Age First Used 
 
  Mean (sd) 
 Age first smoked tobacco (years) 12.4 (2.3) 
 Age first used alcohol (years) 13.2 (1.9) 
 13.9 (3.7) 
 Age first used LSD (years) 
Age first used other opiates (years) 
Age first used cannabis (years) 
16.0 (2.8) 
 Age first used ecstasy (years) 16.6 (4.8) 
 Age first use amphetamine (years) 16.8 (3.9) 
 Age first used heroin (years) 17.2 (3.3) 
 Age first used benzodiazepines 17.3 (3.8) 
 19.4 (4.5) 
 Age first used cocaine (years) 19.0 (5.1) 
 Age first used methadone (years) 20.3 (5.7) 
 Age first used crack (years) 21.8 (4.5) 
 
Table a2.3(c) Drug Using History: Problem Drug Use 
 
  Mean (sd) 
Age cannabis use became a problem 15.8 (3.8) 
 Duration since first use of cannabis (years) 12.4 ( 5.5) 
Duration since first use of heroin (years) 8.8 ( 5.0) 
 
21.0 (5.7) 
8.2 ( 5.3) 
 Age crack use became a problem 
4.2 ( 2.9) 
 Age heroin use became a problem  19.4 ( 3.8) 
 
 Age benzodiazepine use first became a problem  20.1 ( 3.9) 
 Duration since first use of benzodiazepine (years) 8.4 ( 5.9) 
 Age cocaine use became a problem 21.2 ( 4.4) 
Duration since first use of cocaine (years) 7.1 (3.8) 
 Age other opiate use first became a problem 
 Duration since first use of other opiate (years) 
 Age methadone use became a problem 23.1 (7.3) 
 Duration since first use of methadone (years) 6.6 (4.2) 
20.1  ( 2.7) 
 Duration since first use of crack (years) 
 
 
 
a2.4 Health Risk Behaviour 
 
Table a2.4(a) Injecting-Related Health Variables  
 
  n % 
 Percentage injected  
 Ever injected 62 76.5 
 Ever shared injecting equipment 
40 71.4 
38
a  
 Ever used needle after someone 
 Somebody ever used needle after you 28 50.0 
 Ever reused own injecting equip. 48 85.7 
 Ever shared filter/spoons/flush water 69.1 
   
  Mean (sd) 
 Age first injected 19.4 (3.7) 
aPercentages for those who have ever injected. 
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Table a2.4(b) Overdose Rates  
 
  n % 
 
51 63.0 
8 9.9 
 9 11.1 
 8 9.9 
 5 6.2 
Proportion of participants ever overdosed   
 Never overdosed 
 Overdosed once 
More than 1 but maximum of 3 times 
More than 3 but maximum of 5 times 
Overdosed more than 5 times 
 
 
a2.5 Physical and Psychological Health
Table a2.5(a) Suicidal Thoughts and Attempts  
 
 
Table a2.5(b) HIV, HBV, HCV Status  
 
 
 
  
  n 
  
% 
 Suicide 
 Seriously thought of committing suicide ever 42 51.9 
21  Ever attempted suicide 26.3 
 
HCV Status   HIV Status HBV Status 
  n n 
    
% % n % 
    
 Ever tested 67 
 24 
 4 7.1 
 
 
66 82.5 66 83.5 83.8 
Negative* 50 89.3 49 89.1 44.1 
Positive* 3 5.5 56.9 
Awaiting results* 2 3.6 3 5.5 1 1.7 
33 
*Of those ever tested 
 
 
a2.6 Personal/Social Functioning 
 
Table a2.6(a) Demographics: Education 
 
  Mean ( sd) 
 Age left school (years) 14.95 (2.25) 
Highest Educational Level % 
 No formal education 5 6.2 
 Primary 21 
No qualifications 
25.9 
 Lower secondary 33 40.7 
 Upper secondary 17 21.0 
 Third level 5 6.2 
 Highest Educational Qualification   
 18 22.2 
 Junior cert/basic skills/ NVCA level 1 44 54.3 
 Leaving cert 14 17.3 
 Apprenticeship 2 2.5 
 National cert./dip./NCEA 3 3.7 
 Third level 0 0 
 n 
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Table a2.6(b) Demographics: Children 
 
  n % 
 Have children under 18 years   
 No 41 52.6 
 Yes 37 47.4 
 Parents - number of children under care  
 
 None 23 62.2 
 One  10 27.0 
Two or more 4 10.8 
 
 
a2.7 Criminal Activity  
 
Table a2.7(a) Types of Crime Ever Committed  
 
  n % 
 Crime committed   
 Selling/supply drugs 56 72.7 
 Theft from a person 48 62.3 
 Theft from house/home 31 40.3 
 Theft from shop/commercial property 64 83.1 
 Theft from a vehicle 52 67.5 
 Theft of a vehicle 47 60.3 
 Handling stolen goods 65 84.4 
 Fraud/forgery/deception 42 55.3 
 Assault 42 56.0 
 Criminal damage 45 59.2 
 Soliciting 6 8.0 
 Breach of the peace 50 66.7 
 
Table a2.7(b) Arrests by Offence 
 
  Ever Arrested 
  n % 
 Crime committed   
 Selling/supply drugs 25 34.2 
 Theft from a person 26 36.6 
 Theft from house/home 13 18.8 
 Theft from shop/commercial property 44 60.3 
 Theft from a vehicle 24 33.8 
 Theft of a vehicle 30 43.5 
 Handling stolen goods 26 35.1 
 Fraud/forgery/deception 11 16.4 
 Assault 31 44.9 
 Criminal damage 30 44.1 
 Soliciting 2 3.1 
 Breach of the peace 42 61.8 
 
Table a2.7(c) Prison Experience 
 
  n % 
 Imprisonment   
 Ever been in prison 55 69.6 
 Ever remanded in custody 51 64.6 
 Ever received custodial sentence 45 57.0 
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Key Outcome Measures 
 
a2.8 Substance Use 
 
Table a2.8(a) Drug Use in Last Three Months: Percentage Used 
 
  n % 
 Drug use in the last three months   
 Tobacco 72 90.0 
 Heroin 61 75.3 
 Cannabis 52 65.8 
 Alcohol 46 56.8 
 Benzodiazepines 41 
11 
51.3 
 Non-prescribed methadone  37 46.3 
 Cocaine 40 49.4 
 Crack cocaine 13.6 
 Ecstasy 10 12.5 
 Other opiates 5 6.2 
 Amphetamine 4 5.1 
Table a2.8(b) Drug Use in Last Three Months: Mean Days Used 
 
   
Population 
Sub-sample used in 
last three months 
  Mean (sd) Mean (sd) 
 Mean days used in last three months   
 Tobacco 77.5 (29.2) 
 
86.1 (14.0) 
 Cannabis 38.3 (38.6) 58.1 (33.2) 
 Heroin 34.7 (32.6) 46.1 (29.8) 
Non-prescribed methadone  12.3 (24.6) 26.5 (30.6) 
 Benzodiazepines 17.8 (28.7) 34.8 (31.9) 
 Alcohol 13.0 (21.4) 22.8 (24.2) 
 Cocaine 10.3 (21.2) 20.8 (26.4) 
 Crack cocaine 1.5 (5.5) 11.1 (11.1) 
 Other opiates 1.9 (9.9) 30.2 (30.0) 
 Ecstasy 0.5 (1.6) 4.2 (2.5) 
 Amphetamine 0.08 (0.39) 1.5 (1.0) 
 
Table a2.8(c) Drug Use in Last Three Months: Mean Amount Used 
 
   
Population 
Sub-sample used in 
last three months 
  Mean (sd) Mean (sd) 
 Mean amount used in a day in last 
three months 
  
Tobacco (cigarettes) 15.6 (11.0) 17.4 (10.2) 
bHeroin (grams) 0.5 (0.58) 0.6 
 Cannabis (joints) 8.2 (15.3) 11.8 (16.8) 
 Alcohol (units) 8.1 (10.0) 14.4 (9.2) 
 Cocaine (grams) 1.2 (3.0) 2.5 (3.9) 
 Non-Prescribed Methadone 
(mls) 
19.6 (29.3) 44.3 (29.2) 
 Benzodiazepines (mgs) 44.0 (80.2) 96.1 (95.4) 
 
 (0.6) 
a Crack cocaine was excluded due to the inconsistency in how data was reported 
bThese figures were based on 1 bag of heroin containing on average 0.25grams at the time of fieldwork 
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a2.9 Health Risk Behaviour 
 
 
Table a2.9(a) Injecting-Related Variables in Last Three Months  
 
 n % 
 Percentage who injected in last three months  38 46.9 
    
 Frequency of injecting in last three months   
  
More than once 
One time 
1 
 Infrequent (1-9 days) 13 34.2 
 Frequent (10 –24 days) 3 7.9 
 Very frequent (25-79 days) 15 39.5 
 Daily (80-90 days) 7 18.4 
 Used needle after someone in last month  
 No times 33 91.7 
 One time 2 5.6 
 1 2.8 
 Someone used needle after you in last month   
 No times 32 88.9 
 3 8.3 
 More than once 1 2.8 
 Reused own needles in last month   
 No times 21 65.6 
 One time 3.1 
 More than once 10 31.2 
 Used filter/spoons/flush water/ after someone    
 No times 30 85.7 
 One time 2 5.7 
 More than once 3 8.6 
 
  Mean (sd) 
aDays injected in last three months 37.9 (32.6) 
aTimes injected on typical day 4.6 (5.3) 
 
 
 aRelates to those who have injected in last three months. 
 
Table a2.9(b) Overdose Rates in Last Three Months 
 
  n % 
 Overdose in last three months   
 None 78 96.3 
 One or more times 3 3.7 
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Table a2.9(c) Frequency of Unsafe Sex in Last Three Months 
 
          n % 
  Sexual history in last three months   
Participants having sex 46 61.3 
Participants not having sex  29 38.7 
abSexual partners in last three months   
 Having sex with a regular partner  32 
 Having sex with someone other than 
regular partner 
bCondom use with regular partner 
16 36.4 
 Always used condom 7 22.6 
 Sometimes used condom 1 3.2 
 Never used condom 23 74.2 
 
bCondom use with someone other than 
a regular partner 
 Always used condom 10 66.7 
 Sometimes used condom 1 6.7 
       Never used condom 4 26.7 
 
 
 
71.1 
 
   
aThese categories are not mutually exclusive. 
b This is only of those who had sex in the last three months 
 
a2.10 Physical and Psychological Health 
 
Figure a2.1 Participants Self-Assessment of Health 
Good
n=37, 46%, 
Poor
n=12, 15%
Fair
n=27, 34% 
Excellent
n=4, 5%
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Table a2.10(a) Physical Health Symptoms: Mean Days Experienced in Last Three 
Months 
 
  Population Sub-sample 
  Mean (sd) Mean (sd) 
 Physical health symptoms over last three months     
 Poor appetite 47.8 ( 37.6) 60.6 31.8 
 Tiredness/fatigue 40.0 ( 36.3) 
Nausea (feeling sick) 
 29.5 
13.6 
(27.2) 
 
53.1 32.3 
 11.5 (21.5) 26.6 26.0 
Stomach pains 15.8 (26.1) 28.5 
 Difficulty breathing 13.4 (26.0) 37.4 31.7 
 Chest pains (24.7) 34.5 28.9 
 Joint/bone pains 15.1 (26.5) 28.4 30.8 
 Muscle pains 11.4 (22.4) 26.4 27.8 
 Numbness/tingling 12.1 37.1 37.1 
Tremors/shakes 9.5 (23.1) 30.9 33.0 
 
Table a2.10(b) Physical Health Symptoms: Percentages Experienced in Last Three 
Months  
 
%   n 
 Poor appetite in last three months   
 Experienced 63 78.8 
21.3 
 
 75.3 
 20 
Nausea (feeling sick) in last three months 
 35 
45 
Didn’t experience 44.4 
Difficulty breathing in last three months 
 
 Didn’t experience 52 
Chest pains in last three months 
Experienced 
Didn’t experience 
Joint/Bone pains in last three months 
 43 
 Didn’t experience 
 
 
 
Tremors/shakes in last three months   
25 
 Didn’t experience 17 
 Tiredness/Fatigue in last three months  
Experienced 61 
Didn’t experience 24.7 
   
Experienced 43.2 
 Didn’t experience 46 56.8 
 Stomach Pains in last three months   
 Experienced 55.6 
 36 
   
Experienced 29 35.8 
64.2 
   
 32 39.5 
 49 60.5 
   
Experienced 53.1 
38 46.9 
Muscle pains in last three months   
Experienced 35 43.2 
 Didn’t experience 46 56.8 
 Numbness/tingling in last three months   
 Experienced 26 32.5 
Didn’t experience 54 67.5 
 
 Experienced 30.9 
 Didn’t experience 56 69.1 
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Table a2.10(c) Mental Health Symptoms: Mean Days Experienced in Last Three 
Months  
 
  Population Sub-sample 
  Mean (sd) Mean  (sd) 
 Mental health symptoms over last three months     
 Feeling tense 38.7 (34.2) 
36.9 
37.0 
Feeling hopeless about future 28.8 49.5 
 50.5 (35.7) 
33.0 
Feeling lonely 52.7 
(37.7) 53.4 
 Suddenly scared for no reason 16.1 (29.3) (34.7) 
 Feeling fearful 18.9 (30.1) 39.3 (33.0) 
 Nervous/shaking inside 19.9 (30.3) (32.7) 
 Spells of terror/panic 12.6 (26.8) 38.4 (34.9) 
 (35.5) (33.8) 
Feelings of worthlessness 28.8 (36.8) 
 Feeling no interest in things (36.3) 54.4 (31.7) 
 31.8 (36.9) (33.8) 
 Thoughts of ending your life 7.3 (21.2) 28.3 (34.2) 
 
Table a2.10(d) Mental Health Symptoms: Percentages Experienced in Last Three 
Months  
 
  n % 
 Feeling tense in last three months   
 Experienced 58 72.5 
 Didn’t experience 22 27.5 
 Suddenly scared for no reason in last three months 
Experienced 35 
Didn’t experience 
Feeling fearful in last three months 
Experienced 
Didn’t experience 
 Nervousness or shaking inside in last three months 
 
 Spells of terror or panic- last 3 months 
Experienced 
 Didn’t experience 
46 58.2 
45 
 
 
Experienced 
57 74.0 
  
 43.8 
 45 56.3 
   
 38 48.1 
 41 51.9 
  
Experienced 42 53.8 
 Didn’t experience 36 46.2 
  
 26 32.9 
53 67.1 
 Feeling hopeless about the future in last three months 
 Experienced 
 Didn’t experience 33 41.8 
 Feelings of worthlessness in last three months   
 Experienced 57.0 
 Didn’t experience 34 43.0 
 Feeling no interest in things in last three months   
Experienced 48 60.8 
 Didn’t experience 31 39.2 
 Feeling lonely- last 3 months   
Experienced 47 60.3 
 Didn’t experience 31 39.7 
 Thoughts of ending you life in last three months 
 20 26.0 
 Didn’t experience 
 
Table a2.10(e) Suicidal Thoughts and Attempts in Last Six Months 
 
 n % 
Suicide   
  Seriously thought of committing suicide in last six months  18 22.2 
  Attempted suicide in the last six months 5 6.4 
 
     72 
   
a2.11 Personal and Social Functioning  
 
Table a2.11(a) Recent Employment and Income Status   
  % n 
 Occupation over last six months  
 Not working 36 44.4 
25.9 
17.3 
11.1 
1.2 
 
12 
 
26 
58 
26 
Other crime 33 41.8 
 Working (FT/PT) 21 
 In prison 14 
 Disability 9 
 In treatment 1 
aRecent Employment  
 Employed in last three months 14.8 
 Currently employed 8 9.9 
aMain sources of Income last three months  
 Wage/salary 14 17.7 
 Family/friends 32.9 
 Social welfare 73.4 
 Drug dealing 32.9 
 
a These categories are not mutually exclusive.  
n 
Table a2.11(b) Recent Accommodation Status  
 
  % 
 Current Accommodation   
 Family home 15 
45 
4 
1 
1 
 14 
No Fixed Abode 1 
 aAccommodation - over last three months spent time in 
 Family home 
 
 Own house/flat or rental 
 8.8 
 15 18.8 
8 10.0 
 No Fixed Abode 4 5.0 
  
2 2.6 
 
 
 
 3.8 
 
Other 
18.5 
 Drug treatment residence 55.6 
 Own house/flat or rental 4.9 
 House/home friend 1.2 
 Hostel/shelter/B&B 1.2 
Prison 17.3 
 1.2 
  
41 51.3 
Drug treatment residence 45 55.6 
20 25.0 
Hostel/shelter/B&B 7 
Prison 
 Home of friends 
 Usually lives with 
 Partner/spouse 
Parents 37 47.4 
Alone 5 6.4 
bChildren 6 7.7 
bParents and children 3 
bPartner and children 5 6.4 
 20 25.6 
aThese categories are not mutually exclusive. 
bIncludes children over the age of 18 years. 
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Table a2.11(c) Treatment Over Last Six Months: Previously Treated Cohort  
 
 Sub-sample 
 n % 
   Treatment in the last six months 
 Structured/supervised detoxification  19.5 
14.3 
3.9 
7.9 
11.7 
15 
 One-to-one counselling 11 
 Residential drug treatment 3 
 Prescribed methadone 6 
 Group work 9 
 
Table a2.11(d) Treatment Received for a Medical Condition in Last Three Months 
 
 n 
Treatment in last three months 
% 
   
 Attended hospital and stayed overnight 5 
 Attended an A&E 15 19 
Visited an out-patient department 
/received community treatment  
10 12.3 
6.4 
 Visited a GP (not methadone G.P.)  26 34.2 
 
 
Table a2.11(e) Mean Number of Times in Treatment for a Medical Condition in Last 
Three Months 
 
  Mean ( sd) 
aNumber of times attended service 
1.9 (0.9) 
 1.2 (0.6) 
 Number of visits to a GP (not methadone GP)  
 Numbers of visits for out-patient 
appointment/community treatment  
4.4 (7.5) 
  
 Number of days overnight stay in hospital  
Number of visits to Accident and Emergency 
3.8 (3.7) 
  a Of those who attended these services in the last three months 
 
Table a2.11(f) Frequency of Contact and Conflict with Partner, Family/Relatives and 
Friends  
 
  Mean (sd) 
 Number of days contact with   
 Partner 62.7 (33.8) 
 Mother 61.3 (36.5) 
 Father 46.7 (39.9) 
 Siblings 47.2 (38.0) 
 Friends  44.9 (37.8) 
   
 Number of days conflict with  
 
 Siblings 4.2 
 1.3 (4.7) 
Partner 9.1 (20.5) 
 Mother 8.4 (19.2)) 
 Father 9.3 (21.0) 
(15.3)) 
Friends  
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Table a2.11(g) Quality of Relationship with Children  
 
 n  % 
 Type of relationship with children   
 Very good  23 63.9 
 Good 4 11.1 
 Okay/alright 5 13.9 
 Poor 0 0 
 Very poor 4 11.1 
 
a2.12 Criminal Activity  
 
Table a2.12(a) Crime Committed in Last Three Months 
 
%   n 
 Crime committed   
 Selling/supply drugs 30 40.0 
12.2 
5.3 
16.4 
9.2 
11.8 
20 
5 6.8 
 Theft from a person 9 
 Theft from house/home 4 
 Theft from shop/commercial property 12 
 Theft from a vehicle 7 
 Theft of a vehicle 9 
 Handling stolen goods 27.0 
 Fraud/forgery/deception 6 8.0 
 Assault 
 Criminal damage 5 6.8 
 Soliciting 3 4.0 
 Breach of the peace 5 6.8 
 
 
 
Table a2.12(b) Means Days Crimes Committed in Last Three Months 
 
 
Population 
    
 
Sub-sample  
Mean (sd) Mean 
 Frequency of crime in last three months   
 Selling/supply drugs 18.5 (30.1) 
 (2.9) 
(1.7) 
Theft from shop/commercial property 
13.9 
0.3 
 
(10.3) 25.8 (28.8) 
Assault 
( 0.0) 
1.4 (10.4) 
 2.0 (1.4) 
46.2 (31.5) 
Theft from a person 0.4 (1.4) 3.5 
 Theft from house/home 0.3 6.3 (4.8) 
 4.1 (16.0) 25.4 (33.4) 
 Theft from a vehicle 1.3 (8.0) (24.5) 
 Theft of a vehicle (0.8) 2.1 (1.6) 
Handling stolen goods 7.9 (21.3) 29.6 (33.0) 
 Fraud/forgery/deception 2.1 
 0.1 (0.5) 1.5 (1.1) 
 Criminal damage 0.07 (0.3) 1.0 
 Soliciting 34.2 (48.5) 
Breach of the peace 0.06 (0.4) 
  (sd) 
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Table a2.12(c) Arrest by Offence in Last Three Months 
 
  n % 
 Crime Committed   
Selling/supply drugs 3 4.1 
 Theft from a person 0 0 
Theft from house/home 0 0 
Theft from shop/commercial property 2 2.9 
 Theft from a vehicle 0 0 
 Theft of a vehicle 1 1.5 
Handling stolen goods 3 4.1 
0 0.0 
 Assault 1 1.5 
 Criminal damage 2 2.9 
1 1.4 
 Breach of the peace 2 
 
 
 
 
 Fraud/forgery/deception 
 Soliciting 
3.0 
 
 
Table a2.12(d) Current Legal Status 
 
n %   
aCurrent legal problem  
 None 33 41.8 
 On probation/community service 9 11.5 
Serving a sentence in prison 
 On bail – awaiting trial/hearing 
 On bail – awaiting sentencing 2 
On temporary release 2 
Outstanding warrants 12 
Outstanding fines 6 
 14 17.7 
9 11.5 
2.6 
 2.6 
 15.4 
 7.7 
  
a Categories are not mutually exclusive. 
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APPENDIX 3: RESULTS FOR ABSTINENCE GROUP AT BASELINE 
 
 
Background to Treatment 
a3. 1 Index Treatment  
 
One fifth of the ROSIE study population (20.3%, n= 82) were recruited from abstinence-
based treatment programmes. Baseline study recruitment was carried out in twelve 
abstinence-based treatment settings, nine of which were residential drug treatment 
programmes, with the remaining three non-residential facilities. The residential programmes 
were provided by a number of different organisations and were based on different ideologies, 
for example, 12-Step and Minnesota Model-type treatment, a therapeutic community and 
Christian-based programmes. Treatment length within these programmes varied from short 
term (four weeks) to long term (over one year). 
 
 
Table a3.1(a) Gender and Age of Abstinence Group 
 
  n % 
 Gender  
 Male 73 89.0 
 Female 9 11.0 
   
  Mean (sd)   Median 
 Age  
 Age of  male study participants (years) 27.4(5.2) 27.0 
 Age of  female study participants (years) 26.6(4.4) 25.0 
 
Table a3.1(b) Time in Index Treatment at Baseline and Time Waiting for Treatment 
 
Mean (sd)  
aTime in baseline treatment (days)           24.3 (14.6) 
b Lengt 7.6(8.5) 
 
 h of time waiting for treatment (weeks) 
a Excluding participants on methadone in prison as all were not new to index treatment. 
                         b Includes only those on waiting lists for treatment. 
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a3.2 Treatment History 
 
Table a3.2(a) Treatment History at Baseline for Abstinence Group: Previous 
Treatment Received  
 
 n % 
 Percentage in previous treatment   
 Previous treatment received 75 91.5 
 No previous treatment received 
  
7 8.5 
  
  
Population 
Sub-sample –
previously treated 
 n % n % 
a     
 One-to-one counselling 55 67.1 
Prescribed methadone 56.0 
 66.2 
47 58.0 
 
55 73.3 
 42 51.2 42 
Structured/supervised detoxification 49 60.5 49 
 Residential drug treatment 47 63.5 
bNeedle exchange 47 57.3 44 58.7 
 Previous types of formal treatment 
aThese categories are not mutually exclusive.  
 bAttendance at needle-exchange is not considered treatment. 
 
Table a3.2(b) Details of Previous Treatment 
 
  Previously treated 
Mean (sd)  
 Age first sought treatment (years) 
 Age first attending counseling (years) 22.5 (5.5)  
 Number of counselors 4.0 (4.3)  
 Longest period of regular attendance (months) 9.7 (13.0) 
Age first on supervised detoxification (years)  23.0 (5.5) 
 Age first in residential treatment (years) 
  
 
 Age first on methadone/physeptone (years) 22.3 (5.2)  
 Number of episodes 2.1 (2.0)  
 Longest period of attendance (months) 24.2 (25.2)  
  
 
 
  
21.7 (5.3)  
 Number of episodes 2.4 (1.9) 
23.7 (5.1) 
Number of episodes 2.1 (1.8) 
a3.3 Substance Use 
  
Table a3.3(a) Drug Using History: Ever Used 
% 
 
 n 
   
 
 
 
 
Drugs ever used 
Heroin 79   97.5 
76   93.8 
100.0 
  98.7 
  96.3 
64   81.0 
  91.0 
  97.4 
  93.5 
Other opiates 49 
  60.3 
 Tobacco 
 Cannabis 
 
 
 
 
 Ecstasy 76 
  83.6 
80 
Alcohol 76 
Cocaine 77 
Non-prescribed methadone  
Benzodiazepines 71 
 Amphetamine 72 
   64.5 
 LSD 61 
 Crack cocaine 47 
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Table a3.3(b) Drug Using History: Age First Used 
 
  Mean (sd) 
 Age first smoked tobacco (years) 13.3 (3.9) 
 Age first used alcohol (years) 13.4 (2.8) 
 
Age first used LSD (years) 
17.8 (4.5) 
Age first used cannabis (years) 14.3 (3.1) 
 16.4 (2.9) 
 Age first used ecstasy (years) 
 Age first use amphetamine (years) 17.5 (3.7) 
 Age first used heroin (years) 18.6 (5.2) 
 Age first used benzodiazepines 18.6 (4.4) 
 Age first used other opiates (years) 18.8 (3.7) 
 Age first used cocaine (years) 19.3 (4.0) 
 Age first used methadone (years) 20.0 (4.7) 
 Age first used crack (years) 22.2 (4.2) 
 
Table a3.3(c) Drug Using History: Problem Drug Use 
 
  Mean (sd) 
 Age cannabis use became a problem 18.6 (5.9) 
 Duration since first use of cannabis (years) 13.0 (5.2) 
 Age heroin use became a problem  19.6 (4.4) 
 Duration since first use of heroin (years) 8.8 (4.6) 
 Age benzodiazepine use first became a problem  20.7 (4.4) 
 Duration since first use of benzodiazepine (years) 8.5 (5.2) 
 Age cocaine use became a problem 23.1 (4.0) 
 Duration since first use of cocaine (years) 8.0 (4.3) 
 Age other opiate use first became a problem 19.9 (3.8) 
 Duration since first use of other opiate (years) 8.4 (4.9) 
 Age methadone use became a problem 21.7 ( 5.3) 
 Duration since first use of methadone (years) 7.4 (3.8) 
 Age crack use became a problem 23.3 ( 4.4) 
 Duration since first use of crack (years) 5.2 (4.5) 
 
 
a3.4 Health Risk Behaviour 
 
Table a3.4(a) Injecting-Related Health Variables  
 
  n % 
Percentage injected  
 Ever injected 56 68.3 
 
Ever shared filter/spoons/flush water 
aEver shared injecting equipment  
 Ever used needle after someone 39 84.8 
 Somebody ever used needle after you 34 73.9 
 Ever reused own injecting equipment 42 91.3 
 38 82.6 
   
  Mean (sd) 
 Age first injected 20.0 (3.8) 
 
aPercentages for those who have ever injected 
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Table a3.4(b) Overdose Rates  
 
  n % 
 Proportion of participants ever overdosed   
 Never overdosed 35 43.2 
 Overdosed once 10 12.3 
 More than 1 but maximum of 3 times 20 24.7 
 More than 3 but maximum of 5 times 9 11.1 
 Overdosed more than 5 times 7 8.6 
 
 
a3.5 Physical and Psychological Health 
 
Table a3.5(a) Suicidal Thoughts and Attempts  
 
   
  n % 
 Suicide   
 Seriously thought of committing suicide ever 48 58.5 
 Ever attempted suicide 29 35.4 
 
Table a3.5(b) HIV, HBV, HCV Status  
 
  HIV Status HBV Status HCV Status 
  n % n % n % 
        
 Ever tested 56 70.9 55 69.6 56 70.9 
 
 
 
 
Negative* 51 98.2 53 96.4 27 49.1 
Positive* 0 0.0 1 1.8 28 50.9 
Awaiting results* 1 1.8 1 1.8 0 0 
*Of those ever tested 
 
 
a3.6 Personal and Social Functioning 
 
Table a3.6(a) Demographics: Education 
 
  Mean ( sd) 
 Age left school (years) 15.37 (1.40) 
 Highest Educational Level n % 
 No formal education 1 1.2 
 Primary 11 13.4 
 Lower secondary 48 58.5 
 Upper secondary 16 19.5 
 Third level 6 7.3 
 Highest Educational Qualification  
 No qualifications 17 20.7 
 Junior cert/basic skills/ NVCA level 1 43 52.4 
 Leaving cert 11 13.4 
 Apprenticeship 2 2.4 
 National cert./dip./NCEA 8 9.8 
 Third level 1 1.2 
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Table a3.6(b) Demographics: Children 
 
  n % 
 Have children under 18 years   
 No 40 52.6 
 Yes 36 47.4 
 Parents - number of children under care  
 None 28 77.8 
 One  3 
13.9 
8.3 
 Two or more 5 
 
 
a3.7 Criminal Activity  
 
Table a3.7(a) Types of Crime Ever Committed  
 
  n % 
 Crime committed   
Selling/supply drugs 69 87.3 
 Theft from a person 57 72.2 
 Theft from house/home 45 57.0 
 Theft from shop/commercial property 65 82.3 
 Theft from a vehicle 49 62.8 
 Theft of a vehicle 47 59.5 
 Handling stolen goods 71 89.9 
 Fraud/forgery/deception 52 65.0 
 Assault 54 68.4 
 Criminal damage 61 77.2 
 Soliciting 6 7.6 
 Breach of the peace 52 65.8 
 
 
Table a3.7(b) Arrests by Offence 
 
  Ever Arrested 
  n % 
 Crime committed   
Selling/supply drugs 32 43.2 
 Theft from a person 29 45.3 
 Theft from house/home 21 
 Theft from shop/commercial property 40 58.0 
 Theft from a vehicle 22 35.5 
 Theft of a vehicle 26 
 Handling stolen goods 32 44.4 
 Fraud/forgery/deception 17 25.8 
 Assault 30 46.2 
 Criminal damage 34 49.3 
Soliciting 0 0.0 
 Breach of the peace 40 63.5 
 
37.5 
42.6 
 
 
Table a3.7(c) Prison Experience 
n 
 
  % 
 Imprisonment   
 Ever been in prison 58 71.6 
 Ever remanded in custody 57 70.4 
 Ever received custodial sentence 42 51.9 
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Key Outcome Measures 
 
a3.8 Substance Use 
 
Table a3.8(a) Drug Use in Last Three Months: Percentage Used 
 
  n % 
 Drug use in last three months   
 Tobacco 72 92.3 
 Heroin 45 57.7 
 Cannabis 37 
25 
 
9.2 
50.0 
 Alcohol 41 54.7 
 Benzodiazepines 28 35.0 
 Non-prescribed methadone  30.9 
 Cocaine 37 45.1 
 Crack cocaine 14 17.1 
Ecstasy 10 13.2 
 Other opiates 7 
 Amphetamine 4 5.2 
Table a3.8(b) Drug Use Last Three Months: Mean Days Used 
 
   
Population 
Sub-sample used in 
last three months 
  Mean (sd) Mean (sd) 
 Mean days used in last three months   
Tobacco 78.5 (28.1) 85.0 (17.2) 
 Cannabis 27.8 
 Heroin 25.6 (32.0) 45.0 (30.3) 
 Non-prescribed methadone  8.28 (20.3) 26.8 (29.3) 
Benzodiazepines 10.5 (21.1) 30.1 (26.2) 
 Alcohol 17.9 (29.1) 32.8 (32.7) 
 24.0 (23.8) 
 Crack cocaine 2.4 (11.3) 15.0 (25.5) 
 Other opiates 1.9 (9.5) 20.6 (26.0) 
 Ecstasy 2.3 (9.7) 17.1 (22.2) 
Amphetamine 1.2 (6.4) 23.5 
 
(34.1) 55.6 (27.8) 
 
Cocaine 10.7 (19.8) 
 (18.7) 
 
Table a3.8(c) Drug Use in Last Three Months: Mean Amount Used 
 
   
Population 
Sub-sample used in 
last three months 
  Mean (sd) 
  
Mean (sd) 
 Mean amount used in a day in last 
three months 
 Tobacco (cigarettes) 18.0 (12.0) 19.6 (11.5) 
 
(31.1) 
bHeroin (grams) 0.6 (0.9) 1.1 (1.0) 
 Cannabis (joints) 11.8 (25.2) 23.3 
 Alcohol (units) 14.3 (21.8) 25.6 (23.1) 
 Cocaine (grams) 0.9 (1.6) 2.1 (1.8) 
 Non-Prescribed Methadone 
(mls) 
13.2 (27.7) 43.3 (35.3) 
 Benzodiazepines (mgs) 48.3 (154.4) 171.6 (256.1) 
a Crack cocaine was excluded due to the inconsistency in how data was reported. 
bThese figures were based on 1 bag of heroin containing on average 0.25grams at the time of fieldwork 
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a3.9 Health Risk Behaviour 
 
Table a3.9(a) Injecting-Related Variables in Last Three Months  
 
  n % 
 Percentage who injected in last three months 24 29.3 
    
 Frequency of injecting in last three months   
 Infrequent (1-9 days) 5 21.7 
 Frequent (10 –24 days) 3 13.0 
 
 
No times 
95.5 
0 
 Reused own needles in last month 
 No times 
 One time 
 More than once 
 Used filter/spoons/flush water/ after someone  
 No times 18 
 One 0 
5.3 
Very frequent (25-79 days) 14 60.9 
Daily (80-90 days) 1 4.3 
 Used needle after someone in last month    
 16 72.7 
 One time 4 18.2 
 More than once 2 9.1 
 Someone used needle after you in last month   
 No times 21 
 One time 0 
 More than once 1 4.5 
  
13 68.4 
0 0 
6 31.6 
  
94.7 
time 0 
 More than once 1 
 
  Mean (sd) 
aDays injected in last three months 42.9 (31.3) 
aTimes injected on typical day 4.2 (3.0) 
 
 
aRelates to those who have injected in last three months. 
 
 
 % 
Table a3.9 (b) Overdose Rates in the Last Three Months 
 
 n 
 Overdose in last three months   
None 79 97.5 
2.5 
 
 One or more times 2 
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Table a3.9(c) Frequency of Unsafe Sex in Last Three Months 
% 
 
          n 
  Sexual history in last three months   
 Participants having sex 45 55.6 
36 
  
Having sex with a regular partner  
Having sex with someone other than 
regular partner 
 
5 
7 46.7 
   
26.3 
 Participants not having sex  44.4 
abSexual partners in last three months  
 29 69.0 
 
bCondom use with regular partner 
22 52.4 
 Always used condom 33.3 
 Sometimes used condom 3 20.0 
 Never used condom 
 
bCondom use with someone other than 
a regular partner 
 Always used condom 5 
 Sometimes used condom 2 10.5 
       Never used condom 12 63.2 
aThese categories are not mutually exclusive. 
b This is only of those who had sex in the last three months 
 
 
 
a3.10 Physical and Psychological Health 
 
Figure a3.1 Participants Self-Assessment of Health 
Good
46, 57%
Poor
n=10, 12%
Fair
n=18, 22%
Excellent
n=7, 9%
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Table a3.10(a) Physical Health Symptoms: Mean Days Experienced in Last Three 
Months 
 
  Population Sub-sample 
  Mean Mean (sd) 
Physical health symptoms over previous three months 
(sd) 
    
Poor appetite 33.8 ( 34.8) 54.5 28.7 
 Tiredness/fatigue 45.2 ( 38.1) 56.6 34.1 
Nausea (feeling sick) 13.2 (23.5) 27.9 27.5 
 Stomach pains 13.9 (23.6) 
Difficulty breathing 12.2 39.6 34.9 
6.3 (16.4) 26.8 
 Joint/bone pains 17.4 (29.8) 34.4 
Muscle pains 13.4 (22.5) 27.5 24.9 
 Numbness/tingling 8.4 (18.2) 29.9 23.3 
 Tremors/shakes 15.5 (26.7) 34.1 30.5 
 
 
32.2 26.6 
 (26.5) 
 Chest pains 24.8 
35.2 
 
 
 
Table a3.10(b) Physical Health Symptoms: Percentages Experienced in Last Three 
Months  
 
  n % 
 Poor appetite in last three months   
 Experienced 49 62.0 
 
 
47.4 
 
57.0 
30.8 
23.5 
 
Experienced 
 Experienced 
 
Didn’t experience 56 
Didn’t experience 42 
Didn’t experience 30 38.0 
 Tiredness/fatigue in last three months   
 Experienced 63 79.7 
 Didn’t experience 16 20.3 
 Nausea (feeling sick) in last three months  
 Experienced 37 
 Didn’t experience 41 52.6 
 Stomach pains in last three months  
 Experienced 34 43.0 
 Didn’t experience 45 
 Difficulty breathing in last three months   
 Experienced 24 
 Didn’t experience 54 69.2 
 Chest pains in last three months   
 Experienced 19 
 Didn’t experience 62 76.5 
Joint/bone pains in last three months   
 39 49.4 
 Didn’t experience 40 50.6 
 Muscle pains in last three months   
39 48.8 
 Didn’t experience 41 51.3 
 Numbness/tingling in last three months   
Experienced 22 28.2 
 71.8 
 Tremors/shakes in last three months   
 Experienced 35 45.5 
 54.5 
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Table a3.10(c) Mental Health Symptoms: Mean Days Experienced in Last Three 
Months  
 
  Population Sub-sample 
  Mean (sd) (sd) 
 
Mean  
 Mental health symptoms over previous three months    
 Feeling tense 
38.7 
31.5 (35.0) 
 (34.9) 
(23.4) 
(38.1) 
Feeling lonely 
(25.0) 32.4 (34.6) 
  50.5 (37.1) 58.7 (33.3) 
 Suddenly scared for no reason 19.1 (31.1) (34.7) 
 Feeling fearful 44.6 (33.9) 
Nervous/shaking inside 31.3 (36.9) 50.7 
 Spells of terror/panic 9.7 31.5 (33.3) 
 Feeling hopeless about future 38.8 (40.5) 64.7 (32.3) 
 Feelings of worthlessness 40.7 (40.0) 64.0 (31.8) 
 Feeling no interest in things 38.6 58.3 (32.1) 
 42.6 (38.4) 56.3 (34.2) 
 Thoughts of ending your life 10.8 
 
Table a3.10(d) Mental Health Symptoms: Percentages Experienced in Last Three 
Months  
 
  n % 
 Feeling tense in last three months   
 Experienced 62 86.1 
 Didn’t experience 10 13.9 
 Suddenly scared for no reason in last three months   
 Experienced 36 49.3 
 Didn’t experience 37 50.7 
 Feeling fearful in last three months   
70.6 
20 29.4 
 
45 61.6 
38.4 
  
Experienced 30.8 
 Didn’t experience 54 
 Feeling hopeless about the future in last three months 
 Experienced 45 60.0 
30 40.0 
  
 
 
 
 
 
56 
18 
 33.3 
48 
 Experienced 48 
 Didn’t experience 
 Nervousness or shaking inside in last three months  
 Experienced 
 Didn’t experience 28 
 Spells of terror or panic in last three months 
 24 
69.2 
 Didn’t experience 
 Feelings of worthlessness in last three months 
Experienced 47 63.5 
Didn’t experience 27 36.5 
Feeling no interest in things in last three months   
Experienced 49 66.2 
Didn’t experience 25 33.8 
 Feeling lonely in last three months   
 Experienced 75.7 
 Didn’t experience 24.3 
 Thoughts of ending you life in  last 3 months 
Experienced 24 
 Didn’t experience 66.7 
 
Table a3.10(e) Suicidal Thoughts and Attempts in Last Six Months 
 
 
 n % 
Suicide   
Seriously thought of committing suicide in last six months 27 33.8 
Attempted suicide in the last six months 8 9.8 
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a3.11 Personal and Social Functioning  
 
Table a3.11(a) Recent Employment and Income Status  
 
%   n 
 Occupation Over Last Six Months  
 Not Working 31 38.8 
 
In Prison 15.0 
 aRecent Employment  
28.4 
15.9 
 
 Wage/salary 25 30.5 
 Family/friends 17 20.7 
 
Working (FT/PT) 27 33.8 
 12 
 Disability 6 7.5 
 In treatment 4 5.0 
 Employed in last three months 23 
 Currently employed 13 
aMain Sources of Income in Last Three Months  
Social welfare 57 69.5 
 Drug dealing 29 35.4 
 Other crime 33 40.2 
a These categories are not mutually exclusive. 
 
Table a3.11(b) Recent Accommodation Status  
 
  n % 
 Current Accommodation   
 Family home 4 4.9 
 Drug treatment residence 70 85.4 
 Own house/flat or rental 7 
 1 
 
 
 
 
 6.1 
 
 
 
 
 3.8 
 2 2.5 
 ner and children 6 
21 
8.5 
Hostel/shelter/B&B 1.2 
Prison 0 0.0 
 No Fixed Abode 0 0.0 
aAccommodation - over last three months spent time in   
 Family home 39 48.8 
Drug treatment residence 75 91.5 
 Own house/flat or rental 26 31.7 
 Hostel/shelter/B&B 10 12.2 
 Prison 16 19.5 
Home of friends 9 11.1 
No Fixed Abode 5 
Usually lives with   
Partner/spouse 4 5.0 
Parents 30 37.5 
Alone 14 17.5 
bChildren 3 
bParents and children 
bPart 7.5 
 Other 26.2 
aThese categories are not mutually exclusive. 
ears.
 
 
bIncludes children over the age of 18 y  
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Table a3.11(c) Treatment Over Last Six Months: Previously Treated Cohort 
 
 Sub-sample 
 n % 
 Treatment in the last six months   
Structured/supervised detoxification  17 26.2 
16 25.4 
Residential drug treatment 14 20.9 
 5 7.8 
 12 19.0 
 
 One-to-one counselling 
 
Prescribed methadone 
Group work 
 
Table a3.11(d) Treatment Received for a Medical Condition in Last Three Months 
 
 N % 
 Treatment in last three months   
 Attended hospital and stayed overnight 5 6.3 
 Attended an A&E 9 11.1 
 Visited a GP (not methadone G.P.)  27 34.6 
 Visited an out-patient department 
/received community treatment  
14 17.5 
 
Table a3.11(e) Mean Number of Times in Treatment for a Medical Condition in Last 
Three Months 
 
  Mean ( sd) 
aNumber of times attended service 
 Number of days overnight stay in hospital       2.2 (1.8) 
 Number of visits to Accident and Emergency   1.0 (0) 
 Number of visits to a GP (not methadone GP)     2.4 (2.3) 
 Numbers of visits for out-patient 
appointment/community treatment  
3.1 (6.0) 
  
  a Of those who attended these services in the last three months 
 
Table a3.11(f) Frequency of Contact and Conflict with Partner, Family/Relatives and 
Friends  
 Mean (sd) 
 
 
 Number of days contact with   
 Partner 62.0 (30.2) 
46.2 (33.3) 
36.4 (34.5) 
 
 
 Mother 8.3 
Father 8.1 
 Mother 
 Father 31.7 (34.0) 
 Siblings 36.2 (33.0) 
 Friends  
  
 Number of days conflict with  
Partner 13.8 (21.0) 
(19.0) 
 (17.7) 
 Siblings 3.9 (15.8) 
 Friends  3.2 (11.9) 
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Table a3.11(g) Quality of Relationship with Children 
  
n        % 
Type of relationship with children   
 Very good  15 44.1 
 Good 8 
 Poor 
6 17.6 
23.5 
 Okay/alright 4 11.8 
1 2.9 
 Very poor 
 
 
 
 
a3.12 Criminal Activity  
 
Table a3.12(a) Crime Committed in Last Three Months 
 
  n % 
 Crime committed   
 Selling/supply drugs 30 38.0 
13 16.3 
 
 
 
 
 23 
 Fraud/forgery/deception 15 
 10 12.5 
 
 Theft from a person 
Theft from house/home 8 10.0 
Theft from shop/commercial property 12 15.0 
Theft from a vehicle 4 5.1 
Theft of a vehicle 4 4.9 
Handling stolen goods 28.4 
19.0 
 Assault 14 17.3 
Criminal damage 
 Soliciting 0 0 
Breach of the peace 5 6.3 
 
 
 
Table a3.12(b) Means Days Crimes Committed in Last Three Months 
 
   
 
Population 
 
 
Sub-sample  
  Mean (sd) Mean (sd) 
 Frequency of crime in last three months     
 Selling/supply drugs 15.5 (26.6) 
(19.6) 
(19.5) 38.9 
 Theft from a vehicle 
 
(19.0) 27.3 
 Fraud/forgery/deception 3.2 (12.7) 
Soliciting 
42.2 (28.4) 
 Theft from a person 2.3 (9.3) 14.2 
 Theft from house/home 1.3 (8.3) 15.0 (25.7) 
 Theft from shop/commercial property 5.8 (36.9) 
0.5 (3.4) 9.7 (13.6) 
Theft of a vehicle 0.2 (0.8) 3.0 (2.2) 
 Handling stolen goods 7.2 (28.9) 
17.6 (26.2) 
 Assault 0.4 (1.3) 2.4 (2.4) 
 Criminal damage 0.7 (3.5) 5.3 (9.1) 
 0.0 (0.0) 0.0 (0.0) 
 Breach of the peace 0.7 (5.7) 14.0 (24.0) 
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Table a3.12(c) Arrest by Offence in Last Three Months 
 
  n % 
 Crime Committed   
 Selling/supply drugs 4 5.3 
 
 
5.9 
 
 
 
 Theft from a person 3 4.7 
Theft from house/home 1 1.7 
 Theft from shop/commercial property 6 8.8 
 Theft from a vehicle 0 0.0 
 Theft of a vehicle 1 1.6 
Handling stolen goods 3 4.1 
 Fraud/forgery/deception 1 1.4 
 Assault 4 
Criminal damage 3 4.5 
Soliciting 0 0.0 
Breach of the peace 4 6.3 
 
 
Table a3.12(d) Current Legal Status 
  n % 
aCurrent legal problem   
 None 36 44.4 
 Serving a sentence in prison 
 
 On probation/community service 13 16.0 
2 2.5 
 On bail – awaiting trial/hearing 15 18.5 
 On bail – awaiting sentencing 13 16.0 
On temporary release 4 4.9 
 Outstanding warrants 15 18.5 
 Outstanding fines 8 9.9 
 
a Categories are not mutually exclusive. 
 
 
     90 
   
APPENDIX 4: RESULTS FOR NEEDLE EXCHANGE GROUP AT 
BASELINE 
 
 
Background to Treatment  
a4. 1 Index Treatment 
 
A sample of individuals was recruited from needle exchanges (6.4%, n=26).  The majority of 
these participants were recruited within the Greater Dublin Area. To this end, fieldworkers 
conducted the interviews in four needle exchanges in Dublin city, and one in the Wicklow 
area. As no needle exchanges were in operation in other health board areas, recruitment was 
solely in the Eastern Regional Health Authority area.  
 
a4.2 Treatment History 
 
Table a4.2(a) Treatment History at Baseline for Needle Group: Previous Treatment 
Received  
 
 
 
Table a4.1(a) Gender and Age of Needle Exchange Group 
 n % 
 
 Male 20
                  6 
76.9 
 Female    23.1 
   
  Mean (sd) Median 
 Age  
 Age of  male study participants (years) 29.0(5.5) 
31.3(8.5) 
    29.0 
 Age of  female study participants (years)     27.5 
 Gender 
 
 
 n % 
 Percentage in previous treatment   
 Previous treatment received               23 88.5 
 No previous treatment received                 3 11.5 
    
 
Population 
Sub-sample –
previously treated 
n % n % 
aPrevious types of formal treatment    
 One-to-one counseling 
19 82.6 
 
14 58.3 14 66.7 
 Prescribed methadone 19 73.1 
 Structured/supervised detoxification 56.0 14 63.6 
 Residential drug treatment 7 28.0 7 31.8 
bNeedle Exchange 24 92.3 21 91.3 
 
 
  
14 
aThese categories are not mutually exclusive.  
is not considered treatment. 
 
 bAttendance at needle-exchange 
 
 
 
 
 
 
     91 
   
Table a4.2(b) Details of Previous Treatment 
 
  Previously Treated 
  Mean (sd)  
 Age first sought treatment (years) 19.6 (4.5)  
 Age first attending counselling (years) 21.4 (5.1)  
 Number of counsellors 4.2 (3.1)  
 Longest period of regular attendance (months) 20.4 (22.3)  
 Age first on methadone/physeptone (years) 22.2 (4.9)  
 Number of episodes 2.5 (1.8)  
 Longest period of attendance (months) 55.9 (69.6)  
 Age first on supervised detoxification (years)  21.7 (5.1)  
 Number of episodes 2.8 (2.0)  
 Age first in residential treatment (years) 21.9 (5.0)  
 Number of episodes 3.3 (2.1)  
 
 
a4.3 Substance Use 
  
Table a4.3(a) Drug Using History: Ever Used 
 
  n % 
 Drugs ever used   
 Heroin 26 100.0 
 Cannabis 24 96.0 
 Tobacco 25 96.2 
 Alcohol 18 75.0 
 Cocaine 23 92.0 
 Benzodiazepines 19 82.6 
 Non-prescribed methadone  20 83.3 
 Ecstasy 13 76.5 
 Amphetamine 12 63.2 
 LSD 12 75.0 
 Other opiates 16 66.7 
 Crack cocaine 14 60.9 
 
Table a4.3(b) Drug Using History: Age First Used 
 
  Mean  (sd) 
 Age first smoked tobacco (years) 13.9 (3.6) 
 Age first used alcohol (years) 13.6 (1.3) 
 Age first used cannabis (years) 14.4 (2.3) 
 Age first used amphetamine (years) 16.4 (2.0) 
 Age first used LSD (years) 16.6 (1.4) 
 Age first used ecstasy 19.0 (6.5) 
 Age first used heroin (years) 18.4 (3.9) 
 Age first used benzodiazepines 18.0 (5.2) 
 Age first used cocaine (years) 19.8 (4.2) 
 Age first used other opiates (years) 21.1 (5.6) 
 Age first used methadone (years) 20.6 (6.1) 
 Age first used crack (years) 22.5 (6.1) 
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Table a4.3(c) Drug Using History: Problem Drug Use 
 
  Mean (sd) 
 Age cannabis use became a problem 17.9 (3.4) 
 Duration since first use of cannabis (years) 15.1(6.2) 
 Age heroin use became a problem  20.2 (4.3)  
 Duration since first use of heroin (years) 11.2(6.3) 
 Age benzodiazepine use first became a problem  14.0 (5.7) 
 Duration since first use of benzodiazepine 
(years) 
 12.3(7.7) 
 Age cocaine use became a problem 21.1 (4.0) 
 Duration since first use of cocaine (years) 10.4 (6.9) 
 Age methadone use became a problem 18.5 (1.3) 
 Duration since first use of methadone (years) 9.4 (5.5) 
 Age crack use became a problem 19.3 (0.6) 
 Duration since first use of crack  (years) 8.2(6.4) 
 
 
a4.4 Health Risk Behaviour 
 
Table a4.4(a) Injecting-Related Health Variables  
 
  n % 
 Percentage injected  
 Ever injected 26 100.0 
 aEver shared injecting equipment  
 Ever used needle after someone 17 65.4 
 Somebody ever used needle after you 16 61.5 
 Ever reused own injecting equipment 24 92.3 
 Ever shared filter/spoons/flush water 18 69.2 
   
  Mean (sd) 
 Age first injected 19.5 (4.1) 
aPercentages for those who have ever injected. 
 
Table a4.4(b) Overdose Rates  
 
  n % 
Proportion of participants ever overdosed 
 Never overdosed 11 42.3 
 Overdosed once 6 23.1 
 More than 1 but maximum of 3 times 6 23.1 
 More than 3 but maximum of 5 times 2 7.7 
 Overdosed more than 5 times 1 3.8 
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a4.5 Physical and Psychological Health 
 
 
Table a4.5(a) Suicidal Thoughts and Attempts  
  n % 
 Suicide   
 Seriously thought of committing suicide ever 14 63.6 
 Ever attempted suicide 12 54.5 
 
Table a4.5(b) HIV, HBV, HCV Status  
 
  HIV Status HBV Status HCV Status 
  n % n % n % 
        
 Ever tested 18 85.7 18 85.7 20 90.9 
 
 
 
 
Negative* 13 100.0 13 92.9 4 23.5 
Positive* 0 0.0 1 7.1 13 76.5 
Awaiting results* 0 0 0 0 0 0 
*Of those ever tested 
 
 
a4.6 Personal and Social Functioning 
 
Table a4.6(a) Demographics: Education 
 
  Mean ( sd) 
 Age left school (years) 15.10 (1.46) 
 Highest Educational Level n % 
 No formal education 1 3.8 
 Primary 8 30.8 
 Lower secondary 10 38.5 
 Upper secondary 6 23.1 
 Third level 1 3.8 
 Highest Educational Qualification  
 No qualifications 13 50.0 
 Junior cert/basic skills/ NVCA level 1 
 0 
National cert./dip./NCEA 
Third level 
9 34.6 
 Leaving cert 3 11.5 
Apprenticeship 0.0 
 0 0.0 
 1 3.8 
 
Table a4.6(b) Demographics: Children 
 
  n % 
 Have children under 18 years   
 No 13 50.0 
 Yes  13 50.0 
 Parents – number of children in care of participant  
 None 6 46.2 
 One  3 23.1 
 Two or more 4 30.8 
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a4.7 Criminal Activity  
 
Table a4.7(a) Types of Crime Ever Committed  
 
  n % 
 Crime committed   
 Selling/supply drugs 11 61.1 
 Theft from a person 11 61.1 
 
72.2 
 
 
 Breach of the peace 
Theft from house/home 9 47.4 
 Theft from shop/commercial property 13 
 Theft from a vehicle 7 38.9 
Theft of a vehicle 10 55.6 
 Handling stolen goods 14 70.0 
 Fraud/forgery/deception 11 55.0 
 Assault 8 44.4 
Criminal damage 9 50.0 
 Soliciting 1 6.3 
7 43.8 
 
 
Table a4.7(b) Arrests by Offence 
 
 
  Ever Arrested 
  n % 
 Crime committed   
 Selling/supply drugs 5 27.8 
 Theft from a person 3 20.0 
 Fraud/forgery/deception 
 
 Theft from house/home 1 7.1 
 Theft from shop/commercial property 6 31.6 
 Theft from a vehicle 4 28.6 
 Theft of a vehicle 7 43.8 
 Handling stolen goods 5 27.8 
4 26.7 
Assault 6 40.0 
 Criminal damage 5 33.3 
 Soliciting 1 8.3 
 Breach of the peace 5 35.7 
 
 
 
Table a4.7(c) Prison Experience 
 
  n % 
 Imprisonment   
 Ever been in prison 17 68.0 
 Ever remanded in custody 17 68.0 
 Ever received custodial sentence 12 48.0 
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Key Outcome Measures 
 
a4.8 Substance Use 
 
Table a4.8(a) Drug Use in Last Three Months: Percentage Used 
 
  n % 
 Drug use in last three months   
 Tobacco 22 95.7 
 Heroin 25 100.0 
 Cannabis 19 82.6 
 Alcohol 9 39.1 
 Benzodiazepines 10 45.5 
 Cocaine 15 
5 
7.7 
0.0 
57.7 
 Non-prescribed methadone  20.8 
 Crack cocaine 2 
 Ecstasy 0 
 Other opiates 3 13.0 
 Amphetamine 0 0.0 
 
Table a4.8(b) Drug Use Last Three Months: Mean Days Used 
 
   
Population 
Sub-sample used in 
last three months 
  Mean (sd) Mean (sd) 
 Mean days used in last three months   
Tobacco 86.1 (18.8) 
 Cannabis 48.2 (40.6) 58.3 
 Heroin 42.3 
 (7.1) 13.8 (10.0) 
Benzodiazepines 11.8 (26.6) 
 Alcohol 
Cocaine 
 0.4 (1.5) 5.5 
Other opiates 0.9 (3.1) 7.0 (6.6) 
 Ecstasy 0 0.0 0 0.0 
 0 0.0 0 
 90.0 (0.0) 
(37.3) 
(35.1) 42.3 (35.1) 
Non-Prescribed Methadone  2.9 
 26.0 (35.3) 
10.8 (22.4) 27.7 (29.2) 
 11.0 (24.6) 19.7 (30.6) 
Crack cocaine (0.7) 
 
Amphetamine 0.0 
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Table a4.8(c) Drug Use in Last Three Months: Mean Amount Used 
 
   
Population 
Sub-sample used in 
last three months 
  Mean (sd) Mean 
  
(sd) 
 Mean amount used in a day in last 
three months 
 Tobacco (cigarettes) (11.2) 
 (0.5) 
Cannabis (joints) 
(10.1) 
 
 (45.3) 
18.27 18.5 (10.9) 
bHeroin (grams) 0.5 0.5 (0.5) 
 6.6 (7.9) 8.5 (8.3) 
 Alcohol (units) 4.8 9.7 (7.1) 
 Cocaine (grams) 1.8 (2.7) 3.2 (3.0) 
Non-Prescribed Methadone 
(mls) 
12.9 (25.8) 48.4 (22.6) 
Benzodiazepines (mgs) 25.6 (44.6) 76.7 
a Crack cocaine was excluded due to the inconsistency in the way data was reported. 
bThese figures were based on 1 bag of heroin containing on average 0.25grams at the time of fieldwork 
 
 
a4.9 Health Risk Behaviour 
 
Table a4.9(a) Injecting-Related Variables in Last Three Months  
 
  n % 
 Percentage who injected in last three months                     22 84.6 
   
 Frequency of injecting in last three months   
 Not injected  
 Infrequent (1-9 days) 5
 Frequent (10 –24 days) 
Very frequent (25-79 days) 
23.8 
4 19.0 
 5 23.8 
 Daily (80-90 days) 7 33.0 
 Used needle after someone in last three months  
No times 
2 9.1 
 
90.0 
5.0 
 
4.8 
 
 18 81.8 
 One time 2 9.1 
 Two or more times 
Someone used needle after you in last three months   
 No times 18
 One time 1
 Two or more times 1 5.0 
 Reused own needles in last three months  
 No times 9 56.3 
 One time 1 6.3 
 Two or more times 6 37.5 
 Used filter/spoons/flush water/ after someone   
 No times 19 90.5 
 One time 1 4.8 
 Two or more times 1
 
  
aDays injected in last three months 
aTimes injected on typical day 
Mean (sd) 
 44.8 (35.4) 
 5.0 (10.4) 
aRelates to those who have injected in last three months. 
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  Table a4.9 (b) Overdose Rates in Last Three Months 
 
%   n 
 Overdose in last three months   
 None 22 84.6 
 One or more times 4 15.4 
 
 
Table a4.9(c) Frequency of Unsafe Sex in Last Three Months 
 
          n % 
 Sexual history in last three months   
 Participants having sex 20 76.9 
 
 
100 
 
6 35.3 
33.3 
 
bCondom use with someone other than 
a regular partner 
       
Participants not having sex 6 23.1 
ab Sexual partners in last three months   
 Having sex with a regular partner  18 
 Having sex with someone other than 
regular partner 
bCondom use with regular partner 
 Always used condom 5 
 Sometimes used condom 3 20.0 
 Never used condom 7 46.7 
   
 Always used condom 1 20.0 
 Sometimes used condom 3 60.0 
Never used condom 1 20.0 
 
aThese categories are not mutually exclusive. 
b This is only of those who had sex in the last three months 
 
 
 
 
a4.10 Physical and Psychological Health 
 
Figure a4.1 Participants Self-Assessment of Health 
Good
n=7, 27%
Poor
n=9, 35%
Fair
n=10, 38%
Excellent
n = 0, 0%
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Table a4.10(a) Physical Health Symptoms: Mean Days Experienced in Last Three 
Months 
Sub-sample 
 
  Population 
  Mean (sd) Mean (sd) 
   Physical health symptoms over previous three months   
Poor appetite 45.2 (40.5) 61.1 
 Tiredness/fatigue 47.9 62.0 (35.1) 
 8.5 (20.1) 23.4 (28.6) 
 Stomach pains 16.1 (28.7) 
 Difficulty breathing 43.6 (43.1) 
Chest pains 5.4 (20.1) 57.0 (46.7) 
 Joint/bone pains 12.8 (27.0) 38.5 (35.8) 
 Muscle pains 13.5 (27.5) 33.8 (35.5) 
Numbness/tingling 8.3 (26.4) 61.0 
 Tremors/shakes 1.8 12.0 (10.8) 
 (34.9) 
(40.5) 
Nausea (feeling sick) 
40.3 (33.5) 
10.9 (27.7) 
 
 (50.2) 
(5.6) 
 
Table a4.10(b) Physical Health Symptoms: Percentages Experienced in Last Three 
Months  
 
%   n 
 Poor appetite in last three months   
 Experienced 17 73.9 
26.1 
 
77.3 
22.7 
 
Experienced 36.4 
14 63.6 
Stomach pains in last three months   
8 40.0 
Didn’t experience 12 
  
Experienced 5 
 15 
 Chest pains in last three months 
 2 9.5 
 
 Joint/bone pains in last three months 
 Experienced 7 
Didn’t experience 14 
Muscle pains in last three months   
8 
12 
Numbness/tingling in last three months 
Experienced 
 15.0 
17 
 Didn’t experience 6 
 Tiredness/fatigue in last three months  
 Experienced 17 
 Didn’t experience 5 
 Nausea (feeling sick) in last three months  
 8 
 Didn’t experience 
 
 Experienced 
 60.0 
 Difficulty breathing in last three months 
 25.0 
Didn’t experience 75.0 
  
Experienced 
Didn’t experience 19 90.5 
  
33.3 
 66.7 
 
 Experienced 40.0 
 Didn’t experience 60.0 
   
 3 13.6 
 Didn’t experience 19 86.4 
 Tremors/shakes in last three months   
Experienced 3 
 Didn’t experience 85.0 
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Table a4.10(c) Mental Health Symptoms: Mean Days Experienced in Last Three 
Months  
 
 
 Population Sub-sample 
 Mean (sd) Mean  
 Mental health symptoms over previous three months    
 Feeling tense (36.3) 
 43.6 
14.2 (27.8) (35.2) 
 Nervous/shaking inside 18.0 
Spells of terror/panic (7.4) 19.7 
26.9 (36.2) (37.4) 
(39.0) 
Feeling lonely 
12.1 (29.8) 41.0 (45.4) 
24.2 (35.2) 48.3 
Suddenly scared for no reason 17.5 (32.1) (38.7) 
 Feeling fearful 33.8 
(32.7) 42.8 (39.3) 
 3.0 (5.1) 
 Feeling hopeless about future 31.1 (35.1) 39.5 (35.2) 
 Feelings of worthlessness 44.0 
 Feeling no interest in things 29.1 58.1 (36.4) 
 30.3 (39.6) 57.3 (37.5) 
 Thoughts of ending your life 
 (sd) 
 
 
 
Table a4.10(d) Mental Health Symptoms: Percentages Experienced in Last Three 
Months  
 
  n % 
 Feeling tense in last three months   
 Experienced 10 50.0 
 Didn’t experience 10 50.0 
 Suddenly scared for no reason in last three months   
 Experienced 8 40.0 
 
8 42.1 
Didn’t experience 57.9 
 Nervousness or shaking inside in last three months 
Experienced 3 
78.6 
 
11 61.1 
38.9 
 
50.0 
50.0 
 
52.9 
8 
Experienced 
 Didn’t experience 
Didn’t experience 12 60.0 
 Feeling fearful in last three months   
 Experienced 
 11 
  
 Experienced 8 42.1 
 Didn’t experience 11 57.9 
 Spells of terror or panic in last three months   
 15.0 
 Didn’t experience 17 85.0 
 Feeling hopeless about the future in last three months 
 Experienced 11 
 Didn’t experience 3 21.4 
 Feelings of worthlessness in last three months  
 Experienced 
 Didn’t experience 7 
 Feeling no interest in things in last three months  
 Experienced 8 
 Didn’t experience 8 
 Feeling lonely in last three months  
 Experienced 9 
 Didn’t experience 47.1 
 Thoughts of ending you life in last three months 
 5 29.4 
12 70.6 
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Table a4.10(e) Suicidal Thoughts and Attempts in Last Six Months 
% 
 
  n 
 Suicide   
 Seriously thought of committing suicide 
in last six months 
6 27.3 
3 13.6  Attempted suicide in the last six months 
   
a4.11 Personal and Social Functioning  
 
% 
Table a4.11(a) Recent Employment and Income Status  
 
  n 
 Occupation Over Last Six Months 
 Not working 
 Working (FT/PT) 6 
 In prison 0 
 Disability 6 
 In treatment 0 
aRecent Employment  
 Employed last three months 19.2 
 Currently employed 19.2 
aMain Sources of Income in Last Three Months  
 12.0 
 9 36.0 
 Social welfare 22 88.0 
 Drug dealing 
 52.0 
 
12 50.0 
25.0 
0.0 
25.0 
0.0 
 
5 
5 
 
Wage/salary 3 
Family/friends 
10 40.0 
Other crime 13 
a These categories are not mutually exclusive. 
  
  % 
  
Table a4.11(b) Recent Accommodation Status 
n
 Current Accommodation  
 Family home 9 34.6 
 
 
 
 
 
 
 Prison 
7.7 
11.5 
Usually lives with  
15.4 
11.5 
 ildren 
 1 3.8 
 19.2 
23.1 
Own house/flat or rental 11 42.3 
 Hostel/shelter/B&B 3 11.5 
Prison 0 0.0 
Home of friends 1 3.8 
 No Fixed Abode 2 7.7 
aAccommodation - Over last three months spent time in  
Family home 12 46.2 
Drug treatment residence 0 0.0 
 Own house/flat or rental 12 46.2 
 Hostel/shelter/B&B 5 19.2 
1 3.8 
 Home of friends 2
 No Fixed Abode 3
 
 Partner/spouse 4
 Parents 7 26.9 
 Alone 3
bCh 0 0.0 
bParents and children 
bPartner and children 5
 Other 6
aThese categories are not mutually exclusive. 
bIncludes children over the age of 18 years. 
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Table a4.11(c) Treatment Over Last Six Months: Previous Treated Cohort  
 
 Sub-sample 
 
Treatment in the last six months 
n % 
   
 Structured/supervised detoxification  0 0.0 
 One-to-one counselling 2 8.7 
 Residential drug treatment 0 0.0 
 Prescribed methadone 0 0.0 
 Group work 2 8.7 
 
Table a4.11(d) Treatment Received for a Medical Condition in Last Three Months 
 
 n % 
 Treatment in last three months   
 Attended hospital and stayed overnight 3 11.5 
 Attended an A&E 5 
9 
Visited an out-patient department 
/received community treatment  
20.8 
 Visited a GP (not methadone G.P.)  42.9 
 3 11.5 
 
Table a4.11(e) Mean Number of Times in Treatment for a Medical Condition in Last 
Three Months 
 
  Mean ( sd) 
aNumber of times attended service   
1.8 (0.8) 
1.2 (0.5) 
3.0 (3.5) 
 Numbers of visits for out-patient 
appointment/community treatment  
 
Number of days overnight stay in hospital  
 Number of visits to A&E 
 Number of visits to a GP (not methadone G.P.)  
1.0 (0.0) 
  a Of those who attended these services in the last three months 
 
Table a4.11(f) Frequency of Contact and Conflict with Partner, Family/Relatives and 
Friends  
 
  Mean (sd) 
 Mother 51.2 (42.3) 
 Father 32.8 (40.7) 
 Siblings 58.3 (42.7) 
 Friends  42.3 (44.1) 
  
 Number of days conflict with  
 Partner 19.8 (33.9) 
 Mother 14.7 (32.6) 
 Father 2.2 (5.3) 
 Siblings 7.3 (24.9) 
Friends  6.7 (16.9) 
 Number of days contact with   
 Partner 83.9 (17.8) 
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Table a4.11(g) Quality of Relationship with Children 
 
 n        % 
 Type of relationship with children   
 Very good  7 53.8 
 Good 3 23.1 
 Okay/alright 1 
0 
2 
7.7 
 Poor 0 
 Very poor 15.4 
 
 
a4.12 Criminal Activity  
 
Table a4.12(a) Crime Committed in Last Three Months 
 
  n % 
Crime committed   
Selling/Supply drugs 7 31.8 
 Theft from a person 2 9.5 
 Theft from house/home 2 9.1 
Theft from shop/commercial property 3 15.8 
 Theft from a vehicle 9.5 
 Theft of a vehicle 0 0.0 
Handling stolen goods 8 38.1 
 Fraud/forgery/deception 4 20.0 
 Assault 1 4.8 
 Criminal damage 2 9.5 
 Soliciting 1 5.0 
 Breach of the peace 2 10.0 
 
 
 
2 
 
 
 
Table a4.12(b) Means Days Crimes Committed in Last Three Months 
 
   
 
Population 
Sub-sample  
Committed last 
three months  
Mean 
  
(28.2) 
Theft from a person 
4.5 
0.06 
 (0.0) 
 0.0 (0.0) 0.0 
 
(0.0) 
(0.3) 
Breach of the peace 
  Mean (sd) 
Frequency of crime in last three months   
(sd) 
 
 Selling/supply drugs 
0.0 
0.2 
 (0.0) 
(0.7) 
Theft of a vehicle (0.0) 
5.2 
4.9 
 (0.4) 2.0 
1.0 
Soliciting 4.5 
 (0.0) 
11.0 43.8 (44.5) 
 0.0 (0.0) (0.0) 
 Theft from house/home (1.0) (0.0) 
Theft from shop/commercial property (0.2) 1.0 
Theft from a vehicle 0.2 3.0 
Handling stolen goods 1.6 (2.8) (2.7) 
 Fraud/forgery/deception (20.1) 24.5 (43.7) 
Assault 0.1 
 Criminal damage 0.1 (0.0) 
 (20.1) 90.0 (0.0) 
0.0 (0.0) 0.0 
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Table a4.12(c) Arrest by Offence in Last Three Months 
 
Arrested last 
three months 
  
Crime committed   
n % 
 
 Selling/supply drugs 0 0.0 
 Theft from a person 0 0.0 
 Theft from house/home 0 0.0 
 Theft from shop/commercial property 0 0.0 
 Theft from a vehicle 
0 
1 
 1 6.7 
0 0.0 
 Theft of a vehicle 0.0 
 Handling stolen goods 5.6 
 Fraud/forgery/deception 1 7.1 
Assault 
 Criminal damage 1 6.7 
 Soliciting 0 0.0 
 Breach of the peace 1 6.7 
 
Table a4.12(d) Current Legal Status 
 
  n % 
 aCurrent legal problem   
 None 13 52.0 
 On probation/community service 2 7.7 
 Serving a sentence in prison 0 0.0 
 On bail – awaiting trial/hearing 7 26.9 
 On bail – awaiting sentencing 1 3.8 
 On temporary release 0 0.0 
 Outstanding warrants 3 12.0 
 Outstanding fines 0 0.0 
a Categories are not mutually exclusive. 
 
 
 
 
 
 
 
